

APPROVED DRUG PRODUCTS

With Therapeutic Equivalence Evaluations



The "Orange Book"

FDA data supplied by [DrugPatentWatch.com](https://www.drugpatentwatch.com)

HE 20,4270:1984/supp. 6


Pharm
RM
300
A653

Aug 1984 -
Feb 1985
Cum. suppl. 6

REFERENCE
DOES NOT CIRCULATE

THE UNIVERSITY
OF MICHIGAN
MAY 21 1985
PHARMACY
LIBRARY

**CUMULATIVE
SUPPLEMENT 6
AUG'84 - FEB'85**



APPROVED PRESCRIPTION DRUG PRODUCTS

WITH
THERAPEUTIC EQUIVALENCE EVALUATIONS

5TH EDITION

SERIAL

REFERENCE

The University
of Michigan
Pharmacy
Library

U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES
PUBLIC HEALTH SERVICE
FOOD AND DRUG ADMINISTRATION
CENTER FOR DRUGS AND BIOLOGICS

UNIVERSITY OF MICHIGAN
LIBRARIES

MAY 6 1985

DEPOSITED BY THE
UNITED STATES OF AMERICA

Digitized by Google

Original from
UNIVERSITY OF MICHIGAN

FOOD AND DRUG ADMINISTRATION
APPROVED PRESCRIPTION DRUG PRODUCTS
WITH
THERAPEUTIC EQUIVALENCE EVALUATIONS
CUMULATIVE SUPPLEMENT

I. PREFACE

This cumulative supplement is one of a series of monthly updates to the Approved Prescription Drug Products with Therapeutic Equivalence Evaluations, 5th Edition (the List), to cover interim revisions to the annual publication of the List in its entirety. The List is comprised of several parts and some by their nature, are identified by the term "list." The cumulative supplements routinely provide updates to two of these lists: The Drug Product List and the DESI Addendum.

The List cannot be used effectively without the current cumulative supplement. Users may wish to place an asterisk (*) in the List to the left of the ingredient(s) in the Drug Product List and the product name in the Addendum to indicate that changes to that entry appear in the cumulative supplement. It is also suggested that earlier cumulative supplements be discarded to avoid possible confusion. In this way, only the List and current cumulative supplement need be referenced.

A. DRUG PRODUCT LIST

The Drug Product List cumulative supplements include the changes made since August 1, 1984. Each subsequent cumulative supplement replaces the previous month's cumulative supplement.

Information in this cumulative supplement follows the format of the Drug Product List. The presence of any therapeutic equivalence code indicates that the drug product is multisource; the deletion of a therapeutic equivalence code indicates that the drug product has become single source. (An infrequent exception exists when a therapeutic equivalence code is revised. In that case the deletion of the therapeutic equivalence code is followed immediately by the addition of the revised one.)

Context information on drug products is provided in each cumulative supplement for completeness to assist in locating the proper place in the Drug Product List for the revision. (Strength(s) which already exist in the publication will not be repeated for context.) A page number in parentheses referring to the Drug Product List is located to the right of the ingredient(s).

Additions to the Drug Product List are indicated by new information in the cumulative supplement. Additions new to the current cumulative supplement are indicated by the symbol >ADD> to the left of the line on which new information exists. The >ADD> symbol is dropped in subsequent cumulative supplements for that item.

Deletions from the Drug Product List are indicated by overstruck print in the cumulative supplement. Deletions new to the current cumulative supplement are indicated by the symbol >DLT> (DELETE) to the left of the line containing the overstruck print. The >DLT> symbol is dropped in subsequent cumulative supplements for that item.

A newly approved product is identified by the lozenge (⌘) to the right of its strength. This identifier remains throughout all cumulative supplements for this edition.

B. ADDENDUM: DESI Pending List

Information in this cumulative supplement follows the format of the Addendum. Additions and deletions are indicated in the same manner as in the cumulative supplement to the Drug Product List. A change in Current Status of a DESI product is also indicated by an addition and a deletion.

II. SPECIAL NOTES

A. REPORT OF COUNTS FOR THE DRUG PRODUCT LIST

Categories of counts derived from product information in the Drug Product List and from this cumulative supplement are presented. The report includes counts of new molecular entities approved by the agency during the current month.

B. PRODUCTS REQUIRING REVISED LABELING FOR FULL APPROVAL

Drug products in this category (1) initially received approval only on the basis of safety before effectiveness studies were required, or (2) were conditionally approved under the temporary exemption that allowed these products to be marketed while effectiveness studies were being conducted. Listed below are those drugs which are now required to revise their labeling and provide additional information necessary for full approval on the basis of requirements listed in the Federal Register. As approval is granted by the Agency for a specific product, based on additional information submitted by the applicant, the product will be included in the Drug Product List.

<u>Products</u>	<u>Federal Register Reference</u>
dicyclomine hydrochloride	JUN 22, 1984 (49 FR 25681)
isosorbide dinitrate	AUG 3, 1984 (49 FR 31151)
nandrolone decanoate	JUL 15, 1983 (48 FR 32395)

(continued)

ProductsFederal Register Reference

(continued)

neomycin sulfate with either: dexamethasone sodium phosphate, fluocinolone acetonide, flurandrenolide, hydrocortisone, or methylprednisolone acetate. [topical anti-infectives for dermatologic use]	MAR 26, 1984 (49 FR 11888)
neomycin sulfate, polymyxin B sulfate, bacitracin zinc, and hydrocortisone [topical ointment]	MAY 4, 1984 (49 FR 19147)
nitroglycerin (capsule, controlled release; oral)	SEP 7, 1984 (49 FR 35428)
nitroglycerin (tablet, controlled release; oral)	SEP 7, 1984 (49 FR 35428)
parenteral multivitamin products	SEP 17, 1984 (49 FR 36446)
phenazopyridine hydrochloride and sulfamethoxazole	JUL 29, 1983 (48 FR 34516)
sulfanilamide and aminacrine	AUG 22, 1983 (48 FR 38097)
tranilcypromine sulfate	MAR 22, 1984 (49 FR 10708)

C. APPLICANT (NAME) CHANGES

Because it is not practical to identify in the cumulative supplement each and every product involved when an applicant transfers its entire line of approved drug products to another applicant, or when an applicant changes its name, the cumulation of these transfers and name changes will be identified in this Special Notes section only. Where only partial approved product lines are transferred between applicants, each approved product involved will appear as an applicant name change in the cumulative supplement. The current list of applicant holder changes follows.

APPLICANT (NAME) CHANGES

<u>Former Applicant (Name)</u>	<u>New Applicant (Name)</u>	<u>New Abbreviated Name</u>
OHIO MEDICAL ANESTHETICS	ANAQUEST	ANAQUEST

D. ADDENDUM: DRUG PRICE COMPETITION AND PATENT TERM RESTORATION

The addendum of this supplement provides information required of the Agency by the "Drug Price Competition and Patent Term Restoration Act of 1984."

III. REPORT OF COUNTS FOR THE DRUG PRODUCT LIST

DESCRIPTION OF REPORT

The following report provides summary counts derived from product information in the Drug Product List and the current cumulative supplement. The counts appear in two sections. Section A. refers to the products in the List and Section B. to products in the current cumulative supplement. A new column of data will appear in Section A. each three-month period following July '84. Section A. therefore will provide baseline and quarterly data while Section B. provides monthly activity.

USE OF REPORT

From the data presented under Section B., users should be able to observe such things as (1) newly approved, DESI effective and remarketed drug products which are added to the List; (2) products that are being removed from the List as the result of withdrawal of approval, changes from prescription to over-the-counter status and discontinued marketing of products; and, (3) trends in approval of products as either multisource or single source during each month within the quarter. The report does not reflect category changes from multisource to single source and vice versa. However, the net gain that results from all additions, deletions and category changes is reflected in the quarterly counts for multisource and single source products.

Drug Product Definition

For this report, a drug product is the representation in the Drug Product List of an active moiety (includes molecular entity and its salts, esters and derivatives) either as a single entity or as a combination product, provided in a specific dosage form and strength for a given route of administration marketed by a firm under a particular generic or trade name.

New Molecular Entity

The active moiety has not previously been approved (either as the parent compound or as a salt, ester or derivative of the parent compound) in the United States for use in a drug product either as a single ingredient or part of a combination.

Drug Product Count

This report provides counts in several categories from the list composed of domestically marketed drug products approved for both safety and effectiveness under sections 505 and 507 of the Federal Food, Drug, and Cosmetic Act. Counts of products still pending in the DESI review are not provided. Excluded also are those approved drug products marketed by distributors; those marketed solely abroad; and products now regarded as medical devices, biologics or foods.

REPORT OF COUNTS FOR THE DRUG PRODUCT LIST

A. COUNTS CUMULATIVE BY QUARTERS

CATEGORIES COUNTED	JULY '84 (BASELINE)	OCT '84	JAN '85
DRUG PRODUCTS LISTED	7415	7609	7746
SINGLE SOURCE	2005 (27.0%)	2045 (26.9%)	2077 (26.8%)
MULTISOURCE (1)	5410 (72.9%)	5564 (73.1%)	5669 (73.2%)
THERAPEUTICALLY EQUIVALENT	4393 (59.2%)	4497 (59.1%)	4598 (59.4%)
NOT THERAPEUTICALLY EQUIVALENT	999 (13.4%)	1032 (13.5%)	1038 (13.4%)
EXCEPTIONS (2)	18 (0.3%)	26 (0.3%)	23 (0.3%)
NEW MOLECULAR ENTITIES APPROVED	-	4	9
NUMBER OF APPLICANTS	295	300	304

B. ACTIVITY FOR SUPPLEMENT NUMBER 6

	FEB '85	CUMULATIVE
DRUG PRODUCTS ADDED:	44	44
NEWLY APPROVED	43	43
DESI EFFECTIVE	1	1
REMARKETED	0	0
DRUG PRODUCTS REMOVED:	1	1
WITHDRAWN APPROVAL	0	0
RX TO OTC SWITCH	1	1
DISCONTINUED MARKETING	0	0
NET GAIN IN DRUG PRODUCTS	43	43
SINGLE SOURCE PRODUCTS APPROVED	6	6
MULTISOURCE DRUG PRODUCTS APPROVED	38	38
NEW MOLECULAR ENTITIES APPROVED:	0	0
AS THE ENTITY	0	0
AS A SALT, ESTER OR DERIVATIVE	0	0
OF THE ENTITY	0	0

- (1) THERAPEUTIC EQUIVALENCE EVALUATIONS PROVIDED ONLY FOR MULTISOURCE PRODUCTS (I.e., AVAILABLE FROM MORE THAN ONE APPLICANT)
- (2) AMINO ACID-CONTAINING PRODUCTS OF VARYING COMPOSITION (SEE PAGE 1-5 OF THE LIST)

APPROVED PRESCRIPTION DRUG PRODUCTS

DRUG PRODUCT LIST

CUMULATIVE SUPPLEMENT NUMBER 6 / AUGUST '84 - FEBRUARY '85

ACEBUTOLOL HYDROCHLORIDE (PAGE 3-1)

CAPSULE; ORAL

SECTRAL

IVES LABS/AMHO

EQ 200MG BASEM

EQ 400MG BASEM

N 18917

N 18917

N 87463

TABLET; ORAL

/GdHdct/

OXYCET

AA HALSEY DRUG

325MG; 5MG

ACETAMINOPHEN; BUTALBITAL (PAGE 3-1)

TABLET; ORAL

BUTALBITAL AND ACETAMINOPHEN

DANBURY PHARMACAL

325MG; 50MG

N 87550

N 88638

ACETAMINOPHEN; BUTALBITAL; CAFFEINE (PAGE 3-1)

CAPSULE; ORAL

ESGIC

GILBERT LABORATORIES

325MG; 50MG; 40MG

N 88825

N 18828

TABLET; ORAL

ESGIC

AB GILBERT LABORATORIES

325MG; 50MG; 40MG

N 87629

N 88616

FICRIGET

AB SANDOZ PHARMS/SANDOZ

325MG; 50MG; 40MG

N 87804

N 18241

REPAN

AB DM GRAHAM LABS

325MG; 50MG; 40MG

N 18241

N 18241

N 18241

N 18785

N 18785

N 18832

N 18877

ACETAMINOPHEN; CODEINE PHOSPHATE (PAGE 3-1)

TABLET; ORAL

/AA/ /ACETAMINOPHEN 'M' CODEINE PHOSPHATE '44/

/ZENITH LABORATORIES// 325MG; 60MG

ACETAMINOPHEN AND CODEINE PHOSPHATE

AA ZENITH LABORATORIES

300MG; 60MG

N 87083

N 50565

N 50565

N 50565

ACETAMINOPHEN; HYDROCODONE BITARTRATE (PAGE 3-2)

TABLET; ORAL

HYDROCODONE BITARTRATE 'M' ACETAMINOPHEN

AA BARR LABORATORIES

500MG; 5MG

N 88577

N 50565

N 50565

ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE (PAGE 3-2)

CAPSULE; ORAL

TYLOX

MCNEIL PHARM

500MG; 5MG

N 88790

N 62562

TYLOX-325

MCNEIL PHARM

325MG; 5MG

N 88246

N 62562

ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE (PAGE 3-2)

TABLET; ORAL

/GdHdct/

OXYCET

AA HALSEY DRUG

325MG; 5MG

ACETIC ACID, GLACIAL (PAGE 3-3)

SOLUTION/DROPS; OTIC

ACETIC ACID

AT THAMES PHARMACAL

22M

N 88638

ACYCLOVIR (PAGE 3-4)

CAPSULE; ORAL

ZOVIRAX

BURROUGHS WELLCOME

200MG

N 18828

ALLOPURINOL (PAGE 3-5)

TABLET; ORAL

ALLOPURINOL

AB BOLAR PHARMACEUTICAL

100MG

AB 300MG

300MG

AB CHELSEA LABORATORIES

100MG

AB 300MG

300MG

AB DANBURY PHARMACAL

100MG

AB 300MG

300MG

AMIDINOCILLIN (PAGE 3-6)

INJECTABLE; INJECTION

COACTIN

HOFFMANN-LA ROCHE

250MG/VIAL

500MG/VIAL

1GM/VIAL

N 50565

N 50565

N 50565

AMIKACIN SULFATE (PAGE 3-6)

INJECTABLE; INJECTION

AMIKIN

BRISTOL LABS/B-M

EQ 50MG BASE/ML

EQ 250MG BASE/ML

N 62562

N 62562

AMINO ACIDS (PAGE 3-6)

INJECTABLE; INJECTION

BRANCHAMIN 4%
TRAVENOL LABS
4%
BRANCHAMIN 4% IN PLASTIC CONTAINER
TRAVENOL LABS
4%
TRAVASOL 10% W/O ELECTROLYTES IN PLASTIC CONTAINER
TRAVENOL LABS
10%
TRAVASOL 5.5% W/O ELECTROLYTES IN PLASTIC CONTAINER
TRAVENOL LABS
5.5%
TRAVASOL 8.5% W/O ELECTROLYTES IN PLASTIC CONTAINER
TRAVENOL LABS
8.5%

N 18678
N 18684
N 18931
N 18931
N 18931

AMINO ACIDS; DEXTROSE (PAGE 3-7)

INJECTABLE; INJECTION

AMINOSYN 3.5% W/ DEXTROSE 5% IN PLASTIC CONTAINER
ABBOTT LABORATORIES 3.5%;5GM/100ML
AMINOSYN 3.5% W/ DEXTROSE 25% IN PLASTIC CONTAINER
ABBOTT LABORATORIES 3.5%;25GM/100ML
AMINOSYN 4.25% W/ DEXTROSE 25% IN PLASTIC CONTAINER
ABBOTT LABORATORIES 4.25%;25GM/100ML

N 19120
N 19118
N 19119

AMINOPHYLLINE (PAGE 3-8)

TABLET; ORAL

AMINOPHYLLINE

> DLT > /BP/ /CORD LABORATORIES/ /200MG/
> ADD > AB CORD LABORATORIES 200MG

/N' 85261/
N 85261

AMINOPHYLLINE; SODIUM CHLORIDE (PAGE 3-9)

INJECTABLE; INJECTION

AMINOPHYLLINE IN SODIUM CHLORIDE 0.45%

ABBOTT LABORATORIES 100MG/100ML;450MG/100ML

200ML/100ML;450MG/100ML

AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

ABBOTT LABORATORIES 100MG/100ML;450MG/100ML

200MG/100ML;450MG/100ML

400MG/100ML;450MG/100ML

500MG/100ML;450MG/100ML

AMINOPHYLLINE 0.45% IN SODIUM CHLORIDE 0.45%

ABBOTT LABORATORIES//50MG/100ML;450MG/100ML/

AMINOPHYLLINE 0.45% IN SODIUM CHLORIDE 0.45%

ABBOTT LABORATORIES//100MG/100ML;450MG/100ML/

AMINOPHYLLINE 0.45% IN SODIUM CHLORIDE 0.45%

ABBOTT LABORATORIES//200MG/100ML;450MG/100ML/

/N' 85147/
/N' 85147/
/N' 85147/
/N' 85147/

AMITRIPTYLINE HYDROCHLORIDE (PAGE 3-10)

TABLET; ORAL

AMITRIPTYLINE HCL

AMERICAN THERAPEUTIC 25MG

BP 50MG

BP 75MG

BP 100MG

PAR PHARMACEUTICAL 10MG

BP 25MG

BP 50MG

BP 75MG

BP 100MG

BP 150MG

STOMAK LABORATORIES 10MG

BP 25MG

BP 50MG

BP 75MG

BP 100MG

BP 150MG

SUPERPHARM 10MG

BP 25MG

BP 50MG

BP 75MG

BP 100MG

N 88672
N 88673
N 88674
N 88675
N 88697
N 88698
N 88699
N 88700
N 88701
N 88702
N 88883
N 88884
N 88885
N 88886
N 88887
N 88888
N 88853
N 88854
N 88855
N 88856
N 88857

AMOXICILLIN; POTASSIUM CLAVULANATE (PAGE 3-13)

POWDER FOR RECONSTITUTION; ORAL

AUGMENTIN '125'

BEECHAM LABS/BEECHAM 125MG/5ML;

EQ 31.25MG ACID/5ML

AUGMENTIN '250'

BEECHAM LABS/BEECHAM 250MG/5ML;EQ 62.5MG ACID/5ML

N 50575
N 50575

TABLET; ORAL

AUGMENTIN '250'

BEECHAM LABS/BEECHAM 250MG;EQ 125MG ACID

AUGMENTIN '500'

BEECHAM LABS/BEECHAM 500MG;EQ 125MG ACID

N 50564
N 50564

AMPHETAMINE SULFATE (PAGE 3-13)

TABLET; ORAL

AMPHETAMINE SULFATE

LANNETT 5MG

10MG

N 83901
N 83901

ASPIRIN; BUTALBITAL; CAFFEINE (PAGE 3-16)

TABLET; ORAL

BUTALBITAL COMPOUND

ZENITH LABORATORIES 325MG;50MG;40MG

AB

N 85441

ASPIRIN; CAFFEINE; PROPOXYPHENE HYDROCHLORIDE (PAGE 3-16)

CAPSULE; ORAL
PROPOXYPHENE COMPOUND 65
 AA ZENITH LABORATORIES 389MG;32.4MG;65MG
 AA PROPOXYPHENE HCL W/ ASPIRIN AND CAFFEINE
 AA CHELSEA LABORATORIES 389MG;32.4MG;65MG

AEROSOL; INHALATION
 TORNALATE
 WINTHROP-BREON/STERL 0.37MG/INH

N 18770

N 83077

N 85732

ASPIRIN; METHOCARBANOL (PAGE 3-17)

TABLET; ORAL
/METHOCARBANOL W/ ASPIRIN/
 METHOCARBANOL AND ASPIRIN

SYRUP; ORAL

AA BAY LABORATORIES 12.5MG/5ML;10MG/5ML
 AA ANREHYL
 AA MARION LABORATORIES 12.5MG/5ML;10MG/5ML
 AA BOCMAHYL
 AA NATL PHARM MFG/BARRE 12.5MG/5ML;10MG/5ML

N 88626

N 09319

N 88343

BENZOYL PEROXIDE; ERYTHROMYCIN (PAGE 3-21)

GEL; TOPICAL
 BENZAMYCIN
 DERNIK/RORER-AMCHEM 5%;3%
/BENZATHAZINE; RESERFINE/(PAGE 3-21)

N 50557

TABLET; ORAL
 /FAXA-R/
 /AH ROBINSON/
 /50MG;0.125MG/

/N 14861/

BETAMETHASONE DIPROPIONATE (PAGE 3-22)

OINTMENT; TOPICAL

AB ALPHATREX
 SAVAGE LABS/BYK-GLDN EQ 0.05% BASE
 BETAMETHASONE DIPROPIONATE
 AB E FOUGERA/BYK-GLDN EQ 0.05% BASE
 AB PHARMADERN/BYK-GLDN EQ 0.05% BASE
 DIPROLENE
 BX SCHERING EQ 0.05%
 DIPROSONE
 AB SCHERING EQ 0.05%

N 19143

N 19141

N 19140

N 18741

N 17691

BETAMETHASONE VALERATE (PAGE 3-22)

CREAM; TOPICAL

AB BETATREX
 /SAVAGE LABS/BYK-GLDN/EQ 0.1% BASE/
 AB SAVAGE LABS/BYK-GLDN EQ 0.1% BASE
 VALNAC
 AB NHC LABORATORIES EQ 0.1% BASE

/N 18862/

N 18862

N 70050

OINTMENT; TOPICAL

AB VALNAC
 NHC LABORATORIES EQ 0.1% BASE

N 70051

BITOLTEROL MESYLATE (PAGE 3-24)

AEROSOL; INHALATION
 TORNALATE
 WINTHROP-BREON/STERL 0.37MG/INH

BRODIPHENHYDRAMINE HYDROCHLORIDE; CODEINE PHOSPHATE (PAGE 3-24)

SYRUP; ORAL

AA BAY LABORATORIES 12.5MG/5ML;10MG/5ML
 AA ANREHYL
 AA MARION LABORATORIES 12.5MG/5ML;10MG/5ML
 AA BOCMAHYL
 AA NATL PHARM MFG/BARRE 12.5MG/5ML;10MG/5ML

BROMPHENIRAMINE MALEATE; CODEINE PHOSPHATE;
 PHENYLPROPANOLAMINE HYDROCHLORIDE (PAGE 3-25)

SYRUP; ORAL

> ADD > BIFENETANE DC
 > ADD > BAY LABORATORIES 2MG/5ML;10MG/5ML;
 > ADD > 12.5MG/5ML
 > ADD > BROMANATE DC
 > ADD > NATL PHARM MFG/BARRE 2MG/5ML;10MG/5ML;
 > ADD > 12.5MG/5ML
 > ADD > DIMETANE-DC
 > ADD > AH ROBINSON 2MG/5ML;10MG/5ML;
 > ADD > 12.5MG/5ML

N 88904

N 88723

N 11694

BROMPHENIRAMINE MALEATE; PHENYLPROPANOLAMINE HYDROCHLORIDE (PAGE 3-25)

ELIXIR; ORAL

BIFENETAP
 BAY LABORATORIES 4MG/5ML;2.5MG/5ML
 BROMANATE
 NATL PHARM MFG/BARRE 4MG/5ML;2.5MG/5ML
 /ELIXIR; DIMETAP/
 /AH ROBINSON/
 /4MG/5ML;2.5MG/5ML/
 /TABLET; CONTROLLED RELEASE; ORAL/
 /DIMETAP/
 /AH ROBINSON/
 /2MG;7.5MG/
 /EUPHEDRINE HYDROCHLORIDE/(PAGE 3-26)
 /INJECTABLE; INJECTION/
 /EUPHREX/
 /NORWICH EATON/PAGE/
 /EQ 0.5MG BASE/ML/
 /N 14861/

N 88687

N 88688

/N 14861/

/N 14861/

/N 14861/

BUTABARBITAL SODIUM (PAGE 3-26)

ELIXIR; ORAL
/SODIUM BUTABARBITAL/
BUTABARBITAL SODIUM

CAPTROPRII (PAGE 3-31)

TABLET; ORAL
CAPOTEN
ER SQUIBB AND SONS 12.5MG

N18343

CALCITONIN (PAGE 3-27)

INJECTABLE; INJECTION

CALCIHAR
/ARMOUR PHARM/
/ARMOUR PHARM/
ARMOUR PHARM
200 IU/ML
400 IU/VIAL

/N 17769/
/N 17497/
N 17769
N 17497

N 18709
N 18709
N 18709
N 18709

CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE (PAGE 3-28)

SOLUTION; INTRAPERITONEAL

AI DFLFLEX W/ DEXTROSE 1.5% IN PLASTIC CONTAINER
DELMED 25.7MG/100ML; 1.5GM/100ML;
15.2MG/100ML; 56.7MG/100ML;
392MG/100ML

N 18883

AI DFLFLEX W/ DEXTROSE 2.5% IN PLASTIC CONTAINER
DELMED 25.7MG/100ML; 2.5GM/100ML;
15.2MG/100ML; 56.7MG/100ML;
392MG/100ML

N 18883

AI DFLFLEX W/ DEXTROSE 4.25% IN PLASTIC CONTAINER
DELMED 25.7MG/100ML; 4.25GM/100ML;
15.2MG/100ML; 56.7MG/100ML;
392MG/100ML

N 18883

AI DFLFLEX W/ DEXTROSE 1.5% LOW MAGNESIUM IN PLASTIC CONTAINER
DELMED 25.7MG/100ML; 1.5GM/100ML;
5.08MG/100ML; 538MG/100ML;
448MG/100ML

N 18883

AI DFLFLEX W/ DEXTROSE 2.5% LOW MAGNESIUM IN PLASTIC CONTAINER
DELMED 25.7MG/100ML; 2.5GM/100ML;
5.08MG/100ML; 538MG/100ML;
448MG/100ML

N 18883

AI DFLFLEX W/ DEXTROSE 4.25% LOW MAGNESIUM IN PLASTIC CONTAINER
DELMED 25.7MG/100ML; 4.25GM/100ML;
5.08MG/100ML; 538MG/100ML;
448MG/100ML

N 18883

CALCIUM GLUCEPTATE (PAGE 3-30)

INJECTABLE; INJECTION

CALCIUM GLUCEPTATE
/ANTH. MEDICATION SYS//EQ 40MG CALCIUM/5ML/
/N 87455/

N 50581
N 50581

CARBACHOL (PAGE 3-31)

/solution/pkops; phthalic/
INJECTABLE; INJECTION

CEFORANIDE (PAGE 3-33)

INJECTABLE; INJECTION
PRECEF
BRISTOL LABS/B-M

N 62579
N 62579
N 62579
N 62579
N 62579

CEFOXITIN SODIUM; DEXTROSE (PAGE 3-33)

INJECTABLE; INJECTION
MEFOXIN IN DEXTROSE 5%
MS&D/MERCK
EQ 20MG BASE/ML; 50MG/ML
EQ 40MG BASE/ML; 50MG/ML

N 50581
N 50581

CEFOXITIN SODIUM; SODIUM CHLORIDE (PAGE 3-33)

INJECTABLE; INJECTION
MEFOXIN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
MS&D/MERCK
EQ 20MG BASE/ML; 9MG/ML
EQ 40MG BASE/ML; 9MG/ML

N 50581
N 50581

CEFTIZOXIME SODIUM; DEXTROSE (PAGE 3-33)

INJECTABLE; INJECTION
CEFTIZOX IN DEXTROSE 5% IN PLASTIC CONTAINER
SK&F LABORATORIES EQ 20MG BASE/ML;50MG/MLM N 50589
EQ 40MG BASE/ML;50MG/MLM N 50589

CEFTRIAXONE SODIUM (PAGE 3-33)

INJECTABLE; INJECTION
ROCEPHIN
HOFFMANN-LA ROCHE EQ 250MG BASE/VIALM N 50585
EQ 500MG BASE/VIALM N 50585
EQ 1GM BASE/VIALM N 50585
EQ 2GM BASE/VIALM N 50585
EQ 10GM BASE/VIALM N 50585

CELLULOSE SODIUM PHOSPHATE (PAGE 3-34)

POWDER; ORAL
CALCIBIND
MISSION PHARMACAL 300GM/BOTM N 18757

CHLORDIAZEPoxide HYDROCHLORIDE (PAGE 3-37)

CAPSULE; ORAL
CHLORDIAZEPoxide HCL
LEMON 5MG N 88705
10MG N 88706
25MG N 88707

CHLORPROPAMIDE (PAGE 3-42)

TABLET; ORAL
CHLORPROPAMIDE
BARR LABORATORIES 100MG N 88812
250MG N 88813
CHELSEA LABORATORIES 100MG N 86865
COLMED LABORATORIES 100MG N 88708
250MG N 88709
CORD LABORATORIES 100MG N 88725
250MG N 83726
DANBURY PHARMACAL 100MG N 88852
250MG N 88826
DURAMED PHARMS 100MG N 88918
250MG N 88919
LEMON 100MG N 88768
SUPERPHARM 100MG N 88694
ZENITH LABORATORIES 100MG N 88695
GLUCANTIDE 100MG N 88840
LEMON 250MG N 88641

CHYMOPAPAIN (PAGE 3-43)

INJECTABLE; INJECTION
CHYMODIACTIN
SMITH LABORATORIES 4,000 UNITS/VIALM N 18663

CISPLATIN (PAGE 3-44)

INJECTABLE; INJECTION
PLATINOL/
BRISTOL LABS/B-M 10MG/ML/
150MG/VIAL/
PLATINOL-AB 0.5MG/ML N 18057
BRISTOL LABS/B-M 0.5MG/ML

CLONIPHENE CITRATE (PAGE 3-45)

TABLET; ORAL
CLONID
> DLT > /BP/ /MERRELL POW/POW/CHEN/50MG/ N 16131
> ADD > AB MERRELL POW/POW/CHEN/50MG/ N 16131
> DLT > /BP/ /CLONIPHENE CITRATE /50MG/ N 18361
> ADD > AB PLANTEX/IKAPHARM /50MG/ N 18361

CLONIDINE (PAGE 3-45)

FILM, CONTROLLED RELEASE; PERCUTANEOUS
CATAPRES-TTS-1 N 18891
BOEHRINGER INGELHEIM 2.5MG N 18891
CATAPRES-TTS-2 N 18891
BOEHRINGER INGELHEIM 5MG N 18891
CATAPRES-TTS-3 N 18891
BOEHRINGER INGELHEIM 7.5MG

CODEINE PHOSPHATE; PHENYLEPHRINE HYDROCHLORIDE; PROMETHAZINE HYDROCHLORIDE (PAGE 3-46)

SYRUP; ORAL
PHEMERGAN VC W/ CODEINE 10MG/5ML;5MG/5ML;6.25MG/5ML N 08306
AA MYETH LABS/AMHO PROMETH VC W/ CODEINE N 88764
AA NATL PHARM MFG/BARRE 10MG/5ML;5MG/5ML;6.25MG/5ML N 88896
AA PRCMETHAZINE VC W/ CODEINE 10MG/5ML;5MG/5ML;6.25MG/5ML N 88896
AA BAY LABORATORIES

CODEINE PHOSPHATE; PROMETHAZINE HYDROCHLORIDE (PAGE 3-46)

SYRUP; ORAL
PHEMERGAN W/ CODEINE 10MG/5ML;6.25MG/5ML N 08306
AA MYETH LABS/AMHO

CODEINE PHOSPHATE; PROMETHAZINE HYDROCHLORIDE (PAGE 3-46)

<u>SYRUP; ORAL</u>		
<u>PROMETH HZ CODEINE</u>		
AA	NATL PHARM MFG/BARRE 10MG/5ML; 6.25MG/5ML	N 88763
<u>PROMETHAZINE HZ CODEINE</u>		
AA	BAY LABORATORIES 10MG/5ML; 6.25MG/5ML	N 88875

CODEINE PHOSPHATE; PSEUDOEPHEDRINE HYDROCHLORIDE; TRIPROLIDINE HYDROCHLORIDE (PAGE 3-46)

<u>SYRUP; ORAL</u>		
<u>ACTIFER HZ CODEINE</u>		
AA	BURROUGHS WELLCOME 10MG/5ML; 30MG/5ML; 1.25MG/5ML	N 12575
<u>PSEUDOEPHEDRINE</u>		
AA	BAY LABORATORIES 10MG/5ML; 30MG/5ML; 1.25MG/5ML	N 88833

CORTICOTROPIN (PAGE 3-47)

<u>INJECTABLE; INJECTION</u>		
<u>CORTICOTROPIN</u>		
AP	CARTER-GLOGAU LABS 40 UNITS/VIAL	N 88772

CHROMOLYN SODIUM (PAGE 3-48)

<u>SOLUTION/DROPS; OPHTHALMIC</u>		
<u>OPTICROM</u>		
	FISONS 4%	N 18155

CYPROHEPTADINE HYDROCHLORIDE (PAGE 3-51)

<u>TABLET; ORAL</u>		
<u>CYPROHEPTADINE HCL</u>		
> ADD > AA	AM THERAPEUTICS 4MG	N 88798

DESERPIDINE; METHYLCLOTHIAZIDE (PAGE 3-52)

<u>TABLET; ORAL</u>		
<u>ENDURONYL</u>		
BP	ABBOTT LABORATORIES 0.25MG; 5MG	N 12775
<u>ENDURONYL FORTE</u>		
BP	ABBOTT LABORATORIES 0.5MG; 5MG	N 12775
<u>METHYLCLOTHIAZIDE AND DESERPIDINE</u>		
BP	BOLAR PHARMACEUTICAL 0.25MG; 5MG	N 88486
BP	0.5MG; 5MG	N 88452

DESONIDE (PAGE 3-53)

<u>CREAM; TOPICAL</u>		
<u>DESONEN</u>		
AB	OWEN LABS/DERM PRODS 0.052%	N 19048
<u>TRIDESILON</u>		
AB	MILES PHARMS/MILES 0.052%	N 17010

DESOXIMETASONE (PAGE 3-53)

<u>ointment; TOPICAL</u>		
<u>TOPICORT</u>		
	HOECHST-ROUSSEL 0.052%	N 18594

DEXAMETHASONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE (PAGE 3-55)

<u>ointment; OPHTHALMIC</u>		
<u>DEXACIDIN</u>		
> ADD >	COOPERVISION PHARMS 0.12%; EQ 3.5MG BASE/GH;	N 62566
> ADD > AI	10,000 UNITS/GH	
> ADD >		

SUSPENSION/DROPS; OPHTHALMIC

<u>DEXACIDIN</u>		
AI	COOPERVISION PHARMS 0.12%; EQ 3.5MG BASE/ML;	N 62544
	10,000 UNITS/ML	

DEXAMETHASONE SODIUM PHOSPHATE (PAGE 3-55)

<u>SOLUTION/DROPS; OPHTHALMIC</u>		
<u>DEXAMETHASONE SODIUM PHOSPHATE</u>		
AI	CARTER-GLOGAU LABS EQ 0.1% PHOSPHATE	N 88771

DEXAMETHASONE SODIUM PHOSPHATE; NEOMYCIN SULFATE (PAGE 3-56)

<u>SOLUTION/DROPS; OPHTHALMIC</u>		
<u>NECDEGADRON</u>		
AI	MS&D/MERCK EQ 0.1% PHOSPHATE;	N 50322
	EQ 3.5MG BASE/ML	
<u>NEOMYCIN SULFATE-DEXAMETHASONE SODIUM PHOSPHATE</u>		
AI	PHARMAFAIR EQ 0.1% PHOSPHATE;	N 62539
	EQ 3.5MG BASE/ML	

> DLI > /DEXBROPHENTRANINE MALEATE; PSEUDOEPHEDRINE SULFATE (PAGE 3-56)

> DLI >	/TABLET; ORAL/
> DLI >	/DISOPHROL/
> DLI >	/SCHERING/

/4MG; 60MG/

/N 12344/

DEXTROMETHORPHAN HYDROBROMIDE; PROMETHAZINE HYDROCHLORIDE
(PAGE 3-57)

SYRUP; ORAL	
PHENERGAN W/ DEXTROMETHORPHAN	
AA WYETH LABS/AMHO 15MG/5ML; 6.25MG/5ML	N 11265
PROMETH W/ DEXTROMETHORPHAN	
AA NATL PHARM MFG/BARRE 15MG/5ML; 6.25MG/5ML	N 88762
PROMETHAZINE DM	
AA BAY LABORATORIES 15MG/5ML; 6.25MG/5ML	N 88864

DEXTROSE (PAGE 3-57)

INJECTABLE; INJECTION
DEXTROSE 30% IN PLASTIC CONTAINER

AP ABBOTT LABORATORIES 30GM/100ML	N 19345
AP TRAVENOL LABS 30GM/100ML	N 17521
DEXTROSE 38.5% IN PLASTIC CONTAINER	
AP ABBOTT LABORATORIES 38.5GM/100ML	N 18923
<u>DEXTROSE 60% IN PLASTIC CONTAINER</u>	
AP ABBOTT LABORATORIES 60GM/100ML	N 19346

DEXTROSE; HEPARIN SODIUM (PAGE 3-58)

INJECTABLE; INJECTION

<u>HEPARIN SODIUM 10,000 UNITS IN DEXTROSE 5%</u>	
AP ABBOTT LABORATORIES 5GM/100ML; 10,000 UNITS/100ML	N 18911
<u>HEPARIN SODIUM 1000 UNITS AND DEXTROSE 5% IN PLASTIC CONTAINER</u>	
AP AM MCGRAW/HOSP 5GM/100ML; 200 UNITS/100ML	N 19130
<u>HEPARIN SODIUM 12,500 UNITS IN DEXTROSE 5%</u>	
AP ABBOTT LABORATORIES 5GM/100ML; 5,000 UNITS/100ML	N 18911
<u>HEPARIN SODIUM 2000 UNITS AND DEXTROSE 5% IN PLASTIC CONTAINER</u>	
AP AM MCGRAW/HOSP 5GM/100ML; 200 UNITS/100ML	N 19130
<u>HEPARIN SODIUM 25,000 UNITS IN DEXTROSE 5%</u>	
AP ABBOTT LABORATORIES 5GM/100ML; 10,000 UNITS/100ML	N 18911
<u>HEPARIN SODIUM 5000 UNITS AND DEXTROSE 5% IN PLASTIC CONTAINER</u>	
AP AM MCGRAW/HOSP 5GM/100ML; 1,000 UNITS/100ML	N 19130

DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM ACETATE (PAGE 3-58)

INJECTABLE; INJECTION

<u>ISOLYTE P W/ DEXTROSE 5% IN PLASTIC CONTAINER</u>	
AM MCGRAW/HOSP 5GM/100ML; 31MG/100ML; 130MG/100ML;	N 19025
26MG/100ML; 320MG/100ML	

DEXTROSE; THEOPHYLLINE (PAGE 3-62)

INJECTABLE; INJECTION

<u>THEOPHYLLINE AND DEXTROSE 5% IN PLASTIC CONTAINER</u>	
TRAVENOL LABS	
AP 5GM/100ML; 40MG/100ML	N 18649
AP 5GM/100ML; 80MG/100ML	N 18649
AP 5GM/100ML; 160MG/100ML	N 18649
AP 5GM/100ML; 200MG/100ML	N 18649
AP 5GM/100ML; 400MG/100ML	N 18649
<u>THEOPHYLLINE 0.04% AND DEXTROSE 5% IN PLASTIC CONTAINER</u>	
AP AM MCGRAW/HOSP 5GM/100ML; 40MG/100ML	N 19083
<u>THEOPHYLLINE 0.08% AND DEXTROSE 5% IN PLASTIC CONTAINER</u>	
AP AM MCGRAW/HOSP 5GM/100ML; 80MG/100ML	N 19083
<u>THEOPHYLLINE 0.16% AND DEXTROSE 5% IN PLASTIC CONTAINER</u>	
AP AM MCGRAW/HOSP 5GM/100ML; 160MG/100ML	N 19083
<u>THEOPHYLLINE 0.2% AND DEXTROSE 5% IN PLASTIC CONTAINER</u>	
AP AM MCGRAW/HOSP 5GM/100ML; 200MG/100ML	N 19212
<u>THEOPHYLLINE 0.4% AND DEXTROSE 5% IN PLASTIC CONTAINER</u>	
AP AM MCGRAW/HOSP 5GM/100ML; 400MG/100ML	N 19212
<u>THEOPHYLLINE IN DEXTROSE 5% IN PLASTIC CONTAINER</u>	
AP ABBOTT LABORATORIES 5GM/100ML; 40MG/100ML	N 19211
AP 5GM/100ML; 80MG/100ML	N 19211
AP 5GM/100ML; 160MG/100ML	N 19211
AP 5GM/100ML; 200MG/100ML	N 19211
AP 5GM/100ML; 400MG/100ML	N 19211

DICYCLOMINE HYDROCHLORIDE (PAGE 3-64)

CAPSULE; ORAL

BENTYL	
MERRELL DOW/DOW CHEM 10MG	N 07409

INJECTABLE; INJECTION

BENTYL	
MERRELL DOW/DOW CHEM 10MG/ML	N 06370

SYRUP; ORAL

BENTYL	
MERRELL DOW/DOW CHEM 10MG/5ML	N 07961

TABLET; ORAL

BENTYL	
MERRELL DOW/DOW CHEM 20MG	N 07409

DIETHYLPROPION HYDROCHLORIDE (PAGE 3-65)

TABLET; ORAL

AA DIETHYLPROPION HCL	
LEMMON 25MG	N 88642

DIHYDROERGOTAMINE MESYLATE; HEPARIN SODIUM; LIDOCAINE HYDROCHLORIDE (PAGE 3-66)

INJECTABLE; INJECTION

EMBOLEX
SANDOZ PHARMS/SANDOZ 0.5MG/0.5ML; 2,500 UNITS/0.5ML; N 18885
5.33MG/0.5ML
0.5MG/0.7ML; 5,000 UNITS/0.7ML; N 18885
7.46MG/0.7ML

DISOPYRAMIDE PHOSPHATE (PAGE 3-68)

CAPSULE; ORAL

DISOPYRAMIDE PHOSPHATE
BIOCRAFT LABS
EQ 100MG BASE N 70101
EQ 150MG BASE N 70102

MORPAC

SEARLE PHARMS
EQ 100MG BASE N 17447
EQ 150MG BASE N 17447

DISULFIRAM (PAGE 3-68)

TABLET; ORAL

DISULFIRAM
BX PAR PHARMACEUTICAL 250MG N 88792
BX 500MG N 88793

DIVALPROEX SODIUM (PAGE 3-69)

TABLET, ENTERIC COATED; ORAL

DEPAKOTE
ABBOTT LABORATORIES EQ 125MG BASE N 18723

DOXYCYCLINE HYCLATE (PAGE 3-70)

CAPSULE; ORAL

DOXY-LEMMON
LEMMON
EQ 50MG BASE N 62497
DOXYCYCLINE HYCLATE
PAR PHARMACEUTICAL
EQ 50MG BASE N 62434
SUPERPHARM
EQ 50MG BASE N 62469
EQ 100MG BASE N 62469
WEST-WARD
EQ 50MG BASE N 62396
ZENITH LABORATORIES
EQ 50MG BASE N 62500
EQ 100MG BASE N 62500

TABLET; ORAL

DOXYCYCLINE HYCLATE
SUPERPHARM
EQ 100MG BASE N 62494
ZENITH LABORATORIES
EQ 100MG BASE N 62505

DOXYLAMINE SUCCINATE (PAGE 3-70)

TABLET; ORAL

DECAPRYN
MERRELL DOW/DOW CHEM 25MG N 06412
DOXYLAMINE SUCCINATE
QUANTUM PHARMICS 25MG N 88603

EPINEPHRINE BITARTRATE; LIDOCAINE HYDROCHLORIDE (PAGE 3-72)

INJECTABLE; INJECTION

LIGNOSPAN FORTE
DEPROCO EQ 0.02MG BASE/ML; 2% N 88389
LIGNOSPAN STANDARD
DEPROCO EQ 0.01MG BASE/ML; 2% N 88390

ERYTHROMYCIN (PAGE 3-73)

ointment; TOPICAL

AKNE-MYCIN
HERMAL PHARM LABS 2% N 50584

SOLUTION; TOPICAL

SANSAC
AT CHEN LABS/DERM PRODS 2% N 62522

> ADD >

> ADD >

> ADD >

ESTROGENS, CONJUGATED (PAGE 3-76)

TABLET; ORAL

CONJUGATED ESTROGENS
BS ZENITH LABORATORIES 0.3MG N 88569

ETHINYL ESTRADIOL; ETHYNODIOL DIACETATE (PAGE 3-78)

TABLET; ORAL-21

/DENULEN/
DENULEN 1/50-21

TABLET; ORAL-28

/DENULEN-28/
DENULEN 1/50-28

ETHINYL ESTRADIOL; LEVONORGESTREL (PAGE 3-78)

TABLET; ORAL-21

TRIPHASIL-21
MYETH LABS/AMHO
0.03MG, 0.04MG, 0.03MG;
0.05MG, 0.075MG, 0.125MG N 19192

HEPARIN SODIUM (PAGE 3-91)

INJECTABLE; INJECTABLE

AP HEP-FLUSH 10
LYPHONED 10 UNITS/MLM

AP HEPARIN LOCK FLUSH
LYPHONED 100 UNITS/MLM

AP SOLORAK LABORATORIES 10 UNITS/MLM

AP 10 UNITS/MLM

AP 100 UNITS/MLM

AP HEPARIN SODIUM
ELKINS-SINN/AHROBINS/26,444 UNITS/ML/
/26,444 UNITS/ML/
/250 UNITS/ML/

HEPARIN SODIUM; SODIUM CHLORIDE (PAGE 3-93)

INJECTABLE; INJECTION

HEPARIN SODIUM 10,000 UNITS IN SODIUM CHLORIDE 0.9%
ABBOTT LABORATORIES 10,000 UNITS/100ML;
900MG/100MLM

AP HEPARIN SODIUM 10,000 UNITS IN SODIUM CHLORIDE 0.45%
ABBOTT LABORATORIES 10,000 UNITS/100ML;
450MG/100MLM

AP HEPARIN SODIUM 12,500 UNITS IN SODIUM CHLORIDE 0.9%
ABBOTT LABORATORIES 12,500 UNITS/100ML;
900MG/100MLM

AP HEPARIN SODIUM 25,000 UNITS IN SODIUM CHLORIDE 0.9%
ABBOTT LABORATORIES 25,000 UNITS/100ML;
900MG/100MLM

AP HEPARIN SODIUM 5000 UNITS IN SODIUM CHLORIDE 0.45%
ABBOTT LABORATORIES 5,000 UNITS/100ML;
4.5MG/MLM

AP HEPARIN SODIUM 5000 UNITS IN SODIUM CHLORIDE 0.45%
ABBOTT LABORATORIES 5,000 UNITS/100ML;
4.5MG/MLM

HEXACHLOROPHENE (PAGE 3-94)

EMULSION; TOPICAL

AT TUREX

AT XTTRIUM LABS 3/4

HYDRALAZINE HYDROCHLORIDE (PAGE 3-95)

TABLET; ORAL

HYDRALAZINE HCL

AA ANIDE PHARMACEUTICAL 25MG

AA 50MG

AA ASCOT HOSP PHARMS 25MG

AA 50MG

AA CAMALL 10MG

AA 25MG

AA 50MG

AA 100MG

AA 10MG

AA 25MG

AA 50MG

SUPERPHARM

HYDROCHLOROTHIAZIDE (PAGE 3-96)

TABLET; ORAL

HYDROCHLOROTHIAZIDE

> ADD > AB 25MG

> ADD > AB 50MG

> ADD > AB 25MG

> ADD > AB 50MG

> ADD > AB 100MG

HYDROCHLOROTHIAZIDE; METOPROLOL TARTRATE (PAGE 3-98)

TABLET; ORAL

LOPRESSOR HCT 50/25

GEIGY/CIBA-GEIGY 25MG;50MG

LOPRESSOR HCT 100/25

GEIGY/CIBA-GEIGY 25MG;100MG

LOPRESSOR HCT 100/50

GEIGY/CIBA-GEIGY 50MG;100MG

HYDROCHLOROTHIAZIDE; SPIRONOLACTONE (PAGE 3-98)

TABLET; ORAL

SPIRONOLACTONE + HYDROCHLOROTHIAZIDE

AB ASCOT HOSP PHARMS 25MG;25MG

HYDROCHLOROTHIAZIDE; TIMOLOL MALEATE (PAGE 3-98)

TABLET; ORAL

Timolol/
TIMOLIDE 10-25

HYDROCHLOROTHIAZIDE; TRIAMTERENE (PAGE 3-98)

TABLET; ORAL

MAXZIDE

MYLAN PHARMS 50MG;75MG

HYDROCORTISONE (PAGE 3-99)

CREAM; TOPICAL

HYDROCORTISONE

AT THAMES PHARMACAL 2.5/4

HYTONE

/AT/ DERMIK/RORER-AMCHEM /0.5/

ointment; TOPICAL

HYTONE

/AT/ DERMIK/RORER-AMCHEM /0.5/

N 88924
N 88923
N 88827
N 88828
N 88829

N 18303
N 18303
N 18303

N 88025

N 19129

N 88799

N 80472

N 80474

HYDROCORTISONE (PAGE 3-99)

POWDER; FOR RX COMPOUNDING

H-CORT

/AA/ /PARANEX LABORATORIES/100%
/AA/ TORCH LABORATORIES 100%

/N 87834/
N 87834

TABLET; ORAL

SK-PRAHNE

/AB/ /SK&F LABORATORIES/
/AB/ /25MG/
/BP/ /50MG/
AB 10MG
AB 25MG
AB 50MG

/N 18083/
/N 18083/
/N 18083/
N 83827
N 83827
N 83827

HYDROCORTISONE ACETATE (PAGE 3-102)

/AEROSOL; TOPICAL/
/EPIFOAM/
/REED&CARNRICK PHARMS/1%
/N 86457/

HYDROCORTISONE ACETATE; PRAMOXINE HYDROCHLORIDE (PAGE 3-103)

AEROSOL; TOPICAL

EPIFOAM

REED&CARNRICK PHARMS 1%:1%

N 86457

HYDROFLUMETHIAZIDE (PAGE 3-104)

TABLET; ORAL

HYDROFLUMETHIAZIDE

AB CHELSEA LABORATORIES 50MG

N 88528

HYDROFLUMETHIAZIDE; RESERPINE (PAGE 3-104)

TABLET; ORAL

RESERPINE AND HYDROFLUMETHIAZIDE

BP ZENITH LABORATORIES 50MG;0.125MG

N 88932

HYDROXYZINE HYDROCHLORIDE (PAGE 3-105)

TABLET; ORAL

HYDROXYZINE HCL

PUREPAC/KALIPHARMA

AB 10MG
AB 25MG
AB 50MG
AB 10MG
AB 25MG
AB 50MG

N 88120
N 88121
N 88122
N 88794
N 88795
N 88796

IBUPROFEN (PAGE 3-106)

TABLET; ORAL

RUFEN

> ADD > AB
> ADD > AB
BOOTS PHARMACEUTICAL 400MG
600MG

N 70083
N 70088

IMIPRAHINE HYDROCHLORIDE (PAGE 3-107)

INDOMETHACIN (PAGE 3-108)

CAPSULE; ORAL

INDOMETHACIN

AB PAR PHARMACEUTICAL 25MG

AB 50MG

AB PARKE-DAVIS/W-L 25MG

AB 50MG

N 18829
N 18829
N 18806
N 18806

SUPPOSITORY; RECTAL

INDOCIN

MS&D RES LABS/MERCK 50MG

N 17814

INDOMETHACIN SODIUM IRIHYDRATE (PAGE 3-108)

INJECTABLE; INJECTION

INDOCIN I.V.

MS&D/MERCK

EQ 1MG BASE/VIAL

N 18878

IODOHIPPURATE SODIUM, I-123 (PAGE 3-109)

INJECTABLE; INJECTION

NEPHROFLOW

MEDI-PHYSICS

1MCI/ML

N 18289

ISOETHARINE MESYLATE (PAGE 3-110)

AEROSOL; INHALATION

BRONKOMETER

/BACON LABS/STERLING/0.61%
BACON LABS/STERLING 0.34MG/INH

BN ISOETHARINE MESYLATE

BN NATL PHARM MFG/BARRE 0.34MG/INH

/N 12339/
N 12339
N 87858

KANAMYCIN SULFATE (PAGE 3-112)

INJECTABLE; INJECTION

KANTREX

BRISTOL LABS/B-M

EQ 75MG BASE/2ML
EQ 500MG BASE/2ML
EQ 1GM BASE/3ML

N 62564
N 62564
N 62564

METHICILLIN SODIUM (PAGE 3-127)

INJECTABLE; INJECTION

/AP/ /CUBENTIN/
/BEECHAM LABS/BEECHAM/ EQ 500MG BASE/VIAL/
/EQ 3.6GM BASE/VIAL/
/EQ 5.4GM BASE/VIAL/
/EQ 7.6GM BASE/VIAL/
/EQ 9.6GM BASE/VIAL/
/AP/ /N 61493/
/AP/ /N 61493/
/AP/ /N 61493/
/AP/ /N 61493/
/AP/ /N 61493/
/AP/ /N 61493/

INJECTABLE; INJECTION

DURAMORPH PF
ELKINS-SINN/AHROBINS 0.5MG/MLM
1MG/MLM

N 18565
N 18565

NAFCILLIN SODIUM (PAGE 3-135)

INJECTABLE; INJECTION

NAFCIL
BRISTOL LABS/B-M EQ 10GM BASE/VIALM

N 62527

AP

WALLPEN
BEECHAM LABS/BEECHAM EQ 10GM BASE/VIAL

N 61999

> ADD >
> ADD > AP

METHOTREXATE SODIUM (PAGE 3-128)
INJECTABLE; INJECTION
MEXATE
BRISTOL LABS/B-M EQ 250MG BASE/VIALM
MEXATE-AQ
BRISTOL CARIB/B-M/PR EQ 25MG BASE/MLM

N 86358

N 86760

METHYLCLOTHIAZIDE (PAGE 3-129)

TABLET; ORAL

METHYLCLOTHIAZIDE
CHELSEA LABORATORIES 2.5MG
5MG

N 88750

N 88724

METRONIDAZOLE (PAGE 3-133)

INJECTABLE; INJECTION

METRONIDAZOLE
LYPHONED 500MG/100MLM
METRYL IV 500MG/100MLM
LEHNON

N 70071

N 70042

N 62339

TABLET; ORAL

METRONIDAZOLE
PAR PHARMACEUTICAL 250MG
500MG
SIDMAK LABORATORIES 250MG
500MG
SUPERPHARM 250MG
500MG
METRYL
LEHNON 250MG
METRYL 500
LEHNON 500MG

N 70040

N 70039

N 70027

N 70033

N 70008

N 70009

N 70035

N 70044

> ADD > AB

NEOMYCIN SULFATE; POLYMYXIN B SULFATE (PAGE 3-137)

SOLUTION/DROPS; OPHTHALMIC

STATROL
ALCON LABORATORIES EQ 3.5MG BASE/ML;
16,250 UNITS/MLM

N 18932

NOMIFENSINE MALEATE (PAGE 3-140)

CAPSULE; ORAL

HERITAL
HOECHST-ROUSSEL 25MG
50MG

N 18224

N 18224

NOREPINEPHRINE BITARTRATE (PAGE 3-140)

INJECTABLE; INJECTION

LEVOPHED
/BREDON LABS/STERILS//EQ 1MG BASE/ML/
WINTHROP-BREON/STERL EQ 1MG BASE/ML

/N 07513/

N 07513

MICONAZOLE NITRATE (PAGE 3-134)

SUPPOSITORY; VAGINAL

MONISTAT 3
ORTHO PHARMACEUTICAL 200MG

N 18888

NYSTATIN (PAGE 3-141)

SUSPENSION; ORAL

NYSTATIN

AA BAY LABORATORIES
AA PHARMAFAIR

100,000 UNITS/ML
100,000 UNITS/ML

N 62512
N 62541

TABLET; ORAL

NYSTATIN

AA QUANTUM PHARMICS

500,000 UNITS

N 62525

SYRUP; ORAL

PHENERSAN VC

AA HYETH LABS/AMHO

5MG/5ML; 6.25MG/5ML

N 08604

PHENETH VC PLAIN

AA NATL PHARM MFG/BARRE

5MG/5ML; 6.25MG/5ML

N 88761

PROMETHAZINE VC PLAIN

AA BAY LABORATORIES

5MG/5ML; 6.25MG/5ML

N 88897

OXYTRIPHYLLINE (PAGE 3-143)

ELIXIR; ORAL

CHOLEDYL

AA PARKE-DAVIS/M-L

100MG/5ML

N 09268

OXYTRIPHYLLINE

AA BAY LABORATORIES

100MG/5ML

N 88243

INJECTABLE; INJECTION

PHENYTOIN SODIUM

AP SOLOPAK LABORATORIES

50MG/ML

N 88519

AP 50MG/ML

N 88520

AP 50MG/ML

N 88521

OXYPHENBUTAZONE (PAGE 3-143)

TABLET; ORAL

OXYPHENBUTAZONE

AB BOLAR PHARMACEUTICAL

100MG

N 88399

TANDERIL

AB GEIGY/CIBA-GEIGY

100MG

N 12542

CAPSULE; ORAL

DILANTIN

AB PARKE-DAVIS/M-L

100MG

N 84349

EXTENDED PHENYTOIN SODIUM

AB BOLAR PHARMACEUTICAL

100MG

N 88711

PENTAMIDINE ISETHIONATE (PAGE 3-148)

INJECTABLE; INJECTION

PENTAM 300

LYPHOMED

300MG/VIAL

N 19264

PILOCARPINE HYDROCHLORIDE (PAGE 3-154)

GEL; OPHTHALMIC

PILOPINE HS

ALCON LABORATORIES

4%

N 18796

PENTOXIFYLLINE (PAGE 3-149)

TABLET, CONTROLLED RELEASE; ORAL

TRENTAL

HOECHST-ROUSSEL

400MG

N 18631

PHENTERMINE HYDROCHLORIDE (PAGE 3-151)

CAPSULE; ORAL

PHENTERMINE HCL

AA PHARM BASICS

30MG

N 88797

POWDER FOR RECONSTITUTION; ORAL

COLYTE

EDLAW PREPARATIONS

120GM/PACKET; 1.49GM/PACKET;

3.36GM/PACKET; 2.92GM/PACKET;

11.36GM/PACKET

N 18983

227.1GM/PACKET; 2.82GM/PACKET;

6.36GM/PACKET; 5.53GM/PACKET;

21.5GM/PACKET;

360GM/PACKET; 4.47GM/PACKET;

10.09GM/PACKET; 8.76GM/PACKET;

34.08GM/PACKET

N 18983

POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM SULFATE (PAGE 3-155)

POTASSIUM CHLORIDE (PAGE 3-156)

INJECTABLE; INJECTION
POTASSIUM CHLORIDE IN PLASTIC CONTAINER
 AP INVENEX LABS/LIFE 2MEQ/MLM
 AP 2MEQ/MLM

N 88901
 N 88908

PREDNISOLONE (PAGE 3-159)

TABLET; ORAL
 PREDNISOLONE
 BX SUPERPHARM 5MG

N 88892

PREDNISOLONE ACETATE; SULFACETAMIDE SODIUM (PAGE 3-160)

ointment; OPHTHALMIC
 PREDNISOLONE
 AT PHARMAFAIR 0.5%; 10%
 VASODOLIN
 AT COOPERVISION PHARMS 0.5%; 10%

N 88032
 N 88791

PREDNISONE (PAGE 3-161)

SOLUTION; ORAL
 PREDNISONE
 ROXANE LABORATORIES 5MG/5MLM
 PREDNISONE INTENSOL
 ROXANE LABORATORIES 5MG/MLM

N 88703
 N 88810

TABLET; ORAL
 PREDNISONE
 BX SUPERPHARM 5MG
 BX 10MG
 BX 20MG

N 88865
 N 88866
 N 88867

PROCAINAMIDE HYDROCHLORIDE (PAGE 3-163)

TABLET, CONTROLLED RELEASE; ORAL
 PROCAINAMIDE HCL
 BOLAR PHARMACEUTICAL 250MG
 500MG
 750MG

AB
 AB
 AB
 /BC/
 PARKE-DAVIS/M-L 500MG/
 500MG
 250MG
 750MG
 1GM

N 88533
 N 88534
 N 88535
 N 88468
 N 88068
 N 88465
 N 87510
 N 88489

PROCHLORPERAZINE EDISYLATE (PAGE 3-164)

CONCENTRATE; ORAL
 PROCHLORPERAZINE EDISYLATE
 AA BAY LABORATORIES EQ 10MG BASE/MLM

N 88598

SYRUP; ORAL
 PROCHLORPERAZINE EDISYLATE
 AA BAY LABORATORIES EQ 5MG BASE/5MLM

N 88597

PROMETHAZINE HYDROCHLORIDE (PAGE 3-165)

SYRUP; ORAL
 /BAYMETHAZINE/
 PROMETHAZINE PLAIN

PROPOXYPHENE HYDROCHLORIDE (PAGE 3-167)

CAPSULE; ORAL
 PROPOXYPHENE HCL
 AA LEMMON 65MG

N 88615

PROTAMINE SULFATE (PAGE 3-168)

INJECTABLE; INJECTION
 PROTAMINE SULFATE
 UPJOHN 250MG/VIALM

N 07413

PSEUDOEPHEDRINE HYDROCHLORIDE; TRIPROLIDINE HYDROCHLORIDE (PAGE 3-169)

SYRUP; ORAL
 TRILITRON
 NENTRON PHARMS 30MG/5ML; 1.25MG/5MLM
 TRIPROLIDINE HCL AND PSEUDOEPHEDRINE HCL
 PHARMAFAIR 30MG/5ML; 1.25MG/5MLM

N 88474
 N 88541

TABLET; ORAL
 ALLERFEED

AA PRIVATE FORMULATIONS 60MG; 2.5MG
 TRILITRON
 NENTRON PHARMS 60MG; 2.5MG
 TRIPROLIDINE HCL AND PSEUDOEPHEDRINE HCL
 SUPERPHARM 60MG; 2.5MG
 ZENITH LABORATORIES 60MG; 2.5MG

N 88860
 N 88515
 N 88578
 N 85273

QUINIDINE SULFATE (PAGE 3-170)

TABLET; ORAL
 CIN-QUIN
 /AB/ ROHELL LABORATORIES /200MG/

N 87255/

RANITIDINE HYDROCHLORIDE (PAGE 3-171)

INJECTABLE; INJECTION
ZANTAC
GLAXO

EQ 25MG BASE/MLM

N 19090

SODIUM LACTATE (PAGE 3-178)

INJECTABLE; INJECTION
SODIUM LACTATE IN PLASTIC CONTAINER
ABBOTT LABORATORIES 5HEQ/MLM

N 18947

RIOTIDINE HYDROCHLORIDE (PAGE 3-173)

INJECTABLE; INJECTION
/RIOTIDINE HCL/
/AP/ /DUPHAR LABS/
YUTOPAR

/10MG/ML/

/N 18880/

/AP/ ASTRA PHARM PRODS
10MG/ML
15MG/MLM

N 18580
N 18580

TABLET; ORAL

/RIOTIDINE HCL/
/AP/ /DUPHAR LABS/
YUTOPAR

/10MG/

/N 18880/

/AP/ ASTRA PHARM PRODUCTS 10MG

N 18555

SAFFLOWER OIL; SOYBEAN OIL (PAGE 3-174)

INJECTABLE; INJECTION
LIPOSYN II 10%
ABBOTT LABORATORIES 5X:5X
LIPOSYN II 20%
ABBOTT LABORATORIES 10X:10X

N 18997

N 18991

SCOPOLAMINE (PAGE 3-174)

FILM, CONTROLLED RELEASE; PERCUTANEOUS
/TRANSDERM-V/
/AP/ /CIBA/

/1.5MG/

/N 17874/

TRANSDERM-SCOP

CIBA/CIBA-GEIGY

N 17874

SODIUM CHLORIDE (PAGE 3-176)

INJECTABLE; INJECTION
BACTERIOSTATIC SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
ABBOTT LABORATORIES 9MG/ML
INVENEX LABS/LIFE 9MG/MLM

N 18800

N 88909

N 88911

SODIUM CHLORIDE IN PLASTIC CONTAINER
/AM MCGAN/AM HOSP/ /30MG/100ML/

/N 17464/

SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

AM MCGAN/AM HOSP

N 17464

INVENEX LABS/LIFE

N 88912

SULFABENZAMIDE; SULFACETAMIDE; SULFATHIAZOLE (PAGE 3-181)

TABLET; VAGINAL
SULTRIN

N 05794

AT ORTHO PHARMACEUTICAL 184MG;143.75MG;172.5MG

TRIPLE SULFA

N 88463

AT E FOUGERA/ALTANA 184MG;143.75MG;172.5MG

N 88462

AT PHARMADERM/ALTANA 184MG;143.75MG;172.5MG

SUCCINYLCHOLINE CHLORIDE (PAGE 3-181)

INJECTABLE; INJECTION

SUCCHYLCHOLINE CHLORIDE

/AP/ /TRAVENOL LABS/ /50MG/VIAL/
/AP/ /TRAVENOL LABS/ /10MG/VIAL/

/N 80263/
/N 80263/

SULFAMETHOXAZOLE; TRIMETHOPRIM (PAGE 3-183)

TABLET; ORAL	
<u>SULFAMETHOPRIM</u>	
> ADD > AB	
> ADD > AB	PAR PHARMACEUTICAL 400MG; 80MG
> ADD > AB	SULFAMETHOPRIM-DS
> ADD > AB	PAR PHARMACEUTICAL 800MG; 160MG
	<u>SULFAMETHOXAZOLE & TRIMETHOPRIM</u>
AB	HEATHER DRUG 400MG; 80MG
AB	800MG; 160MG
AB	<u>SULFAMETHOXAZOLE AND TRIMETHOPRIM</u>
AB	BARR LABORATORIES 400MG; 80MG
AB	<u>SULFAMETHOXAZOLE AND TRIMETHOPRIM DOUBLE STRENGTH</u>
AB	BARR LABORATORIES 800MG; 160MG
AB	<u>TRIMETH/SULFA D/S</u>
AB	CHELSEA LABORATORIES 800MG; 160MG
AB	<u>TRIMETH/SULFA S/S</u>
AB	CHELSEA LABORATORIES 400MG; 80MG

TERBUTALINE SULFATE (PAGE 3-187)

AEROSOL; INHALATION
BRETHAIRE
GEIGY/CIBA-GEIGY 0.2MG/INH

THEOPHYLLINE (PAGE 3-190)

CAPSULE; ORAL	
> ADD > BP	<u>SOMOPHYLLIN-T</u>
> ADD > BP	FISONS 100MG
> ADD > BP	200MG
> ADD >	250MG
CAPSULE, CONTROLLED RELEASE; ORAL	
BC	<u>ELIXOPHYLLIN SR</u>
BC	BERLEX/SCHERING 125MG
	250MG
BC	<u>SLO-BID</u>
BC	WILLIAM H RORER 50MG
BC	100MG
BC	200MG
BC	300MG
BC	<u>SLO-PHYLLIN</u>
BC	WILLIAM H RORER 125MG
	<u>SOMOPHYLLIN-CRT</u>
> ADD > BC	FISONS 200MG
> ADD > BC	300MG
> ADD >	50MG
> ADD >	<u>THEO-24</u>
> ADD > BC	SEARLE/SEARLE PHARMS 200MG
> ADD > BC	300MG
> ADD >	<u>THEOPHYL-SR</u>
> ADD > BC	MCNEIL PHARM 125MG
> ADD >	250MG

THEOPHYLLINE (PAGE 3-190)

CAPSULE, CONTROLLED RELEASE; ORAL	
N 70022	<u>THEOPHYLLINE</u>
> ADD > BC	CENTRAL PHARMS 125MG
> ADD > BC	250MG
N 70032	<u>THEOVENT</u>
N 18946	BC 125MG
N 18946	BC 250MG
N 70006	<u>THEOCHRON</u>
> ADD > BC	FOREST LABORATORIES 100MG
> ADD > BC	200MG
N 70007	
N 70000	
N 70002	

THIORIDAZINE HYDROCHLORIDE (PAGE 3-192)

TABLET; ORAL	
AB	<u>THIORIDAZINE HCL</u>
AB	BARR LABORATORIES 150MG
AB	200MG
> ADD > AB	CORD LABORATORIES 100MG
	ROXANE LABORATORIES 100MG
N 18762	

TOBRAMYCIN (PAGE 3-194)

SOLUTION/DROPS; OPHTHALMIC
TOBREX
ALCON LABORATORIES 0.3%

TOCAINIDE HYDROCHLORIDE (PAGE 3-194)

TABLET; ORAL	
N 86826	<u>TONOCARD</u>
N 86826	MS&D/MERCK 400MG
	600MG
N 88269	
N 87892	
N 87893	
N 87894	
N 85203	<u>TOLAZAMIDE (PAGE 3-194)</u>
N 88302	<u>TOLAZAMIDE</u>
N 88302	ZENITH LABORATORIES 100MG
N 87763	AB 250MG
N 87763	AB 500MG
N 87943	<u>TOLINASE</u>
N 87944	UPJOHN 100MG
N 86480	AB 250MG
N 86471	AB 500MG

> ADD > TOLAZOLINE HYDROCHLORIDE (PAGE 3-194)

> ADD > INJECTABLE; INJECTION
 > ADD > PRISCOLINE
 > ADD > CIBA/CIBA-GEIGY 25MG/MLM
 > ADD > SYRUP; ORAL
 > ADD > TRIPROLINE HCL
 > ADD > AA HALSEY DRUG 1.25MG/5MLM N 88735

TOLBUTAMIDE (PAGE 3-194)

TABLET; ORAL
TOLENTAMIDE
 AB SUPERPHARM 500MG N 88893
 SUSPENSION; ORAL
 /TRIPLE Sulfam/
 /AB/ /VALE. CHEMICAL/ /500MG/5ML/ /N. 80167/

TOLMETIN SODIUM (PAGE 3-194)

CAPSULE; ORAL
 TOLECTIN DS
 /MCNEIL LABORATORIES//EQ. 400MG BASE/
 MCNEIL PHARM EQ 400MG BASE
 > DLT > /N. 18084/
 > ADD > N 18084

TABLET; ORAL

TOLECTIN
 /MCNEIL LABORATORIES//EQ. 200MG BASE/
 MCNEIL PHARM EQ 200MG BASE
 > DLT > /N. 17628/
 > ADD > N 17628

TRIAMCINOLONE ACETONIDE (PAGE 3-195)

CREAM; TOPICAL
 ARISTOCERT A
 LEDERLE LABS/AM CYAN 0.025%
 AT 0.1%
 AT 0.5%
 AT
 OINTMENT; TOPICAL
 ARISTOCERT A
 LEDERLE LABS/AM CYAN 0.1%
 AT 0.5%
 AT
 TRIAMCINOLONE ACETONIDE
 AT PHARMADERN/BYK-GLDN 0.025%
 AT 0.1%
 AT
 TRYMEX
 AT SAVAGE LABS/BYK-GLDN 0.025%
 AT 0.1%
 AT

TRILOSTANE (PAGE 3-199)

CAPSULE; ORAL
 MODRASTANE
 WINTHROP LABS/STERL 30MG
 60MG
 N 18719
 N 18719

TRIPROLIDINE HYDROCHLORIDE (PAGE 3-200)

SYRUP; ORAL
TRIPROLIDINE HCL
 AA HALSEY DRUG 1.25MG/5MLM N 88735

TRISULFAPYRIMIDINES (PAGE 3-200)

SUSPENSION; ORAL
 /TRIPLE Sulfam/
 /AB/ /VALE. CHEMICAL/ /500MG/5ML/ /N. 80167/

VECURONIUM BROMIDE (PAGE 3-202)

INJECTABLE; INJECTION
 /NORCURON (NC-45)/
 NORCURON
 > DLT > /N. 18084/
 > ADD > N 18084

VERAPAMIL HYDROCHLORIDE (PAGE 3-202)

TABLET; ORAL
 CALAN
 AB SEARLE/SEARLE PHARMS 80MG
 AB 120MG
 ISOPTIN
 AB KNOLL PHARMACEUTICAL 80MG
 AB 120MG
 N 18817
 N 18817
 N 18593
 N 18593

DESI PENDING LIST - 'EXEMPT' (COURT ORDER) CATEGORY
 CUMULATIVE SUPPLEMENT NUMBER 6 / AUGUST '84 - FEBRUARY '85

/ISOSORBIDE DINITRATE/ (PAGE AD5)
 (ALL PRODUCTS - SEE SPECIAL NOTE B.)

/TABLETS, ORAL/
 /ISOSORBIDE DINITRATE/
 /BARR. LABORATORIES/ /10mg/
 /N'87564/

/ISOSORBIDE DINITRATE/ (PAGE AD5)
 (ALL PRODUCTS - SEE SPECIAL NOTE B.)

/TABLETS, SUBLINGUAL/
 /ISOSORBIDE DINITRATE/
 /BARR. LABORATORIES/ /10mg/
 /N'87565/

/TABLETS, CONTROLLED RELEASE, ORAL/
 /ISOSORBIDE DINITRATE/
 /FOREST. LABORATORIES/ /20mg/
 /N'88428/

NITROGLYCERIN (PAGE AD7)

/CAPSULES, CONTROLLED RELEASE, ORAL/
 (ALL PRODUCTS - SEE SPECIAL NOTE B.)

/TABLETS, CONTROLLED RELEASE, ORAL/
 (ALL PRODUCTS - SEE SPECIAL NOTE B.)

CURRENT STATUS - INEFFECTIVE

CURRENT STATUS - INEFFECTIVE

/BENTON, W. /PHENOBARBITAL/ /MERRELL, DON/DON CHEN/
 /DICLOFENAC HYDROCHLORIDE, PHENOBARBITAL/

TUSS-ORNADE SK&F LABORATORIES
 CARAMIPHEN EDISYLATE; CHLORPHENTIRAMINE MALEATE;
 ISOPROPANIDE IODIDE; PHENYLPROPANOLAMINE HYDROCHLORIDE

BEROCCA C HOFFMANN-LA ROCHE
 ASCORBIC ACID; BIOTIN; DEXPANTHENOL; NIACINAMIDE; PYRIDOXINE
 HYDROCHLORIDE; RIBOFLAVIN; THIAMINE HYDROCHLORIDE

BEROCCA C 500 HOFFMANN-LA ROCHE
 ASCORBIC ACID; BIOTIN; DEXPANTHENOL; NIACINAMIDE; PYRIDOXINE
 HYDROCHLORIDE; RIBOFLAVIN; THIAMINE HYDROCHLORIDE

M.V.I. PEDIATRIC USV PHARMACEUTICAL
 ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL;
 ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PHYTONADIONE;
 PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN PHOSPHATE SODIUM;
 THIAMINE HYDROCHLORIDE; VITAMIN A; VITAMIN E

DIMETAPP AH ROBINS
 BRONCHOPHENTIRAMINE MALEATE; PHENYLEPHRINE HYDROCHLORIDE;
 PHENYLPROPANOLAMINE HYDROCHLORIDE

> DLT > /CETACORT/ /OMEN, LABS/DERM, PRODS/
 > DLT > /HYDROCORTISONE/

ELIXIR DIMETAPP AH ROBINS
 BRONCHOPHENTIRAMINE MALEATE; PHENYLEPHRINE HYDROCHLORIDE;
 PHENYLPROPANOLAMINE HYDROCHLORIDE

> DLT > /HC (HYDROCORTISONE)/ /C. AND, N. PHARMACAL/
 > DLT > /HYDROCORTISONE/

> DLT > /HYDROCORTISONE/ /TOMME, PAULSEN/
 > DLT > /HYDROCORTISONE/

> DLT > /ILAC, CH/ /ELI, LILLY/
 > DLT > /ERYTHROMYCIN/

> DLT > /NEOSPORIN'S/ /BURROUGHS, WELLCOME/
 > DLT > /GRANICIDIN, NEOMYCIN SULFATE, POLYMYXIN B, SULFATE/

/TERRA-CORTIL/ /PRIZER, LABS/PRIZER/
 /HYDROCORTISONE, DEXTETRAACETYL, HCL/

> DLT > /NUTRACORT/ /OMEN, LABS/DERM, PRODS/
 > DLT > /HYDROCORTISONE/

> DLT > /PRISCOLINE/ /CIBA/CIBA-GEIGY/
 > DLT > /TOLAZOLINE, HYDROCHLORIDE/

ADDENDUM D: DRUG PRICE COMPETITION AND PATENT TERM RESTORATION

On September 24, 1984, the President signed into law the Drug Price Competition and Patent Term Restoration Act of 1984. The Act amends section 505 of the Federal Food, Drug and Cosmetic Act, authorizing the Agency to accept abbreviated new drug applications for most previously approved drug products. This new legislation also provides for extending the term of a patent which claims a product, use, or method of manufacture that was subject to a regulatory review period in accordance with the Act.

The statute requires that FDA make publicly available a list of approved drug products containing the following information:

- 1) an alphabetical list of all drugs by official and proprietary name approved for safety and effectiveness, with monthly updates;
- 2) the application number and approval date for each drug product approved from January 1, 1982; and
- 3) whether in vitro and/or in vivo bioequivalence studies are required for ANDA approval.

The Approved Prescription Drug Products with Therapeutic Equivalence Evaluations, 5th Edition, (APDP) and its monthly supplements will be used to satisfy this new requirement.

In addition, the APDP will identify drugs which qualify under the new statute for periods of exclusivity (during which ANDAs and paper NDAs for those drugs may not be submitted or made effective as identified below) and will provide information on the current patent status of the listed drugs. Exclusivity prevents the filing and/or approval of ANDAs or paper NDAs. It does not prevent the filing or approval of a second full NDA. Applications qualifying for periods of exclusivity are:

- (1) A new drug application approved between January 1, 1982, and September 24, 1984, for a drug product all active ingredients (including any ester or salt of the active ingredient) of which had never been approved in any other application. Approval of an ANDA or paper NDA for the same drug may not be made effective for a period of ten years from the date of the approval of the original application.

- (2) A new drug application approved after September 24, 1984, for a drug product all active ingredients (including any ester or salt of the active ingredient) of which had never been approved in any other new drug application. Generally, no subsequent ANDA or paper NDA for the same drug may be submitted for a period of five years from the date of approval of the original application, except that such an application may be submitted after four years if it contains a certification that a patent claiming the drug is invalid or will not be infringed by the product for which approval is sought.
- (3) A new drug application approved after September 24, 1984, for a drug product involving an active ingredient (or any ester or salt of that active ingredient) that has been approved in an earlier new drug application and which includes reports of new clinical investigations (other than bioavailability studies). Such investigations must have been conducted or sponsored by the applicant or for which the applicant had a right of reference, and the investigations must have been essential to approval of the application. If these requirements are met, the approval of a subsequent ANDA or paper NDA may not be made effective for the same drug before the expiration of three years from the date of approval of the original application.
- (4) A supplement to a new drug application approved after September 24, 1984, which contains reports of new clinical investigations (other than bioavailability studies) essential to the approval of the supplement and conducted or sponsored by the applicant or to which the applicant had a right of reference. The approval of a subsequent application for a change approved in the supplement may not be made effective for three years from the date of approval of the original supplement.
- (5) A new drug application (or supplement to a new drug application) approved during the period from January 1, 1982, to September 24, 1984, which includes an active ingredient (including any ester or salt of the active ingredient) that has been approved in another application. The approval of a subsequent application for the drug or a significant change made in a supplement may not be made effective for two years from September 24, 1984.

The Act required approved new drug applications to be supplemented with the required patent information by October 24, 1984. Patent information must now be filed with all newly submitted drug applications, and no NDA may be approved after September 24, 1984, without the pertinent patent information. The patent numbers and the expiration dates of any appropriate product or use patent on a marketed drug that is the subject of an approved NDA will be published in the APDP. Patent information on unapproved applications or on patents beyond the scope (i.e., process or manufacturing) of the Act will not be published.

The following explains how the APDP implements this.

Antibiotics, Insulin and Biologicals

Title I of the Act has been interpreted by the Agency not to include products approved under sections 506 or 507 of the Federal Food, Drug and Cosmetic Act (antibiotic and insulin products). Because of this, (1) antibiotic and insulin products are not considered eligible for exclusivity protection, (2) holders of approved applications for insulin and antibiotic products need not submit the patent information as required of NDA application holders, and (3) Antibiotic Form 6 sponsors are not required to provide the patent certification statement which must be included in ANDAs.

However, Title II, the patent term restoration portion of the Act, specifically addresses antibiotic, non-antibiotic, and human biological products (as those terms are used in the Federal Food, Drug and Cosmetic and Public Health Service Acts) in its provisions.

Bioavailability/Bioequivalence Requirements

The therapeutic equivalence evaluation codes in Appendix D of the APDP will enable firms to determine whether in vitro and/or in vivo bioavailability/bioequivalence study data must be included with their ANDA submissions.

Currently, drugs approved prior to 1962 fall into three major biopharmaceutic classes: (1) those which pose an actual or potential bioequivalence problem, and for which demonstration of bioequivalence through in vivo testing and acceptable dissolution performance is necessary; (2) those which pose an actual or potential bioequivalence problem but for which an in vivo study may be waived if acceptable dissolution performance is demonstrated (the list of such drugs is provided under TABLE I); and (3) those which pose no actual or potential bioequivalence problem and for which the only biopharmaceutic requirement is demonstration of acceptable dissolution for solid oral dosage forms.

All firms submitting an abbreviated new drug application for a single source drug product or a drug product which was first approved after 1962 will be required to demonstrate in vivo bioequivalence or else submit information sufficient to permit the Agency to waive demonstration of in vivo bioequivalence. Manufacturers of drug products formulated in dosage forms which do not present bioequivalence problems, such as an intravenous solution, may request that the in vivo bioequivalence requirement be waived.

Before the passage of the Drug Price Competition and Patent Term Restoration Act, the Agency approved various drugs with bioavailability/bioequivalence problems and deferred the in vivo testing requirement for a number of reasons. The new law requires information to show that the proposed ANDA drug product is bioequivalent to the listed drug. Therefore, new applications for drugs such as amitriptyline hydrochloride which formerly may have been approved without an in vivo study now require an in vivo study as a condition for approval under the new Act.

Topicals

In the absence of contrary data, FDA regarded all pharmaceutically equivalent topical products of pre-1962 (DESI) drugs to be therapeutically equivalent. However, the Agency required that applicants for topical drug products initially approved after 1962, including "paper NDAs," either demonstrate the safety and efficacy of their products through clinical trials or through a bioequivalence study in order to be approved and evaluated as therapeutically equivalent.

The new Act requires applicants to demonstrate the bioequivalence of their topical drug product to the listed drug as one of the requirements for ANDA approval. This is the same policy that is presently being used in the "paper NDA" approval process. The Agency is now reviewing the therapeutic equivalence evaluation policy that has been made on the pre-1962 topical products to determine whether a change in this policy is warranted. In the meantime, an in vivo demonstration of bioequivalence will be required for approval of all topical products unless a waiver or in vitro alternatives can be justified by the applicant.

OTC Drug Products Eligible for Abbreviated New Drug Applications

Previous editions of the APDP excluded OTC drug products, because the main purpose of that publication was to provide information to states regarding FDA's recommendation as to which generic prescription drug products were acceptable candidates for drug product selection. With the passage of the Drug Price Competition and Patent Term Restoration Act of 1984, the Agency now has the responsibility to publish an up-to-date list of all marketed drug products, OTC as well as prescription, that have been approved for safety and efficacy and for which new drug applications are required. There are some drugs for which there are both approved and unapproved OTC drug products in the market place. This situation occurs as a result of the Agency's current OTC compliance policy which allows the marketing of various unapproved OTC drug products pending the effective date of the applicable final OTC monograph. The OTC products included in APDP cumulative supplement TABLE II are limited to those for which approved applications are currently required as a condition of marketing. Appropriate patent numbers, exclusivity information, and expiration dates are also included.

NDA's Approved by the Office of Biological Research and Review Not Previously Published in the APDP

All products accepted and approved under Section 505 of the Act as NDAs by the Office of Biological Research and Review (OBRR) will now be published in the APDP (see TABLE III). The application holder should have submitted relevant patent and exclusivity information as for other NDA drug products. These products will be listed drugs and ANDA applications may be submitted for marketing of drugs from this group. Appropriate patent numbers, exclusivity information, and expiration dates are also included.

Patent and Exclusivity Information

It was originally planned that TABLE IV of Cumulative Supplement 2 to the APDP would contain patent and exclusivity information. Because some firms submitted patent information in excess of that covered by the statute, FDA has reviewed all of the patent information to assure that only appropriate patents are listed. The patents that FDA regards as covered by the statutory provisions for submission of patent information are those on the active ingredient or ingredients, or use patents for a particular indication or method of using the product. The Agency will not publish patents relating to chemical intermediates, methods of manufacturing, excipients or formulations. TABLE IV contains patent numbers and expiration dates and, for drug products approved after 1982, the date of approval and application number as required by the Act.

Firms submitting ANDAs after September 24, 1984, that certified that no patent information had been filed should now amend their applications with the appropriate patent certification statement.

TABLES II-IV now identify all drugs which qualify under the new statute for periods of exclusivity. (See pages A-1 & A-2 of the Addendum for an explanation of exclusivity).

FDA has finished reviewing all patent and exclusivity information received initially from interested parties. The Agency believes TABLES II-IV now contain all appropriate patent and exclusivity information that the Agency regards as being covered by the new statute. This table will be updated monthly to include appropriate patent and exclusivity information for new approvals. The exclusivity information column in TABLES II-IV designates the date on which the exclusivity ends and the basis for the exclusivity through the use of codes as explained on pages A-6 and A-7.

FDA invites comments from all interested parties on whether it has excluded any patent or exclusivity information that should have been included, or included patent or exclusivity information that should have been excluded. Any revisions to the list will be published in subsequent supplements.

DO TO SPACE LIMITATIONS IN THE EXCLUSIVITY COLUMNS OF TABLES I-IV THE FOLLOWING ABBREVIATIONS HAVE BEEN DEVELOPED. PLEASE REFER BACK TO THIS PAGE FOR AN EXPLANATION OF THE EXCLUSIVITY ABBREVIATIONS FOUND IN THE TABLES.

ABBREVIATIONS

NC	NEW COMBINATION
NCE	NEW CHEMICAL ENTITY
NDF	NEW DOSAGE FORM
NE	NEW ESTER OR SALT OF AN ACTIVE INGREDIENT
NP	NEW PRODUCT
NR	NEW ROUTE
PP	PARENTERAL IN PLASTIC CONTAINER
RTO	PRESCRIPTION TO OTC STATUS CHANGE
NS	NEW STRENGTH
D	NEW DOSING SCHEDULE (SEE REFERENCE, BELOW)
I	NEW INDICATION (SEE REFERENCE, BELOW)

REFERENCES

NEW DOSING SCHEDULE

D-1	ONCE A DAY APPLICATION
D-2	ONCE DAILY DOSING
D-3	SEVEN DAYS/SEVEN DAYS/SEVEN DAYS DOSING SCHEDULE
D-4	SEVEN DAYS/FOURTEEN DAYS DOSING SCHEDULE
D-5	TEN DAYS/ELEVEN DAYS DOSING SCHEDULE
D-6	SEVEN DAYS/NINE DAYS/FIVE DAYS DOSING SCHEDULE
D-7	BID DOSING
D-8	INTRAVENOUS, EPIDURAL AND INTRATHECAL DOSING

INDICATIONS

I-1	SEVERE HYPERTENSION IN PEDIATRICS AND NON-MALIGNANT HYPERTENSION
I-2	DYSMENORRHEA
I-3	TREATMENT OF TINEA VERSICOLOR
I-4	SYMPTOMATIC GASTROESOPHAGEAL REFLUX
I-5	NEPHROTOMOGRAPHY
I-6	CONTRAST ENHANCEMENT IN CRANIAL COMPUTED TOMOGRAPHY
I-7	VENOGRAPHY OF LOWER EXTREMITIES
I-8	WHOLE-BODY COMPUTED TOMOGRAPHY
I-9	GATED CARDIAC POOL IMAGING
I-10	POST-MYOCARDIAL INFARCTION
I-11	COLORECTAL SURGERY
I-12	NAUSEA AND VOMITING ASSOCIATED WITH EMETOGENIC CANCER CHEMOTHERAPY
I-13	CISPLATIN INDUCED EMESIS
I-14	DIABETIC GASTROPARESIS
I-15	POST-MYOCARDIAL INFARCTION
I-16	ACROMEGALY
I-17	PITUITARY TUMORS
I-18	POSTMENOPAUSAL OSTEOPOROSIS
I-19	ANTIDOTE FOR ACETAMINOPHEN OVERDOSAGE
I-20	CONGESTIVE HEART FAILURE BID DOSAGE SCHEDULE
I-21	ACUTE OTITIS MEDIA
I-22	EXERCISE INDUCED BRONCHOSPASMS
I-23	MI OR STROKE
I-24	COMBINED USE WITH NICOTINIC ACID TO LOWER CHOLESTEROL LEVEL
I-25	BLASTOMYCOSES DERMATITIDES
I-26	PEDIATRIC SUBARACHNOID VASCULAR
I-27	PETRIELLIDIUM BOYDII INFECTION
I-28	HEREDITARY ANGIOEDEMA
I-29	INTRACORONARY USE
I-30	PEDIATRIC USE
I-31	DIRECT ISOTOPIC CYSTOGRAPHY

TABLE I. LIST OF DRUG PRODUCTS WHICH MUST DEMONSTRATE IN VIVO BIOAVAILABILITY ONLY IF PRODUCT FAILS TO ACHIEVE ADEQUATE DISSOLUTION

ACETAMINOPHEN; ASPIRIN; BUTALBITAL; TABLET; ORAL CAPSULE OR TABLET; ORAL 160-165MG; 160-165MG; 50MG	AMINOPHYLLINE TABLET; ORAL 100MG 200MG	ASPIRIN; MEPROBANATE TABLET; ORAL 325MG; 200MG
ACETAMINOPHEN; ASPIRIN; BUTALBITAL; CAPSULE OR TABLET; ORAL 325MG; 325MG; 50MG	ASPIRIN; BUTALBITAL; CAPSULE OR TABLET; ORAL 325; 50MG 650; 50MG	ASPIRIN; METHOCARBAMOL TABLET; ORAL 325MG; 200MG
ACETAMINOPHEN; ASPIRIN; BUTALBITAL; CAPSULE OR TABLET; ORAL 160-165MG; 160-165MG; 50MG; 40MG	ASPIRIN; BUTALBITAL, CAFFEINE CAPSULE OR TABLET; ORAL 325MG; 50MG; 40MG; 650MG; 50MG; 40MG;	CHLOROTHIAZIDE TABLET; ORAL 250MG
ACETAMINOPHEN; ASPIRIN; BUTALBITAL; CAPSULE OR TABLET; ORAL 325MG; 325MG; 50MG; 40MG	ASPIRIN; CAFFEINE; CARISOPRODOL TABLET; ORAL 160MG; 32MG; 200MG	ESTROGENS, CONJUGATED; MEPROBANATE TABLET; ORAL 0.4MG; 200MG 0.4MG; 400MG
ACETAMINOPHEN; BUTALBITAL CAPSULE OR TABLET; ORAL 325; 50MG 650; 50MG	ASPIRIN; CAFFEINE; CARISOPRODOL; CODEINE PHOSPHATE TABLET; ORAL 160MG; 32MG; 200MG; 16MG	HYDROXYZINE HYDROCHLORIDE TABLET; ORAL 10MG 25MG 50MG 100MG
ACETAMINOPHEN; BUTALBITAL; CAFFEINE CAPSULE OR TABLET; ORAL 325MG; 50MG; 40MG 650MG; 50MG; 40MG	ASPIRIN; CARISOPRODOL TABLET; ORAL 325MG; 200MG	
	ASPIRIN; CARISOPRODOL; CODEINE PHOSPHATE 325MG; 200MG; 10MG	

TABLE II. OTC DRUG PRODUCTS WHICH CURRENTLY REQUIRE APPROVED APPLICATIONS AS A CONDITION OF MARKETING

<u>ACTIVE INGREDIENT(S)</u> <u>STRENGTH(S)</u>	<u>TRADE NAME</u> <u>(DOSAGE FORM; ROUTE)</u>	<u>APPLICANT NAME</u>	<u>NDA NO.</u> <u>APPROVAL DATE</u>	<u>PATENT NO.</u> <u>EXP. DATE</u>	<u>EXCLUSIVITY</u> <u>EXP. DATE</u>
ACETAMINOPHEN 120MG	NEOPAP (SUPPOSITORY; RECTAL)	WEBCON PHARMS/ALCON	16-401 11-07-68		
ACETAMINOPHEN 650MG	TYLENOL (SUPPOSITORY; RECTAL)	MCNEIL LABORATORIES	17-756 05-26-76		
ACETAMINOPHEN 120MG	TYLENOL (SUPPOSITORY; RECTAL)	MCNEIL LABORATORIES	17-756 05-26-76		
ACETAMINOPHEN 120MG	ACEPHEN (SUPPOSITORY; RECTAL)	G AND W LABORATORIES	18-060 02-09-78		
ACETAMINOPHEN 650MG	ACEPHEN (SUPPOSITORY; RECTAL)	G AND W LABORATORIES	18-060 02-09-78		
ACETAMINOPHEN 650MG	ACETAMINOPHEN (SUPPOSITORY; RECTAL)	UPSHER-SMITH LABS	18-337 04-22-80		
ACETAMINOPHEN 120MG	ACETAMINOPHEN (SUPPOSITORY; RECTAL)	UPSHER-SMITH LABS	18-337 09-12-83		
ALUMINUM HYDROXIDE; MAGNESIUM TRISILICATE 80MG; 20MG	GAVISCON (TABLET, CHEWABLE; ORAL)	MARION LABORATORIES	18-685 12-09-83	NP 09-24-86	
ALUMINUM HYDROXIDE; MAGNESIUM TRISILICATE 160MG; 40MG	GAVISCON-2 (TABLET, CHEWABLE; ORAL)	MARION LABORATORIES	18-685 12-09-83	NP 09-24-86	
BROMPHENTRINE MALEATE 8MG	DIMETANE (TABLET, CONTROLLED RELEASE; ORAL)	AH ROBINS	10-799 06-10-83	RTO 09-24-86	
BROMPHENTRINE MALEATE 12MG	DIMETANE (TABLET, CONTROLLED RELEASE; ORAL)	AH ROBINS	10-799 06-10-83	RTO 09-24-86	
CHLORHEXIDINE GLUCONATE 0.5%	HIBITANE (TINCTURE; TOPICAL)	ICI AMERICAS	18-049 12-18-78		
CHLORHEXIDINE GLUCONATE 0.5%	HIBISTAT (SOLUTION; TOPICAL)	ICI AMERICAS	18-300 05-23-80		

TABLE II. OTC DRUG PRODUCTS WHICH CURRENTLY REQUIRE APPROVED APPLICATIONS AS A CONDITION OF MARKETING

<u>ACTIVE INGREDIENT(S)</u> <u>STRENGTH(S)</u>	<u>TRADE NAME</u> <u>(DOSAGE FORM; ROUTE)</u>	<u>APPLICANT NAME</u>	<u>NDA NO.</u> <u>APPROVAL DATE</u>	<u>PATENT NO.</u> <u>EXP. DATE</u>	<u>EXCLUSIVITY</u> <u>EXP. DATE</u>
CHLORHEXIDINE GLUCONATE 4%	EXIDINE (SOLUTION; TOPICAL)	XTTRIUM LABS	19-125 12-24-84		
CHLORHEXIDINE GLUCONATE 4%	EXIDINE (AEROSOL; TOPICAL)	XTTRIUM LABS	19-127 12-24-84		NDF 12-24-87
CHLORHEXIDINE GLUCONATE 4%	HIBICLENS (SOLUTION; TOPICAL)	ICI AMERICAS	17-768 09-17-76		
CHLORHEXIDINE GLUCONATE 4%	HIBICLENS (SPONGE; TOPICAL)	ICI AMERICAS	18-423 08-27-81		
CHLORPHENIRAMINE MALEATE 8MG	TELDRIN (CAPSULE, CONTROLLED RELEASE; ORAL)	MENLEY & JAMES/SKF	17-369 05-11-78		
CHLORPHENIRAMINE MALEATE 12MG	TELDRIN (CAPSULE, CONTROLLED RELEASE; ORAL)	MENLEY & JAMES/SKF	17-369 05-11-78		
CHLORPHENIRAMINE MALEATE 8MG	CHLOR-TRIMETON (TABLET, CONTROLLED RELEASE; ORAL)	SCHERING	07-638 10-18-78		
CHLORPHENIRAMINE MALEATE 12MG	CHLOR-TRIMETON (TABLET, CONTROLLED RELEASE; ORAL)	SCHERING	07-638 10-18-78		
CHLORPHENIRAMINE MALEATE; PHENYLPROPANOLAMINE HYDROCHLORIDE 8MG; 75MG	CONTAC (CAPSULE, CONTROLLED RELEASE; ORAL)	MENLEY & JAMES/SKF	18-099 02-04-80		
CHLORPHENIRAMINE MALEATE; PHENYLPROPANOLAMINE HYDROCHLORIDE 12MG; 75MG	TRIAMINIC-12 (TABLET, CONTROLLED RELEASE; ORAL)	DORSEY LABS/SANDOZ	18-115 07-23-81		
CHLORPHENIRAMINE MALEATE; PHENYLPROPANOLAMINE HYDROCHLORIDE 4MG; 25MG	DEMAZIN (TABLET, CONTROLLED RELEASE; ORAL)	SCHERING	18-556 05-14-84		NS 09-24-86

TABLE II. OTC DRUG PRODUCTS WHICH CURRENTLY REQUIRE APPROVED APPLICATIONS AS A CONDITION OF MARKETING

<u>ACTIVE INGREDIENT(S)</u> <u>STRENGTH(S)</u>	<u>TRADE NAME</u> <u>(DOSAGE FORM; ROUTE)</u>	<u>APPLICANT NAME</u>	<u>NDA NO.</u> <u>APPROVAL DATE</u>	<u>PATENT NO.</u> <u>EXP. DATE</u>	<u>EXCLUSIVITY</u> <u>EXP. DATE</u>
CHLORPHENIRAMINE MALEATE; PHENYLPROPANOLAMINE HYDROCHLORIDE 8MG; 75MG	PHENYLPROPANOLAMINE HCL W/ CHLORPHENIRAMINE MALEATE (CAPSULE, CONTROLLED RELEASE; ORAL)	CENTRAL PHARMS	18-809 05-07-84		
CHLORPHENIRAMINE MALEATE; PSEUDOEPHEDRINE SULFATE 8MG; 120MG	CHLOR-TRIMETON (TABLET, CONTROLLED RELEASE; ORAL)	SCHERING	18-397 03-31-81		
CHLORPHENIRAMINE POLISTIREX; PHENYLPROPANOLAMINE POLISTIREX EQ 4MG MALEATE/5ML; EQ 37.5MG HCL/5ML	CORSYM (SYRUP; ORAL)	PENNWALT PHARM	18-050 01-04-84		NDF 09-24-86
DEXBROMPHENIRAMINE MALEATE; PSEUDOEPHEDRINE SULFATE 2MG; 60MG	DISOPHROL (TABLET; ORAL)	SCHERING	12-394 06-03-60		RTO 09-24-86
DEXBROMPHENIRAMINE MALEATE; PSEUDOEPHEDRINE SULFATE 6MG; 120MG	DRIXORAL (TABLET, CONTROLLED RELEASE; ORAL)	SCHERING	13-483 09-13-82		RTO 09-24-86
DEXBROMPHENIRAMINE MALEATE; PSEUDOEPHEDRINE SULFATE 6MG; 120MG	DISOPHROL (TABLET, CONTROLLED RELEASE; ORAL)	SCHERING	13-483 09-13-82		RTO 09-24-86
DEXTROMETHORPHAN RESIN COMPLEX EQ 30MG HBR/5ML	DELSYM (SUSPENSION, CONTROLLED RELEASE; ORAL)	PENNWALT PHARM	18-658 10-08-82		NDF 09-24-86
DIPHENHYDRAMINE HYDROCHLORIDE 12.5MG/5ML	BENLYN (SYRUP; ORAL)	PARKE-DAVIS/W-L	06-514 08-07-81		
DOXYLAMINE SUCCINATE 25MG	UNISOM (TABLET; ORAL)	PFIZER	18-066 10-06-78		
IBUPROFEN 200MG	ADVIL (TABLET; ORAL)	WHITEHALL LABS/AMHO	18-989 05-18-84	3385886 05-28-85	NS 09-24-86
IBUPROFEN 200MG	NUPRIN (TABLET; ORAL)	UPJOHN MANUFACTURING	19-012 05-18-84	3385886 05-28-85	NS 09-24-86

TABLE II. OTC DRUG PRODUCTS WHICH CURRENTLY REQUIRE APPROVED APPLICATIONS AS A CONDITION OF MARKETING

<u>ACTIVE INGREDIENT(S)</u> <u>STRENGTH(S)</u>	<u>TRADE NAME</u> <u>(DOSAGE FORM; ROUTE)</u>	<u>APPLICANT NAME</u>	<u>NDA NO.</u> <u>APPROVAL DATE</u>	<u>PATENT NO.</u> <u>EXP. DATE</u>	<u>EXCLUSIVITY</u> <u>EXP. DATE</u>
INSULIN SUSPENSION, ISOPHANE, BEEF 40 UNITS/ML	SEMILENTE INSULIN (INJECTABLE; INJECTION)	SQUIBB-NOVO	17-929 02-08-77		
INSULIN SUSPENSION, ISOPHANE, BEEF 100 UNITS/ML	SEMILENTE INSULIN (INJECTABLE; INJECTION)	SQUIBB-NOVO	17-929 02-08-77		
INSULIN SUSPENSION, ISOPHANE, BIOSYNTHETIC HUMAN 100 UNITS/ML	HUMULIN N (INJECTABLE; INJECTION)	ELI LILLY	18-781 10-28-82		
INSULIN SUSPENSION, ISOPHANE, MIXED BEEF AND PORK 40 UNITS/ML	NPH ILETIN (BEEF-PORK) (INJECTABLE; INJECTION)	LILLY RES LABS DIV	17-936 02-08-77		
INSULIN SUSPENSION, ISOPHANE, MIXED BEEF AND PORK 100 UNITS/ML	NPH ILETIN (BEEF-PORK) (INJECTABLE; INJECTION)	LILLY RES LABS DIV	17-936 02-08-77		
INSULIN SUSPENSION, ISOPHANE, PURIFIED BEEF 100 UNITS/ML	NPH ILETIN II (INJECTABLE; INJECTION)	ELI LILLY	18-479 06-12-80		
INSULIN SUSPENSION, ISOPHANE, PURIFIED PORK 100 UNITS/ML	INSULIN INSULATARD NPH NORDISK (INJECTABLE; INJECTION)	NORDISK	18-194 01-16-80		
INSULIN SUSPENSION, ISOPHANE, PURIFIED PORK 100 UNITS/ML	NPH ILETIN II (PORK) (INJECTABLE; INJECTION)	ELI LILLY	18-345 12-05-79		
INSULIN SUSPENSION, ISOPHANE, PURIFIED PORK 100 UNITS/ML	PROTAPHANE (INJECTABLE; INJECTION)	SQUIBB-NOVO	18-623 07-30-81		
INSULIN SUSPENSION, ISOPHANE, PURIFIED PORK; INSULIN, PURIFIED PORK 100 UNITS/ML	INSULIN NORDISK MIXTARD (PORK) (INJECTABLE; INJECTION)	NORDISK	18-195 01-16-80		

TABLE II. OTC DRUG PRODUCTS WHICH CURRENTLY REQUIRE APPROVED APPLICATIONS AS A CONDITION OF MARKETING

<u>ACTIVE INGREDIENT(S)</u> <u>STRENGTH(S)</u>	<u>TRADE NAME</u> <u>(DOSAGE FORM; ROUTE)</u>	<u>APPLICANT NAME</u>	<u>NDA NO.</u> <u>APPROVAL DATE</u>	<u>PATENT NO.</u> <u>EXP. DATE</u>	<u>EXCLUSIVITY</u> <u>EXP. DATE</u>
INSULIN SUSPENSION, PROTAMINE ZINC, MIXED BEEF AND PORK 100 UNITS/ML	PROTAMINE, ZINC & ILETIN (BEEF-PORK) (INJECTABLE; INJECTION)	ELI LILLY	17-932 02-08-77		
INSULIN SUSPENSION, PROTAMINE ZINC, MIXED BEEF AND PORK; INSULIN, MIXED BEEF AND PORK 100 UNITS/ML	PROTAMINE, ZINC & ILETIN (BEEF-PORK) (INJECTABLE; INJECTION)	ELI LILLY	17-932 02-08-77		
INSULIN SUSPENSION, PROTAMINE ZINC, PURIFIED BEEF 40 UNITS/ML	PROTAMINE ZINC INSULIN (INJECTABLE; INJECTION)	ER SQUIBB AND SONS	17-928 02-08-77		
INSULIN SUSPENSION, PROTAMINE ZINC, PURIFIED BEEF 100 UNITS/ML	PROTAMINE ZINC INSULIN (INJECTABLE; INJECTION)	ER SQUIBB AND SONS	17-928 02-08-77		
INSULIN SUSPENSION, PROTAMINE ZINC, PURIFIED BEEF; INSULIN, PURIFIED BEEF 100 UNITS/ML	PROTAMINE ZINC AND ILETIN II (INJECTABLE; INJECTION)	ELI LILLY	18-476 06-12-80		
INSULIN SUSPENSION, PROTAMINE ZINC, PURIFIED PORK; INSULIN, PURIFIED PORK 100 UNITS/ML	PROTAMINE ZINC AND ILETIN II(PORK) (INJECTABLE; INJECTION)	ELI LILLY	18-346 12-05-79		
INSULIN ZINC SUSPENSION, BEEF 40 UNITS/ML	LENTE INSULIN (INJECTABLE; INJECTION)	SQUIBB-NOVO	17-998 02-08-77		
INSULIN ZINC SUSPENSION, BEEF 100 UNITS/ML	LENTE INSULIN (INJECTABLE; INJECTION)	SQUIBB-NOVO	17-998 02-08-77		
INSULIN ZINC SUSPENSION, BIOSYNTHETIC HUMAN 100 UNITS/ML	MONOTARD HUMAN (INJECTABLE; INJECTION)	SQUIBB-NOVO	18-777 08-30-83		
INSULIN ZINC SUSPENSION, EXTENDED, PURIFIED BEEF 100 UNITS/ML	ULTRATARD (INJECTABLE; INJECTION)	SQUIBB-NOVO	18-385 03-17-80		

TABLE II. OTC DRUG PRODUCTS WHICH CURRENTLY REQUIRE APPROVED APPLICATIONS AS A CONDITION OF MARKETING

<u>ACTIVE INGREDIENT(S)</u> <u>STRENGTH(S)</u>	<u>TRADE NAME</u> <u>(DOSAGE FORM; ROUTE)</u>	<u>APPLICANT NAME</u>	<u>NDA NO.</u> <u>APPROVAL DATE</u>	<u>PATENT NO.</u> <u>EXP. DATE</u>	<u>EXCLUSIVITY</u> <u>EXP. DATE</u>
INSULIN ZINC SUSPENSION, EXTENDED, PURIFIED BEEF 100 UNITS/ML	ULTRALENTE INSULIN (INJECTABLE; INJECTION)	SQUIBB-NOVO	17-997 02-08-77		
INSULIN ZINC SUSPENSION, PROMPT, BEEF 100 UNITS/ML	SEMILENTE INSULIN (INJECTABLE; INJECTION)	SQUIBB-NOVO	17-996 02-08-77		
INSULIN ZINC SUSPENSION, PROMPT, PURIFIED PORK 100 UNITS/ML	SEMITARD (INJECTABLE; INJECTION)	SQUIBB-NOVO	18-382 03-17-80		
INSULIN ZINC SUSPENSION, PURIFIED BEEF 100 UNITS/ML	LENTE ILETIN II (INJECTABLE; INJECTION)	ELI LILLY	18-477 06-12-80		
INSULIN ZINC SUSPENSION, PURIFIED BEEF AND PORK 100 UNITS/ML	LENTARD (INJECTABLE; INJECTION)	SQUIBB-NOVO	18-384 03-17-80		
INSULIN ZINC SUSPENSION, PURIFIED PORK 100 UNITS/ML	LENTE ILETIN II (PORK) (INJECTABLE; INJECTION)	ELI LILLY	18-347 12-05-79		
INSULIN ZINC SUSPENSION, PURIFIED PORK 100 UNITS/ML	MONOTARD (INJECTABLE; INJECTION)	SQUIBB-NOVO	18-383 03-17-80		
INSULIN, BIOSYNTHETIC HUMAN 100 UNITS/ML	ACTRAPID HUMAN (INJECTABLE; INJECTION)	SQUIBB-NOVO	18-778 08-30-83		
INSULIN, BIOSYNTHETIC HUMAN 100 UNITS/ML	HUMULIN R (INJECTABLE; INJECTION)	ELI LILLY	18-780 10-28-82		
INSULIN, PORK 40 UNITS/ML	INSULIN (INJECTABLE; INJECTION)	SQUIBB-NOVO	17-926 02-08-77		
INSULIN, PORK 100 UNITS/ML	INSULIN (INJECTABLE; INJECTION)	SQUIBB-NOVO	17-926 02-08-77		

TABLE II. OTC DRUG PRODUCTS WHICH CURRENTLY REQUIRE APPROVED APPLICATIONS AS A CONDITION OF MARKETING

<u>ACTIVE INGREDIENT(S)</u> <u>STRENGTH(S)</u>	<u>TRADE NAME</u> <u>(DOSAGE FORM; ROUTE)</u>	<u>APPLICANT NAME</u>	<u>NDA NO.</u> <u>APPROVAL DATE</u>	<u>PATENT NO.</u> <u>EXP. DATE</u>	<u>EXCLUSIVITY</u> <u>EXP. DATE</u>
INSULIN, PURIFIED BEEF 100 UNITS/ML	REGULAR ILETIN II (INJECTABLE; INJECTION)	ELI LILLY	18-478 06-12-80		
INSULIN, PURIFIED PORK 100 UNITS/ML	INSULIN NORDISK QUICK (PORK) (INJECTABLE; INJECTION)	NORDISK INSULIN LABS	18-193 01-16-80		
INSULIN, PURIFIED PORK 100 UNITS/ML	REGULAR ILETIN II (PORK) (INJECTABLE; INJECTION)	ELI LILLY	18-344 12-05-79		
INSULIN, PURIFIED PORK 100 UNITS/ML	ACTRAPID (INJECTABLE; INJECTION)	SQUIBB-NOVO	18-381 03-17-80		
INSULIN SUSPENSION, ISOPHANE, PURIFIED HUMAN 100 UNITS/ML	NOVOLIN N (INJECTABLE; INJECTION)	NOVO INDUSTRI A/S	19-065 01-23-85		
NONOXYNOL-9 1GM	TODAY (SPONGE; VAGINAL)	VLI CORPORATION	18-683 04-01-83		NDF 09-24-86
POTASSIUM IODIDE 130MG	THYRO-BLOCK (TABLET; ORAL)	WALLACE LABS/C-W	18-307 11-09-79		
POTASSIUM IODIDE 1GM/ML	POTASSIUM IODIDE (SOLUTION; ORAL)	ROXANE LABORATORIES	18-551 02-19-82		NDF 09-24-86
POTASSIUM IODIDE 130MG	IOSAT (TABLET; ORAL)	ANBEX	18-664 10-14-82		
PSEUDOEPHEDRINE HYDROCHLORIDE 120MG	SUDAFED S. A. (CAPSULE, CONTROLLED RELEASE; ORAL)	BURROUGHS WELLCOME	17-941 01-15-79		
PSEUDOEPHEDRINE HYDROCHLORIDE; TRIPROLIDINE HYDROCHLORIDE 30MG/5ML; 1.25MG/5ML	ACTIFED (SYRUP; ORAL)	BURROUGHS WELLCOME	11-935 11-26-82		RTO 09-24-86
PSEUDOEPHEDRINE HYDROCHLORIDE; TRIPROLIDINE HYDROCHLORIDE 60MG; 2.5MG	ACTIFED (TABLET; ORAL)	BURROUGHS WELLCOME	11-936 11-26-82		RTO 09-24-86

TABLE II. OTC DRUG PRODUCTS WHICH CURRENTLY REQUIRE APPROVED APPLICATIONS AS A CONDITION OF MARKETING

<u>ACTIVE INGREDIENT(S)</u> <u>STRENGTH(S)</u>	<u>TRADE NAME</u> <u>(DOSAGE FORM; ROUTE)</u>	<u>APPLICANT NAME</u>	<u>NDA NO.</u> <u>APPROVAL DATE</u>	<u>PATENT NO.</u> <u>EXP. DATE</u>	<u>EXCLUSIVITY</u> <u>EXP. DATE</u>
PSEUDOEPHEDRINE HYDROCHLORIDE; TRIPROLIDINE HYDROCHLORIDE 60MG; 2.5MG	ACTIFED (CAPSULE; ORAL)	BURROUGHS WELLCOME	19-208 01-15-85		RTO 09-24-86
PSEUDOEPHEDRINE HYDROCHLORIDE; TRIPROLIDINE HYDROCHLORIDE 30MG/5ML; 1.25MG/5ML	ALLERBAN PLUS (SYRUP; ORAL)	BAY LABORATORIES	88-116 03-04-83		RTO 09-24-86
PSEUDOEPHEDRINE HYDROCHLORIDE; TRIPROLIDINE HYDROCHLORIDE 60MG; 2.5MG	TRI-SUDO (TABLET; ORAL)	MD PHARMACEUTICAL	85-024 01-10-84		RTO 09-24-86
PSEUDOEPHEDRINE HYDROCHLORIDE; TRIPROLIDINE HYDROCHLORIDE 60MG; 2.5MG	TRIPODRINE (TABLET; ORAL)	DANBURY PHARMACAL	88-112 01-20-83		RTO 09-24-86
PSEUDOEPHEDRINE HYDROCHLORIDE; TRIPROLIDINE HYDROCHLORIDE 30MG/5ML; 1.25MG/5ML	TRIOFED (SYRUP; ORAL)	NATL PHARM MFG/BARRE	88-115 03-04-83		RTO 09-24-86
PSEUDOEPHEDRINE HYDROCHLORIDE; TRIPROLIDINE HYDROCHLORIDE 30MG/5ML; 1.25MG/5ML	TRIPOSED (SYRUP; ORAL)	HALSEY DRUG	88-213 03-30-84		RTO 09-24-86
PSEUDOEPHEDRINE HYDROCHLORIDE; TRIPROLIDINE HYDROCHLORIDE 60MG; 2.5MG	TRIPROLIDINE HCL AND PSEUDOEPHEDRINE HCL (TABLET; ORAL)	CHELSEA LABORATORIES	88-118 01-26-84		RTO 09-24-86
PSEUDOEPHEDRINE HYDROCHLORIDE; TRIPROLIDINE HYDROCHLORIDE 60MG; 2.5MG	TRIPOSED (TABLET; ORAL)	HALSEY DRUG	88-192 05-01-84		RTO 09-24-86
PSEUDOEPHEDRINE HYDROCHLORIDE; TRIPROLIDINE HYDROCHLORIDE 60MG; 2.5MG	TRIPROLIDINE AND PSEUDOEPHEDRINE (TABLET; ORAL)	BOLAR PHARMACEUTICAL	88-318 01-13-84		RTO 09-24-86
PSEUDOEPHEDRINE HYDROCHLORIDE; TRIPROLIDINE HYDROCHLORIDE 30MG/5ML; 1.25MG/5ML	TRIPOSED (SYRUP; ORAL)	HALSEY DRUG	88-213 05-01-84		RTO 09-24-86

TABLE II. OTC DRUG PRODUCTS WHICH CURRENTLY REQUIRE APPROVED APPLICATIONS AS A CONDITION OF MARKETING

<u>ACTIVE INGREDIENT(S)</u> <u>STRENGTH(S)</u>	<u>TRADE NAME</u> <u>(DOSAGE FORM; ROUTE)</u>	<u>APPLICANT NAME</u>	<u>NDA NO.</u> <u>APPROVAL DATE</u>	<u>PATENT NO.</u> <u>EXP. DATE</u>	<u>EXCLUSIVITY</u> <u>EXP. DATE</u>
PSEUDOEPHEDRINE SULFATE 120MG	AFRINOL (TABLET, CONTROLLED RELEASE; ORAL)	SCHERING	18-191 10-30-80		
TIOCONAZOLE 1%	TROSYD (CREAM; TOPICAL)	PFIZER CEN RES/PFIZR	18-682 02-18-83	4062966 12-13-94	NCE 02-18-93
TRIPROLIDINE HYDROCHLORIDE 2.5MG	ACTIDIL (TABLET; ORAL)	BURROUGHS WELLCOME	11-110 04-14-58		RTO 09-24-86
TRIPROLIDINE HYDROCHLORIDE 2.5MG	TRIPROLIDINE HCL (TABLET; ORAL)	BOLAR PHARMACEUTICAL	84-453 02-06-76		RTO 09-24-86
TRIPROLIDINE HYDROCHLORIDE 2.5MG	TRIPROLIDINE HCL (TABLET; ORAL)	DANBURY PHARMACAL	85-094 02-07-77		RTO 09-24-86
TRIPROLIDINE HYDROCHLORIDE 2.5MG	TRIPROLIDINE HCL (TABLET; ORAL)	DRUMMER/PHOENIX	85-610 03-21-78		RTO 09-24-86
TRIPROLIDINE HYDROCHLORIDE 1.25MG/5ML	ACTIDIL (SYRUP; ORAL)	BURROUGHS WELLCOME	11-496 07-24-58		RTO 09-24-86
TRIPROLIDINE HYDROCHLORIDE 1.25MG/5ML	BAYIDYL (SYRUP; ORAL)	BAY LABORATORIES	87-963 01-18-83		RTO 09-24-86
TRIPROLIDINE HYDROCHLORIDE 1.25MG/5ML	TRIPROLIDINE HCL (SYRUP; ORAL)	NATL PHARM MFG/BARRE	85-940 07-13-79		RTO 09-24-86
TRIPROLIDINE HYDROCHLORIDE 1.25MG/5ML	TRIPROLIDINE HCL (SYRUP; ORAL)	PHARMS ASSOC/BEACH	87-514 02-10-82		RTO 09-24-86

TABLE III. NDA'S APPROVED BY THE OFFICE OF BIOLOGICAL RESEARCH AND REVIEW NOT PREVIOUSLY PUBLISHED

<u>ACTIVE INGREDIENT(S)</u> <u>STRENGTH(S)</u>	<u>TRADE NAME</u> <u>(DOSAGE FORM; ROUTE)</u>	<u>APPLICANT NAME</u>	<u>NDA NO.</u> <u>APPROVAL DATE</u>	<u>PATENT NO.</u> <u>EXP. DATE</u>	<u>EXCLUSIVITY</u> <u>EXP. DATE</u>
ANTICOAGULANT CITRATE DEXTROSE SOLUTION USP	NONE (INJECTABLE; INJECTION)	CUTTER BIOL/MILES	10-102 12-14-61		
ANTICOAGULANT CITRATE DEXTROSE SOLUTION USP	NONE (INJECTABLE; INJECTION)	DELMED	11-912 9-2-59		
ANTICOAGULANT CITRATE DEXTROSE SOLUTION USP	NONE (INJECTABLE; INJECTION)	TRAVENOL LABS	10-855 06-11-59		
ANTICOAGULANT CITRATE DEXTROSE SOLUTION USP	NONE (INJECTABLE; INJECTION)	TRAVENOL LABS	16-918 3-17-78		
ANTICOAGULANT CITRATE PHOSPHATE DEXTROSE ADENINE-1 SOLUTION	NONE (INJECTABLE; INJECTION)	CUTTER BIOL/MILES	80-77 11-6-80		
ANTICOAGULANT CITRATE PHOSPHATE DEXTROSE ADENINE SOLUTION	NONE (INJECTABLE; INJECTION)	DELMED	78-519 4-23-80		
ANTICOAGULANT CITRATE PHOSPHATE DEXTROSE ADENINE SOLUTION	NONE (INJECTABLE; INJECTION)	TERUMO AMERICA	82-528 11-3-82		
ANTICOAGULANT CITRATE PHOSPHATE DEXTROSE ADENINE SOLUTION	NONE (INJECTABLE; INJECTION)	TRAVENOL LABS	77-420 5-12-78		
ANTICOAGULANT CITRATE PHOSPHATE DEXTROSE SOLUTION USP	NONE (INJECTABLE; INJECTION)	CUTTER BIOL/MILES	16-527 6-22-70		
ANTICOAGULANT CITRATE PHOSPHATE DEXTROSE SOLUTION USP	NONE (INJECTABLE; INJECTION)	CUTTER BIOL/MILES	80-222 8-23-82		
ANTICOAGULANT CITRATE PHOSPHATE DEXTROSE SOLUTION USP	NONE (INJECTABLE; INJECTION)	DELMED	16-907 5-15-73		
ANTICOAGULANT CITRATE PHOSPHATE DEXTROSE SOLUTION USP	NONE (INJECTABLE; INJECTION)	TERUMO AMERICA	78-1211 6-10-81		
ANTICOAGULANT CITRATE PHOSPHATE DEXTROSE SOLUTION USP	NONE (INJECTABLE; INJECTION)	TRAVENOL LABS	17-401 12-6-77		
ANTICOAGULANT CITRATE PHOSPHATE DEXTROSE SOLUTION USP	NONE (INJECTABLE; INJECTION)	TRAVENOL LABS	81-1012 6-28-83		

TABLE III. NDA'S APPROVED BY THE OFFICE OF BIOLOGICAL RESEARCH AND REVIEW NOT PREVIOUSLY PUBLISHED

<u>ACTIVE INGREDIENT(S)</u> <u>STRENGTH(S)</u>	<u>TRADE NAME</u> <u>(DOSAGE FORM; ROUTE)</u>	<u>APPLICANT NAME</u>	<u>NDA NO.</u> <u>APPROVAL DATE</u>	<u>PATENT NO.</u> <u>EXP. DATE</u>	<u>EXCLUSIVITY</u> <u>EXP. DATE</u>
ANTICOAGULANT CITRATE PHOSPHATE SOLUTION USP WITH: AS-1: DEXTROSE USP 2.2GM/100ML, SODIUM CHLORIDE USP 0.9GM/100ML, MANNITOL USP 0.75GM/100ML, ADENINE 0.27GM/100ML	ADSOL [®] RED CELL PRESERVATION SOLUTION (INJECTABLE; INJECTION)	TRAVENOL LABS	81-1104 5-16-83		
ANTICOAGULANT CITRATE PHOSPHATE DOUBLE DEXTROSE SOLUTION WITH: AS-2: CITRIC ACID USP 0.42GM/100ML, DIBASIC SODIUM PHOSPHATE USP 0.285GM/100ML, SODIUM CHLORIDE USP 0.718 GM/100ML, ADENINE 0.017GM/100ML, DEXTROSE USP 0.396GM/100ML, SODIUM CITRATE USP 0.588GM/100ML	AS-2 NUTRICEL ADITIVE SYSTEM (INJECTABLE; INJECTION)	CUTTER BIOL/MILES	82-915 9-22-83		
ANTICOAGULANT CITRATE PHOSPHATE DOUBLE DEXTROSE SOLUTION WITH: AS-3: CITRIC ACID USP 0.042 GM/100ML, MONOBASIC SODIUM PHOSPHATE USP 0.276GM/100ML, SODIUM CHLORIDE USP 0.410 GM/100ML, ADENINE 0.30 GM/100ML, DEXTROSE USP 1.10 GM/100ML, SODIUM CITRATE USP 0.588GM/100ML	AS-3 NUTRICEL ADITIVE SYSTEM (INJECTABLE; INJECTION)	CUTTER BIOL/MILES	82-915 10-19-84		
ANTICOAGULANT HEPARIN SOLUTION USP	NONE (INJECTABLE; INJECTION)	DELMED	77-822 5-17-78		
ANTICOAGULANT HEPARIN SOLUTION USP	NONE (INJECTABLE; INJECTION)	TRAVENOL LABS	81-1217 5-16-83		
ANTICOAGULANT SODIUM CITRATE SOLUTION USP	NONE (INJECTABLE; INJECTION)	ALPHA THERAPEUTIC	81-416 10-12-83		
ANTICOAGULANT SODIUM CITRATE SOLUTION USP	NONE (INJECTABLE; INJECTION)	CUTTER BIOL/MILES	76-305 6-30-78		
ANTICOAGULANT SODIUM CITRATE SOLUTION USP	NONE (INJECTABLE; INJECTION)	DELMED	16-702 12-28-70		

TABLE III. NDA'S APPROVED BY THE OFFICE OF BIOLOGICAL RESEARCH AND REVIEW NOT PREVIOUSLY PUBLISHED

<u>ACTIVE INGREDIENT(S)</u> <u>STRENGTH(S)</u>	<u>TRADE NAME</u> <u>(DOSAGE FORM; ROUTE)</u>	<u>APPLICANT NAME</u>	<u>NDA NO.</u> <u>APPROVAL DATE</u>	<u>PATENT NO.</u> <u>EXP. DATE</u>	<u>EXCLUSIVITY</u> <u>EXP. DATE</u>
ANTICOAGULANT SODIUM CITRATE SOLUTION USP	NONE (INJECTABLE; INJECTION)	TERUMO AMERICA	78-1214 2-8-80		
ANTICOAGULANT SODIUM CITRATE SOLUTION USP	NONE (INJECTABLE; INJECTION)	TRAVENOL LABS	77-923 1-20-78		
DEXTRAN 40, 10% 10GM/100ML IN DEXTROSE 5% 5GM/100ML	NONE (INJECTABLE; INJECTION)	ABBOTT LABORATORIES	16-375 7-25-67		
DEXTRAN 40, 10% 10GM/100ML IN SODIUM CHLORIDE 0.9% 0.9GM/100ML	NONE (INJECTABLE; INJECTION)	ABBOTT LABORATORIES	16-375 7-25-67		
DEXTRAN 75, 6% 6GM/100ML IN DEXTROSE 5% 5GM/100ML	NONE (INJECTABLE; INJECTION)	ABBOTT LABORATORIES	8-819 3-31-53		
DEXTRAN 75, 6% 6GM/100ML IN SODIUM CHLORIDE 0.9% 0.9GM/100ML	NONE (INJECTABLE; INJECTION)	ABBOTT LABORATORIES	8-819 3-31-53		
DEXTRAN 75, 6% 6GM/100ML IN SODIUM CHLORIDE 0.9% 0.9GM/100ML	NONE (INJECTABLE; INJECTION)	ABBOTT LABORATORIES	18-253 2-4-83		
DEXTRAN 40, 10% 10GM/100ML IN DEXTROSE 5% 5GM/100ML	NONE (INJECTABLE; INJECTION)	AMERICAN MCGAW	16-767 4-6-70		
DEXTRAN 40, 10% 10GM/100ML IN SODIUM CHLORIDE 0.9% 0.9GM/100ML	NONE (INJECTABLE; INJECTION)	AMERICAN MCGAW	16-767 4-6-70		

TABLE III. NDA'S APPROVED BY THE OFFICE OF BIOLOGICAL RESEARCH AND REVIEW NOT PREVIOUSLY PUBLISHED

ACTIVE INGREDIENT(S) STRENGTH(S)	TRADE NAME (DOSAGE FORM; ROUTE)	APPLICANT NAME	NDA NO. APPROVAL DATE	PATENT NO. EXP. DATE	EXCLUSIVITY EXP. DATE
DEXTRAN 70, 6% 6GM/100ML IN SODIUM CHLORIDE 0.9% 0.9GM/100ML	NONE (INJECTABLE; INJECTION)	AMERICAN MCGAW	9-024 8-18-69		
DEXTRAN 40, 10% 10GM/100ML IN DEXTROSE 5% 5GM/100ML	NONE (INJECTABLE; INJECTION)	CUTTER BIOL/MILES	16-653 9-23-69		
DEXTRAN 40, 10% 10GM/100ML IN SODIUM CHLORIDE 0.9% 0.9GM/100ML	NONE (INJECTABLE; INJECTION)	CUTTER BIOL/MILES	16-653 9-23-69		
DEXTRAN 70, 6% 6GM/100ML IN SODIUM CHLORIDE 0.9% 0.9GM/100ML	NONE (INJECTABLE; INJECTION)	CUTTER BIOL/MILES	8-716 8-11-69		
DEXTRAN 40, 10% 10GM/100ML IN DEXTROSE 5% 5GM/100ML	NONE (INJECTABLE; INJECTION)	PHARMACHEM	16-836 11-14-70		
DEXTRAN 40, 10% 10GM/100ML IN SODIUM CHLORIDE 0.9% 0.9GM/100ML	NONE (INJECTABLE; INJECTION)	PHARMACHEM	16-836 11-14-70		
DEXTRAN 75, 6% 6GM/100ML IN SODIUM CHLORIDE 0.9% 0.9GM/100ML	NONE (INJECTABLE; INJECTION)	PHARMACHEM	8-564 9-19-52		
DEXTRAN 75, 6% 6GM/100ML IN SODIUM CHLORIDE 0.9% 0.9GM/100ML	NONE (INJECTABLE; INJECTION)	PHARMACHEM	16-759 8-19-70		
DEXTRAN 1 150MG/ML IN SODIUM CHLORIDE 0.6% 6MG/ML	PROMIT (INJECTABLE; INJECTION)	PHARMACIA LABS	83-715 10-30-84		NCE 10-30-89

TABLE III. NDA'S APPROVED BY THE OFFICE OF BIOLOGICAL RESEARCH AND REVIEW NOT PREVIOUSLY PUBLISHED

<u>ACTIVE INGREDIENT(S)</u> <u>STRENGTH(S)</u>	<u>TRADE NAME</u> <u>(DOSAGE FORM; ROUTE)</u>	<u>APPLICANT NAME</u>	<u>NDA NO.</u> <u>APPROVAL DATE</u>	<u>PATENT NO.</u> <u>EXP. DATE</u>	<u>EXCLUSIVITY</u> <u>EXP. DATE</u>
DEXTRAN 40, 10% 10GM/100ML IN DEXTROSE 5% 5GM/100ML	RHEOMACRODEX ^R (INJECTABLE; INJECTION)	PHARMACIA LABS	14-716 1-18-67		
DEXTRAN 40, 10% 10GM/100ML IN SODIUM CHLORIDE 0.9% 0.9GM/100ML	RHEOMACRODEX ^R (INJECTABLE; INJECTION)	PHARMACIA LABS	14-716 1-18-67		
DEXTRAN 70, 6% 6GM/100ML IN DEXTROSE 5% 5GM/100ML	MACRODEX ^R (INJECTABLE; INJECTION)	PHARMACIA LABS	6-826 6-8-54		
DEXTRAN 70, 6% 6GM/100ML IN SODIUM CHLORIDE 0.9% 0.9GM/100ML	MACRODEX ^R (INJECTABLE; INJECTION)	PHARMACIA LABS	6-826 6-8-54		
DEXTRAN 40, 10% 10GM/100ML IN DEXTROSE 5% 5GM/100ML	GENTRAN ^R 40 (INJECTABLE; INJECTION)	TRAVENOL LABS	16-628 11-4-68		
DEXTRAN 40, 10% 10GM/100ML IN SODIUM CHLORIDE 0.9% 0.9GM/100ML	GENTRAN ^R 40 (INJECTABLE; INJECTION)	TRAVENOL LABS	16-628 11-4-68		
DEXTRAN 40, 10% 10GM/100ML DEXTROSE 5% 5GM/100ML	GENTRAN ^R 40 (INJECTABLE; INJECTION)	TRAVENOL LABS	84-619 2-22-85		
DEXTRAN 40, 10% 10GM/100ML IN SODIUM CHLORIDE 0.9% 0.9GM/100ML	GENTRAN ^R 40 (INJECTABLE; INJECTION)	TRAVENOL LABS	84-620 2-22-85		
DEXTRAN 75, 6% 6GM/100ML IN SODIUM CHLORIDE 0.9% 0.9GM/100ML	GENTRAN ^R 75 (INJECTABLE; INJECTION)	TRAVENOL LABS	16-607 1-26-70		

TABLE III. NDA'S APPROVED BY THE OFFICE OF BIOLOGICAL RESEARCH AND REVIEW NOT PREVIOUSLY PUBLISHED

<u>ACTIVE INGREDIENT(S)</u> <u>STRENGTH(S)</u>	<u>TRADE NAME</u> <u>(DOSAGE FORM; ROUTE)</u>	<u>APPLICANT NAME</u>	<u>NDA NO.</u> <u>APPROVAL DATE</u>	<u>PATENT NO.</u> <u>EXP. DATE</u>	<u>EXCLUSIVITY</u> <u>EXP. DATE</u>
DEXTRAN 75, 6% INVERTED SUGAR 10% 6GM/100ML; 10GM/100ML IN SODIUM CHLORIDE 0.9% 0.9GM/100ML	6% GENTRAN ^R 75 AND 10% TRAVENT ^R (INJECTABLE; INJECTION)	TRAVENOL LABS	8-788 2-9-53		
HETASTARCH, 6% 6GM/100ML IN SODIUM CHLORIDE 0.9% 0.9GM/100ML	HESPAR ^R (INJECTABLE; INJECTION)	AM CRITICAL CARE	16-889 7-17-72	3523938 8-11-87	
PROPIOLACTONE 99% 99GM/100ML	BETAPRONE (SOLUTION; CHEMICAL STERILIZING AGENT)	ONEAL JONES&FELDMAN	11-657 9-11-59		
UROKINASE 5000 IU/VIAL	ABBOKINASE OPEN-CATHETER (INJECTABLE; INJECTION)	ABBOTT LABORATORIES	76-1021 12-15-83	NS 09-24-86	
UROKINASE 250,000 IU/VIAL	ABBOKINASE (INJECTABLE; INJECTION)	ABBOTT LABORATORIES	76-1021 7-31-78	I-29 09-24-86	
UROKINASE 250,000 IU/VIAL	BREOKINASE (INJECTABLE; INJECTION)	STERLING DRUG	17-873 8-28-79		

TABLE IV. NDA'S APPROVED FROM 1-1-82 TO 2-28-85 AND NDA'S WITH APPROPRIATE PATENT AND EXCLUSIVITY INFORMATION

<u>ACTIVE INGREDIENT(S)</u> <u>STRENGTH(S)</u>	<u>TRADE NAME</u> <u>(DOSAGE FORM; ROUTE)</u>	<u>APPLICANT NAME</u>	<u>NDA NO.</u> <u>APPROVAL DATE</u>	<u>PATENT NO.</u> <u>EXP. DATE</u>	<u>EXCLUSIVITY</u> <u>EXP. DATE</u>
ACEBUTOLOL HYDROCHLORIDE EQ 200MG BASE	SECTRAL (CAPSULE; ORAL)	IVES LABS/AMHO	18-917 12-28-84	3726919 04-10-90 3857952 12-31-91	NCE 12-28-89
ACEBUTOLOL HYDROCHLORIDE EQ 300MG BASE	SECTRAL (CAPSULE; ORAL)	IVES LABS/AMHO	18-917 12-28-84	3726919 04-10-90 3857952 12-31-91	NCE 12-28-89
ACEBUTOLOL HYDROCHLORIDE EQ 400MG BASE	SECTRAL (CAPSULE; ORAL)	IVES LABS/AMHO	18-917 12-28-84	3726919 04-10-90 3857952 12-31-91	NCE 12-28-89
ACETAMINOPHEN; PENTAZOCINE HYDROCHLORIDE 625MG; EQ 25MG BASE	TALACEN (TABLET; ORAL)	STERLING DRUG	18-458 09-23-82	4105659 08-08-95	NC 09-24-86
ACETIC ACID, GLACIAL 250MG/100ML	ACETIC ACID 0.25% IN PLASTIC CONTAINER (SOLUTION; URETHRAL)	TRAVENOL LABS	18-523 02-19-82		
ACETOHYDROXAMIC ACID 250MG	LITHOSTAT (TABLET; ORAL)	URO-RESEARCH	18-749 05-31-83		NCE 05-31-93
ACYCLOVIR 5%	ZOVIRAX (OINTMENT; TOPICAL)	BURROUGHS WELLCOME	18-604 03-29-82	4199574 04-22-97	NCE 03-29-92
ACYCLOVIR 200MG	ZOVIRAX (CAPSULE; ORAL)	BURROUGHS WELLCOME	18-828 01-25-85	4199574 04-22-97	NCE 03-29-92
ACYCLOVIR SODIUM EQ 500MG BASE/VIAL	ZOVIRAX (INJECTABLE; INJECTION)	BURROUGHS WELLCOME	18-603 10-22-82	4199574 04-22-97	NCE 03-29-92
ALBUTEROL 0.09MG/INH	PROVENTIL (AEROSOL; INHALATION)	SCHERING	17-559 05-01-81	3644353 02-22-89 3705233 12-05-89	1-22 09-24-86
ALBUTEROL 0.09MG/INH	VENTOLIN (AEROSOL; INHALATION)	GLAXO	18-473 05-01-81	3644353 02-22-89 3705233 12-05-89	

TABLE IV. NDA'S APPROVED FROM 1-1-82 TO 2-28-85 AND NDA'S WITH APPROPRIATE PATENT AND EXCLUSIVITY INFORMATION

<u>ACTIVE INGREDIENT(S)</u> <u>STRENGTH(S)</u>	<u>TRADE NAME</u> <u>(DOSAGE FORM; ROUTE)</u>	<u>APPLICANT NAME</u>	<u>NDA NO.</u> <u>APPROVAL DATE</u>	<u>PATENT NO.</u> <u>EXP. DATE</u>	<u>EXCLUSIVITY</u> <u>EXP. DATE</u>
ALBUTEROL SULFATE EQ 2MG BASE	PROVENTIL (TABLET; ORAL)	SCHERING	17-853 05-07-82	3644353 02-22-89 3705233 12-05-89	NE 09-24-86
ALBUTEROL SULFATE EQ 4MG BASE	PROVENTIL (TABLET; ORAL)	SCHERING	17-853 05-07-82	3644353 02-22-89 3705233 12-05-89	NE 09-24-86
ALCLOMETASONE DIPROPIONATE 0.05%	VADERM (OINTMENT; TOPICAL)	SCHERING	18-702 12-14-82	4124707 11-07-95	NCE 12-14-92
ALCLOMETASONE DIPROPIONATE 0.05%	VADERM (CREAM; TOPICAL)	SCHERING	18-707 12-14-82	4124707 11-07-95	NCE 12-14-92
ALLOPURINOL 100MG	ALLOPURINOL (TABLET; ORAL)	BOLAR PHARMACEUTICAL	18-241 11-16-84		
ALLOPURINOL 300MG	ALLOPURINOL (TABLET; ORAL)	BOLAR PHARMACEUTICAL	18-241 11-16-84		
ALLOPURINOL 100MG	ALLOPURINOL (TABLET; ORAL)	CHELSEA LABORATORIES	18-785 09-28-84		
ALLOPURINOL 300MG	ALLOPURINOL (TABLET; ORAL)	CHELSEA LABORATORIES	18-785 09-28-84		
ALLOPURINOL 100MG	ALLOPURINOL (TABLET; ORAL)	DANBURY PHARMACAL	18-832 09-28-84		
ALLOPURINOL 300MG	ALLOPURINOL (TABLET; ORAL)	DANBURY PHARMACAL	18-877 09-28-84		
ALLOPURINOL 100MG	ZYLOPRIM (TABLET; ORAL)	BURROUGHS WELLCOME	16-084 08-19-66	3624205 11-30-88	
ALLOPURINOL 300MG	ZYLOPRIM (TABLET; ORAL)	BURROUGHS WELLCOME	16-084 01-14-74	3624205 11-30-88	
ALLOPURINOL 100MG	LOPURIN (TABLET; ORAL)	BOOTS PHARMACEUTICAL	18-297 06-10-80	3624205 11-30-88	

TABLE IV. NDA'S APPROVED FROM 1-1-82 TO 2-28-85 AND NDA'S WITH APPROPRIATE PATENT AND EXCLUSIVITY INFORMATION

<u>ACTIVE INGREDIENT(S)</u> <u>STRENGTH(S)</u>	<u>TRADE NAME</u> <u>(DOSAGE FORM; ROUTE)</u>	<u>APPLICANT NAME</u>	<u>NDA NO.</u>		<u>PATENT NO.</u>		<u>EXCLUSIVITY</u>	
			<u>APPROVAL DATE</u>		<u>EXP. DATE</u>		<u>EXP. DATE</u>	
ALLOPURINOL 300MG	LOPURIN (TABLET; ORAL)	BOOTS PHARMACEUTICAL	18-297	06-10-80	3624205	11-30-88		
ALPRAZOLAM 0.25MG	XANAX (TABLET; ORAL)	UPJOHN	18-276	10-16-81	3987052	10-19-93		
					3980789	09-14-93		
ALPRAZOLAM 0.5MG	XANAX (TABLET; ORAL)	UPJOHN	18-276	10-16-81	3987052	10-19-93		
					3980789	09-14-93		
ALPRAZOLAM 1MG	XANAX (TABLET; ORAL)	UPJOHN	18-276	10-16-81	3987052	10-19-93		
					3980789	09-14-93		
AMCINONIDE 0.1%	CYCLOCORT (CREAM; TOPICAL)	LEDERLE LABS/AM CYAN	18-116	10-18-71	4158055	06-12-96		
AMCINONIDE 0.1%	CYCLOCORT (OINTMENT; TOPICAL)	LEDERLE LABS/AM CYAN	18-498	11-13-81	4158055	06-12-96		
AMLORIDE HYDROCHLORIDE; HYDROCHLOROTHIAZIDE 5MG; 50MG	MODURETIC 5/50 (TABLET; ORAL)	MS&D/MERCK	18-201	10-05-81	3781430	12-25-90		
AMINO ACIDS 6.9%	FREAMINE HBC 6.9% (INJECTABLE; INJECTION)	AM MCGAW/AM HOSP	16-822	05-17-83			NS	09-24-86
AMINO ACIDS 6.5%	RENAMIN W/O ELECTROLYTES (INJECTABLE; INJECTION)	TRAVENOL LABS	17-493	10-15-82			NS	09-24-86
AMINO ACIDS 8.5%	NOVAMINE 8.5% (INJECTABLE; INJECTION)	CUTTER LABS/MILES	17-957	08-09-82				
AMINO ACIDS 11.4%	NOVAMINE 11.4% (INJECTABLE; INJECTION)	CUTTER LABS/MILES	17-957	08-09-82				
AMINO ACIDS 8%	HEPATAMINE 8% (INJECTABLE; INJECTION)	AM MCGAW/AM HOSP	18-676	08-03-82	3950529	04-13-93	NS	09-24-86

TABLE IV. NDA'S APPROVED FROM 1-1-82 TO 2-28-85 AND NDA'S WITH APPROPRIATE PATENT AND EXCLUSIVITY INFORMATION

<u>ACTIVE INGREDIENT(S)</u> <u>STRENGTH(S)</u>	<u>TRADE NAME</u> <u>(DOSAGE FORM; ROUTE)</u>	<u>APPLICANT NAME</u>	<u>NDA NO.</u> <u>APPROVAL DATE</u>	<u>PATENT NO.</u> <u>EXP. DATE</u>	<u>EXCLUSIVITY</u> <u>EXP. DATE</u>
AMINO ACIDS 4%	BRANCHAMIN 4% (INJECTABLE; INJECTION)	TRAVENOL LABS	18-678 09-28-84	4438144 03-20-01	NS 09-24-86
AMINO ACIDS 4%	BRANCHAMIN 4% IN PLASTIC CONTAINER (INJECTABLE; INJECTION)	TRAVENOL LABS	18-684 09-28-84	4438144 03-20-01	NS 09-24-86
AMINO ACIDS 6.5%	NEOPHAM 6.5% (INJECTABLE; INJECTION)	CUTTER-VITRUM	18-792 01-17-84		NS 09-24-86
AMINO ACIDS 3.5%	AMINOSYN 3.5% IN PLASTIC CONTAINER (INJECTABLE; INJECTION)	ABBOTT LABORATORIES	18-804 05-15-84		NS 09-24-86
AMINO ACIDS 3.5%	AMINOSYN 3.5% IN PLASTIC CONTAINER (INJECTABLE; INJECTION)	ABBOTT LABORATORIES	18-875 08-08-84		NS 09-24-86
AMINO ACIDS 5.2%	AMINESS 5.2% ESSENTIAL AMINO ACIDS W/ HISTADINE (INJECTABLE; INJECTION)	CUTTER-VITRUM	18-901 04-06-84		
AMINO ACIDS 5.5%	TRAVASOL 5.5% W/O ELECTROLYTES IN PLASTIC CONTAINER (INJECTABLE; INJECTION)	TRAVENOL LABS	18-931 08-23-84		NS 09-24-86
AMINO ACIDS 8.5%	TRAVASOL 8.5% W/O ELECTROLYTES IN PLASTIC CONTAINER (INJECTABLE; INJECTION)	TRAVENOL LABS	18-931 08-23-84		
AMINO ACIDS 10%	TRAVASOL 10% W/O ELECTROLYTES IN PLASTIC CONTAINER (INJECTABLE; INJECTION)	TRAVENOL LABS	18-931 08-23-84		
AMINO ACIDS 6%	TROPHAMINE 6% (INJECTABLE; INJECTION)	AM MCGAW/AM HOSP	19-018 07-20-84		NS 09-24-86

TABLE IV. NDA'S APPROVED FROM 1-1-82 TO 2-28-85 AND NDA'S WITH APPROPRIATE PATENT AND EXCLUSIVITY INFORMATION

<u>ACTIVE INGREDIENT(S)</u> <u>STRENGTH(S)</u>	<u>TRADE NAME</u> <u>(DOSAGE FORM; ROUTE)</u>	<u>APPLICANT NAME</u>	<u>NDA NO.</u> <u>APPROVAL DATE</u>	<u>PATENT NO.</u> <u>EXP. DATE</u>	<u>EXCLUSIVITY</u> <u>EXP. DATE</u>
AMINO ACIDS; CALCIUM ACETATE; GLYCERIN; MAGNESIUM ACETATE; PHOSPHORIC ACID; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE 3%; 26MG/100ML; 3GM/100ML; 54MG/100ML; 41MG/100ML; 149MG/100ML; 204MG/100ML; 117MG/100ML	PERIPHERAMINE (INJECTABLE; INJECTION)	AM MCGAW/AM HOSP	18-582 05-08-82		NC 09-24-86
AMINO ACIDS; DEXTROSE 3.5%; 5%	AMINOSYN 3.5% W/ DEXTROSE 5% IN PLASTIC CONTAINER (INJECTABLE; INJECTION)	ABBOTT LABORATORIES	19-120 10-11-84		
AMINO ACIDS; DEXTROSE 3.5%; 25%	AMINOSYN 3.5% W/ DEXTROSE 25% IN PLASTIC CONTAINER (INJECTABLE; INJECTION)	ABBOTT LABORATORIES	19-118 10-11-84		
AMINO ACIDS; DEXTROSE 4.25%; 25%	AMINOSYN 4.25% W/ DEXTROSE 25% IN PLASTIC CONTAINER (INJECTABLE; INJECTION)	ABBOTT LABORATORIES	19-119 10-11-84		
AMINO ACIDS; MAGNESIUM ACETATE; PHOSPHORIC ACID; POTASSIUM ACETATE; SODIUM CHLORIDE 3.5%; 21MG/100ML; 40MG/100ML; 128MG/100ML; 234MG/100ML	AMINOSYN 3.5% M IN PLASTIC CONTAINER (INJECTABLE; INJECTION)	ABBOTT LABORATORIES	18-804 05-15-84		NC 09-24-86
AMINO ACIDS; MAGNESIUM ACETATE; PHOSPHORIC ACID; POTASSIUM ACETATE; SODIUM CHLORIDE 3.5%; 21MG/100ML; 40MG/100ML; 128MG/100ML; 234MG/100ML	AMINOSYN 3.5% M IN PLASTIC CONTAINER (INJECTABLE; INJECTION)	ABBOTT LABORATORIES	18-875 08-08-84		NC 09-24-86
AMINOACETIC ACID 1.5GM/100ML	AMINOACETIC ACID 1.5% IN PLASTIC CONTAINER (SOLUTION; IRRIGATION)	TRAVENOL LABS	18-522 02-19-82		

TABLE IV. NDA'S APPROVED FROM 1-1-82 TO 2-28-85 AND NDA'S WITH APPROPRIATE PATENT AND EXCLUSIVITY INFORMATION

<u>ACTIVE INGREDIENT(S)</u> <u>STRENGTH(S)</u>	<u>TRADE NAME</u> <u>(DOSAGE FORM; ROUTE)</u>	<u>APPLICANT NAME</u>	<u>NDA NO.</u> <u>APPROVAL DATE</u>	<u>PATENT NO.</u> <u>EXP. DATE</u>	<u>EXCLUSIVITY</u> <u>EXP. DATE</u>
AMINOCAPROIC ACID 250MG/ML	AMINOCAPROIC ACID (INJECTABLE; INJECTION)	ELKINS-SINN/AHROBINS	18-590 10-29-82		
AMINOGLUTETHIMIDE 250MG	CYTADREN (TABLET; ORAL)	CIBA/CIBA-GEIGY	18-202 10-29-80	3595960 07-27-88 3944671 03-16-93	
AMINOPHYLLINE 300MG/5ML	SOMOPHYLLIN (ENEMA; RECTAL)	FISONS	18-232 04-02-82		NR 09-24-86
AMINOPHYLLINE; SODIUM CHLORIDE 100MG/100ML; 450MG/100ML	AMINOPHYLLINE W/ SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER (INJECTABLE; INJECTION)	ABBOTT LABORATORIES	18-924 12-12-84		
AMINOPHYLLINE; SODIUM CHLORIDE 200MG/100ML; 450MG/100ML	AMINOPHYLLINE W/ SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER (INJECTABLE; INJECTION)	ABBOTT LABORATORIES	18-924 12-12-84		
AMINOPHYLLINE; SODIUM CHLORIDE 400MG/100ML; 450MG/100ML	AMINOPHYLLINE W/ SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER (INJECTABLE; INJECTION)	ABBOTT LABORATORIES	18-924 12-12-84		
AMINOPHYLLINE; SODIUM CHLORIDE 500MG/100ML; 450MG/100ML	AMINOPHYLLINE W/ SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER (INJECTABLE; INJECTION)	ABBOTT LABORATORIES	18-924 12-12-84		
AMITRIPTYLINE HYDROCHLORIDE 10MG	ELAVIL (TABLET; ORAL)	MS&D/MERCK	12-703 04-07-61	3384663 05-21-85 3428735 02-18-86	
AMITRIPTYLINE HYDROCHLORIDE 25MG	ELAVIL (TABLET; ORAL)	MS&D/MERCK	12-703 07-05-74	3384663 05-21-85 3428735 02-18-86	

TABLE IV. NDA'S APPROVED FROM 1-1-82 TO 2-28-85 AND NDA'S WITH APPROPRIATE PATENT AND EXCLUSIVITY INFORMATION

<u>ACTIVE INGREDIENT(S)</u> <u>STRENGTH(S)</u>	<u>TRADE NAME</u> <u>(DOSAGE FORM; ROUTE)</u>	<u>APPLICANT NAME</u>	<u>NDA NO.</u> <u>APPROVAL DATE</u>	<u>PATENT NO.</u> <u>EXP. DATE</u>	<u>EXCLUSIVITY</u> <u>EXP. DATE</u>
AMITRIPTYLINE HYDROCHLORIDE 50MG	ELAVIL (TABLET; ORAL)	MS&D/MERCK	12-703 04-07-61	3384663 05-21-85 3428735 02-18-86	
AMITRIPTYLINE HYDROCHLORIDE 75MG	ELAVIL (TABLET; ORAL)	MS&D/MERCK	12-703 10-28-76	3384663 05-21-85 3428735 02-18-86	
AMITRIPTYLINE HYDROCHLORIDE 100MG	ELAVIL (TABLET; ORAL)	MS&D/MERCK	12-703 10-28-76	3384663 05-21-85 3428735 02-18-86	
AMITRIPTYLINE HYDROCHLORIDE 150MG	ELAVIL (TABLET; ORAL)	MS&D/MERCK	12-703 09-17-76	3384663 05-21-85 3428735 02-18-86	
AMITRIPTYLINE HYDROCHLORIDE 10MG/ML	ELAVIL (INJECTABLE; INJECTION)	MS&D/MERCK	12-704 04-11-61	3384663 05-21-85 3428735 02-18-86	
AMITRIPTYLINE HYDROCHLORIDE; CHLORDIAZEPOXIDE 12.5MG; 5MG	LIMBITROL (TABLET; ORAL)	HOFFMANN-LA ROCHE	16-949 12-23-77	3384663 05-21-85 4316897 02-23-99	
AMITRIPTYLINE HYDROCHLORIDE; CHLORDIAZEPOXIDE 25MG; 10MG	LIMBITROL (TABLET; ORAL)	HOFFMANN-LA ROCHE	16-949 12-23-77	3384663 05-21-85 4316897 02-23-99	
AMITRIPTYLINE HYDROCHLORIDE; PERPHENAZINE 10MG; 4MG	ETRAFON A (TABLET; ORAL)	SCHERING	14-713 12-30-65	3384663 05-21-85	
AMITRIPTYLINE HYDROCHLORIDE; PERPHENAZINE 25MG; 2MG	ETRAFON 2-25 (TABLET; ORAL)	SCHERING	14-713 12-30-65	3384663 05-21-85	

TABLE IV. NDA'S APPROVED FROM 1-1-82 TO 2-28-85 AND NDA'S WITH APPROPRIATE PATENT AND EXCLUSIVITY INFORMATION

<u>ACTIVE INGREDIENT(S)</u> <u>STRENGTH(S)</u>	<u>TRADE NAME</u> <u>(DOSAGE FORM; ROUTE)</u>	<u>APPLICANT NAME</u>	<u>NDA NO.</u> <u>APPROVAL DATE</u>	<u>PATENT NO.</u> <u>EXP. DATE</u>	<u>EXCLUSIVITY</u> <u>EXP. DATE</u>
ANITRIPTYLINE HYDROCHLORIDE; PERPHENAZINE 25MG; 4MG	ETRAFON-FORTE (TABLET; ORAL)	SCHERING	14-713 12-30-65	3384663 05-21-85	
ANITRIPTYLINE HYDROCHLORIDE; PERPHENAZINE 10MG; 2MG	ETRAFON 2-10 (TABLET; ORAL)	SCHERING	14-713 12-30-65	3384663 05-21-85	
ANITRIPTYLINE HYDROCHLORIDE; PERPHENAZINE 10MG; 4MG	TRIAVIL 4-10 (TABLET; ORAL)	MS&D/MERCK	14-715 12-30-65	3384663 05-21-85 3428735 02-18-86	
ANITRIPTYLINE HYDROCHLORIDE; PERPHENAZINE 25MG; 2MG	TRIAVIL 2-25 (TABLET; ORAL)	MS&D/MERCK	14-715 08-23-65	3384663 05-21-85 3428735 02-18-86	
ANITRIPTYLINE HYDROCHLORIDE; PERPHENAZINE 10MG; 2MG	TRIAVIL 2-10 (TABLET; ORAL)	MS&D/MERCK	14-715 04-04-67	3384663 05-21-85 3428735 02-18-86	
ANITRIPTYLINE HYDROCHLORIDE; PERPHENAZINE 25MG; 4MG	TRIAVIL 4-25 (TABLET; ORAL)	MS&D/MERCK	14-715 08-25-65	3384663 05-21-85 3428735 02-18-86	
ANITRIPTYLINE HYDROCHLORIDE; PERPHENAZINE 50MG; 4MG	TRIAVIL 4-50 (TABLET; ORAL)	MS&D/MERCK	14-715 03-15-78	3384663 05-21-85 3428735 02-18-86	
ANOXAPINE 25MG	ASENDIN (TABLET; ORAL)	LEDERLE LABS/AM CYAN	18-021 09-22-80	3546226 12-08-87 3663696 05-16-89 3681357 08-01-89	

TABLE IV. NDA'S APPROVED FROM 1-1-82 TO 2-28-85 AND NDA'S WITH APPROPRIATE PATENT AND EXCLUSIVITY INFORMATION

<u>ACTIVE INGREDIENT(S)</u> <u>STRENGTH(S)</u>	<u>TRADE NAME</u> <u>(DOSAGE FORM; ROUTE)</u>	<u>APPLICANT NAME</u>	<u>NDA NO.</u> <u>APPROVAL DATE</u>	<u>PATENT NO.</u> <u>EXP. DATE</u>	<u>EXCLUSIVITY</u> <u>EXP. DATE</u>
AMOXAPINE 50MG	ASENDIN (TABLET; ORAL)	LEDERLE LABS/AM CYAN	18-021 09-22-80	3546226 12-08-87 3663696 05-16-89 3681357 08-01-89	
AMOXAPINE 100MG	ASENDIN (TABLET; ORAL)	LEDERLE LABS/AM CYAN	18-021 09-22-80	3546226 12-08-87 3663696 05-16-89 3681357 08-01-89	
AMOXAPINE 150MG	ASENDIN (TABLET; ORAL)	LEDERLE LABS/AM CYAN	18-021 09-22-80	3546226 12-08-87 3663696 05-16-89 3681357 08-01-89	
AMRINONE LACTATE EQ 5MG BASE/ML	INOCOR (INJECTABLE; INJECTION)	WINTHROP LABS/STERL	18-700 07-31-84	4072746 02-07-95	NCE 07-31-94
ASPIRIN; CAFFEINE; DIHYDROCODEINE BITARTRATE 356.4MG; 30MG; 16MG	SYNALGOS-DC (CAPSULE; ORAL)	IVES LABS/AMHO	11-483 09-06-83		
ASPIRIN; CAFFEINE; ORPHENADRINE CITRATE 385MG; 30MG; 25MG	NORGESIC (TABLET; ORAL)	RIKER LABS/3M	13-416 10-27-82		
ASPIRIN; CAFFEINE; ORPHENADRINE CITRATE 770MG; 60MG; 50MG	NORGESIC FORTE (TABLET; ORAL)	RIKER LABS/3M	13-416 10-27-82		
ASPIRIN; CAFFEINE; PROPOXYPHENE HYDROCHLORIDE 389MG; 32.4MG; 32MG	DARVON COMPOUND (CAPSULE; ORAL)	ELI LILLY INDSTRS/PR	10-996 03-08-83		

TABLE IV. NDA'S APPROVED FROM 1-1-82 TO 2-28-85 AND NDA'S WITH APPROPRIATE PATENT AND EXCLUSIVITY INFORMATION

<u>ACTIVE INGREDIENT(S)</u> <u>STRENGTH(S)</u>	<u>TRADE NAME</u> <u>(DOSAGE FORM; ROUTE)</u>	<u>APPLICANT NAME</u>	<u>NDA NO.</u>		<u>PATENT NO.</u>		<u>EXCLUSIVITY</u>	
			<u>APPROVAL DATE</u>		<u>EXP. DATE</u>		<u>EXP. DATE</u>	
ASPIRIN; CAFFEINE; PROPOXYPHENE HYDROCHLORIDE 389MG; 32.4MG; 65MG	DARVON COMPOUND-65 (CAPSULE; ORAL)	ELI LILLY INDSTRS/PR	10-996	03-08-83				
ASPIRIN; CARISOPRODOL 325MG; 200MG	SOMA COMPOUND (TABLET; ORAL)	WALLACE PHARMS/C-W	12-365	07-11-83				
ASPIRIN; CARISOPRODOL; CODEINE PHOSPHATE 325MG; 200MG; 16MG	SOMA COMPOUND W/ CODEINE (TABLET; ORAL)	WALLACE PHARMS/C-W	12-366	07-11-83				
ASPIRIN; MEPROBAMATE 325MG; 200MG	EQUAGESIC (TABLET; ORAL)	WYETH LABS/AMHO	11-702	12-29-83				
ASPIRIN; PENTAZOCINE HYDROCHLORIDE 325MG; EQ 12.5MG BASE	TALWIN COMPOUND (TABLET; ORAL)	WINTHROP LABS/STERL	16-891	11-12-75	4105659	08-08-95		
ATENOLOL 50MG	TENORMIN (TABLET; ORAL)	STUART PHARMS/ICI AM	18-240	08-19-81	3663607	05-16-89		
					3934032	01-20-93		
					3836671	09-17-91		
					3663607	05-16-89		
					3934032	01-20-93		
					3836671	09-17-91		
ATENOLOL; CHLORTHALIDONE 100MG; 25MG	TENORETIC 100 (TABLET; ORAL)	STUART PHARMS/ICI AM	18-760	06-08-84	3663607	05-16-89	NC	09-24-86
					3934032	01-20-93		
					3836671	09-17-91		

TABLE IV. NDA'S APPROVED FROM 1-1-82 TO 2-28-85 AND NDA'S WITH APPROPRIATE PATENT AND EXCLUSIVITY INFORMATION

<u>ACTIVE INGREDIENT(S)</u> <u>STRENGTH(S)</u>	<u>TRADE NAME</u> <u>(DOSAGE FORM; ROUTE)</u>	<u>APPLICANT NAME</u>	<u>NDA NO.</u> <u>APPROVAL DATE</u>	<u>PATENT NO.</u> <u>EXP. DATE</u>	<u>EXCLUSIVITY</u> <u>EXP. DATE</u>
ATENOLOL; CHLORTHALIDONE 50MG; 25MG	TENORETIC 50 (TABLET; ORAL)	STUART PHARMS/ICI AM	18-760 06-08-84	3663607 05-16-89 3934032 01-20-93 3836671 09-17-91	NC 09-24-86
ATRACURIUM BESYLATE 10MG/ML	TRACRIUM (INJECTABLE; INJECTION)	BURROUGHS WELLCOME	18-831 11-23-83	4179507 12-18-96	NCE 11-23-93
ATROPINE SULFATE; DIFENOXIN HYDROCHLORIDE 0.025MG; 0.5MG	MOTOFEN HALF-STRENGTH (TABLET; ORAL)	MCNEIL LABORATORIES	17-744 07-14-78	3646207 02-28-89	
ATROPINE SULFATE; DIFENOXIN HYDROCHLORIDE 0.025MG; 1MG	MOTOFEN (TABLET; ORAL)	MCNEIL LABORATORIES	17-744 07-14-78	3646207 02-28-89	
AZATADINE MALEATE 1MG	OPTIMINE (TABLET; ORAL)	SCHERING	17-601 03-29-77	3419565 12-31-85 3717647 02-20-90	
AZATADINE MALEATE; PSEUDOEPHEDRINE SULFATE 1MG; 120MG	TRINALIN (TABLET, CONTROLLED RELEASE; ORAL)	SCHERING	18-506 03-23-82	3419565 12-31-85 3717647 02-20-90	NC 09-24-86
BACLOFEN 10MG	LIORESAL (TABLET; ORAL)	GEIGY/CIBA-GEIGY	17-851 11-22-77	3471548 10-07-86	NS 09-24-86
BACLOFEN 20MG	LIORESAL DS (TABLET; ORAL)	GEIGY/CIBA-GEIGY	17-851 01-20-82	3471548 10-07-86	
BENDROFLUMETHIAZIDE 2.5MG	NATURETIN-2.5 (TABLET; ORAL)	ER SQUIBB AND SONS	12-164 12-07-59	3392168 07-09-85	
BENDROFLUMETHIAZIDE 5MG	NATURETIN-5 (TABLET; ORAL)	ER SQUIBB AND SONS	12-164 12-07-59	3392168 07-09-85	
BENDROFLUMETHIAZIDE 10MG	NATURETIN-10 (TABLET; ORAL)	ER SQUIBB AND SONS	12-164 03-29-77	3392168 07-09-85	

TABLE IV. NDA'S APPROVED FROM 1-1-82 TO 2-28-85 AND NDA'S WITH APPROPRIATE PATENT AND EXCLUSIVITY INFORMATION

<u>ACTIVE INGREDIENT(S)</u> <u>STRENGTH(S)</u>	<u>TRADE NAME</u> <u>(DOSAGE FORM; ROUTE)</u>	<u>APPLICANT NAME</u>	<u>NDA NO.</u> <u>APPROVAL DATE</u>	<u>PATENT NO.</u> <u>EXP. DATE</u>	<u>EXCLUSIVITY</u> <u>EXP. DATE</u>
BENDROFLUMETHIAZIDE; NADOLOL 5MG; 40MG	CORZIDE (TABLET; ORAL)	ER SQUIBB AND SONS	18-647 05-25-83	3982021 09-21-93 3935267 01-27-93	NC 09-24-86
BENDROFLUMETHIAZIDE; NADOLOL 5MG; 80MG	CORZIDE (TABLET; ORAL)	ER SQUIBB AND SONS	18-647 05-25-83	3982021 09-21-93 3935267 01-27-93	NC 09-24-86
BENTIROMIDE 500MG/7.5ML	CHYMEX (SOLUTION; ORAL)	ADRIA LABORATORIES	18-366 12-29-83	3801562 04-02-91 3745212 07-10-90	NCE 12-29-93
BETAMETHASONE 0.6MG	CELESTONE (TABLET; ORAL)	SCHERING	12-657 04-17-61	3485854 12-23-86	
BETAMETHASONE 0.6MG/5ML	CELESTONE (SYRUP; ORAL)	SCHERING	14-215 04-18-64	3485854 12-23-86	
BETAMETHASONE 0.2%	CELESTONE (CREAM; TOPICAL)	SCHERING	14-762 04-10-64	3485854 12-23-86	
BETAMETHASONE ACETATE; BETAMETHASONE SODIUM PHOSPHATE 3MG/ML; EQ 3MG BASE/ML	CELESTONE SOLUSPAN (INJECTABLE; INJECTION)	SCHERING	14-602 03-03-65	3485854 12-23-86	
BETAMETHASONE DIPROPIONATE EQ 0.05% BASE	DIPROLENE (OINTMENT; TOPICAL)	SCHERING	18-741 07-27-83		
BETAMETHASONE DIPROPIONATE EQ 0.05% BASE	BETAMETHASONE DIPROPIONATE (CREAM; TOPICAL)	PHARMADERM/BYK-GLDN	19-136 06-26-84		
BETAMETHASONE DIPROPIONATE EQ 0.05% BASE	BETAMETHASONE DIPROPIONATE (CREAM; TOPICAL)	E FOUGERA/BYK-GLDN	19-137 06-26-84		
BETAMETHASONE DIPROPIONATE EQ 0.05% BASE	ALPHATREX (CREAM; TOPICAL)	SAVAGE LABS/BYK-GLDN	19-138 06-26-84		

TABLE IV. NDA'S APPROVED FROM 1-1-82 TO 2-28-85 AND NDA'S WITH APPROPRIATE PATENT AND EXCLUSIVITY INFORMATION

<u>ACTIVE INGREDIENT(S)</u> <u>STRENGTH(S)</u>	<u>TRADE NAME</u> <u>(DOSAGE FORM; ROUTE)</u>	<u>APPLICANT NAME</u>	<u>NDA NO.</u> <u>APPROVAL DATE</u>	<u>PATENT NO.</u> <u>EXP. DATE</u>	<u>EXCLUSIVITY</u> <u>EXP. DATE</u>
BETAMETHASONE DIPROPIONATE EQ 0.05% BASE	BETAMETHASONE DIPROPIONATE (OINTMENT; TOPICAL)	PHARMADERM/BYK-GLDN	19-140 09-04-84		
BETAMETHASONE DIPROPIONATE EQ 0.05% BASE	BETAMETHASONE DIPROPIONATE (OINTMENT; TOPICAL)	E FOUGERA/BYK-GLDN	19-141 09-04-84		
BETAMETHASONE DIPROPIONATE EQ 0.05% BASE	ALPHATREX (OINTMENT; TOPICAL)	SAVAGE LABS/BYK-GLDN	19-143 09-04-84		
BETAMETHASONE DIPROPIONATE EQ 0.05% BASE	DIPROSONE (CREAM; TOPICAL)	SCHERING	17-536 01-29-75		D-1 09-24-86
BETAMETHASONE DIPROPIONATE EQ 0.05% BASE	DIPROSONE (OINTMENT; TOPICAL)	SCHERING	17-691 04-15-76		D-1 09-24-86
BETAMETHASONE DIPROPIONATE EQ 0.05% BASE	DIPROSONE (LOTION; TOPICAL)	SCHERING	17-781 02-01-77		D-1 09-24-86
BETAMETHASONE DIPROPIONATE EQ 0.1% BASE	DIPROSONE (AEROSOL; TOPICAL)	SCHERING	17-829 05-24-77		D-1 09-24-86
BETAMETHASONE DIPROPIONATE; CLOTRIMAZOLE EQ 0.05% BASE; 1%	LOTTRISONE (CREAM; TOPICAL)	SCHERING	18-827 07-10-84	3660577 05-02-89 3705172 12-05-89 4298604 11-03-98 3839573 10-01-91	NC 09-24-86
BETAMETHASONE VALERATE EQ 0.1% BASE	BETA-VAL (CREAM; TOPICAL)	LEMMON	18-642 03-24-83		
BETAMETHASONE VALERATE EQ 0.1% BASE	BETADERM (CREAM; TOPICAL)	TJ ROACO	18-839 06-30-83		
BETAMETHASONE VALERATE EQ 0.1% BASE	BETAMETHASONE VALERATE (CREAM; TOPICAL)	PHARMADERM/BYK-GLDN	18-860 08-31-83		
BETAMETHASONE VALERATE EQ 0.1% BASE	BETAMETHASONE VALERATE (CREAM; TOPICAL)	E FOUGERA/BYK-GLDN	18-861 08-31-83		

TABLE IV. NDA'S APPROVED FROM 1-1-82 TO 2-28-85 AND NDA'S WITH APPROPRIATE PATENT AND EXCLUSIVITY INFORMATION

<u>ACTIVE INGREDIENT(S)</u> <u>STRENGTH(S)</u>	<u>TRADE NAME</u> <u>(DOSAGE FORM; ROUTE)</u>	<u>APPLICANT NAME</u>	<u>NDA NO.</u> <u>APPROVAL DATE</u>	<u>PATENT NO.</u> <u>EXP. DATE</u>	<u>EXCLUSIVITY</u> <u>EXP. DATE</u>
BETAMETHASONE VALERATE EQ 0.1% BASE	BETATREX (CREAM; TOPICAL)	SAVAGE LABS/BYK-GLDN	18-862 08-31-83		
BETAMETHASONE VALERATE EQ 0.1% BASE	BETATREX (OINTMENT; TOPICAL)	SAVAGE LABS/BYK-GLDN	18-863 08-31-83		
BETAMETHASONE VALERATE EQ 0.1% BASE	BETAMETHASONE VALERATE (OINTMENT; TOPICAL)	PHARMADERM/BYK-GLDN	18-864 08-31-83		
BETAMETHASONE VALERATE EQ 0.1% BASE	BETAMETHASONE VALERATE (OINTMENT; TOPICAL)	E FOUGERA/BYK-GLDN	18-865 08-31-83		
BETAMETHASONE VALERATE EQ 0.1% BASE	BETAMETHASONE VALERATE (LOTION; TOPICAL)	E FOUGERA/BYK-GLDN	18-866 08-31-83		
BETAMETHASONE VALERATE EQ 0.1% BASE	BETATREX (LOTION; TOPICAL)	SAVAGE LABS/BYK-GLDN	18-867 08-31-83		
BETAMETHASONE VALERATE EQ 0.1% BASE	BETAMETHASONE VALERATE (LOTION; TOPICAL)	PHARMADERM/BYK-GLDN	18-870 08-31-83		
BETHANIDINE SULFATE 10MG	TENATHAN (TABLET; ORAL)	AH ROBINS	17-675 05-29-81	3495013 02-10-87	
BETHANIDINE SULFATE 25MG	TENATHAN (TABLET; ORAL)	AH ROBINS	17-675 05-29-81	3495013 02-10-87	
BITOLTEROL MESYLATE 0.8%	TORNALATE (AEROSOL; INHALATION)	WINTHROP-BREON/STERL	18-770 12-28-84	4138581 02-06-96	NCE 12-28-89
BRETYLIUM TOSYLATE 50MG/ML	BRETYLOL (INJECTABLE; INJECTION)	AM CRITICAL CARE/AHS	17-954 07-18-78	RE29618 04-29-86	
BROMOCRIPTINE MESYLATE EQ 2.5MG BASE	PARLODEL (TABLET; ORAL)	SANDOZ PHARMS/SANDOZ	17-962 06-28-78	3752888 08-14-90 3752814 08-14-90	I-16 12-14-87
BROMOCRIPTINE MESYLATE EQ 5MG BASE	PARLODEL (CAPSULE; ORAL)	SANDOZ PHARMS/SANDOZ	17-962 03-01-82	3752888 08-14-90 3752814 08-14-90	I-16 12-14-87

TABLE IV. NDA'S APPROVED FROM 1-1-82 TO 2-28-85 AND NDA'S WITH APPROPRIATE PATENT AND EXCLUSIVITY INFORMATION

<u>ACTIVE INGREDIENT(S)</u> <u>STRENGTH(S)</u>	<u>TRADE NAME</u> <u>(DOSAGE FORM; ROUTE)</u>	<u>APPLICANT NAME</u>	<u>NDA NO.</u>		<u>PATENT NO.</u>		<u>EXCLUSIVITY</u>	
			<u>APPROVAL DATE</u>		<u>EXP. DATE</u>		<u>EXP. DATE</u>	
BROMODIPHENHYDRAMINE HYDROCHLORIDE; CODEINE PHOSPHATE 12.5MG/5ML; 10MG/5ML	AMBYL (SYRUP; ORAL)	MARION LABORATORIES	09-319 01-10-84					
BROMPHENIRAMINE MALEATE; CODEINE PHOSPHATE; PHENYLPROPANOLAMINE HYDROCHLORIDE 2MG/5ML; 10MG/5ML; 12.5MG/5ML	DIMETANE-DC (SYRUP; ORAL)	AH ROBINS	11-694 03-29-84					
BROMPHENIRAMINE MALEATE; DEXTROMETHORPHAN HYDROBROMIDE; PSEUDOEPHEDRINE HYDROCHLORIDE 2MG/5ML; 10MG/5ML; 30MG/5ML	DIMETANE-DX (SYRUP; ORAL)	AH ROBINS	11-694 03-29-84					
BROMPHENIRAMINE MALEATE; DEXTROMETHORPHAN HYDROBROMIDE; PSEUDOEPHEDRINE HYDROCHLORIDE 2MG/5ML; 10MG/5ML; 30MG/5ML	DIMETANE-DX (SYRUP; ORAL)	AH ROBINS	19-279 08-24-84					
BROMPHENIRAMINE MALEATE; PHENYLPROPANOLAMINE HYDROCHLORIDE 12MG; 75MG	DIMETAPP (TABLET, CONTROLLED RELEASE; ORAL)	AH ROBINS	12-436 04-02-84					
BROMPHENIRAMINE MALEATE; PHENYLPROPANOLAMINE HYDROCHLORIDE 4MG/5ML; 25MG/5ML	ELIXIR DIMETAPP (ELIXIR; ORAL)	AH ROBINS	13-087 03-29-84					
BUMETANIDE 1MG	BUMEX (TABLET; ORAL)	HOFFMANN-LA ROCHE	18-225 02-28-83	3634583 01-11-89 3806534 04-23-91	NCE 02-28-93			
BUMETANIDE 0.5MG	BUMEX (TABLET; ORAL)	HOFFMANN-LA ROCHE	18-225 02-28-83	3634583 01-11-89 3806534 04-23-91	NCE 02-28-93			
BUMETANIDE 0.25MG/ML	BUMEX (INJECTABLE; INJECTION)	HOFFMANN-LA ROCHE	18-226 02-28-83	3634583 01-11-89 3806534 04-23-91	NCE 02-28-93			

TABLE IV. NDA'S APPROVED FROM 1-1-82 TO 2-28-85 AND NDA'S WITH APPROPRIATE PATENT AND EXCLUSIVITY INFORMATION

<u>ACTIVE INGREDIENT(S)</u> <u>STRENGTH(S)</u>	<u>TRADE NAME</u> <u>(DOSAGE FORM; ROUTE)</u>	<u>APPLICANT NAME</u>	<u>NDA NO.</u> <u>APPROVAL DATE</u>	<u>PATENT NO.</u> <u>EXP. DATE</u>	<u>EXCLUSIVITY</u> <u>EXP. DATE</u>
BUPIVACAINE HYDROCHLORIDE; DEXTROSE 0.75%; 8.25%	MARCAINE SPINAL (INJECTABLE; INJECTION)	BREON LABS/STERLING	18-692 05-04-84		NC 09-24-86
BUPIVACAINE HYDROCHLORIDE; EPINEPHRINE BITARTRATE 0.5%; 0.0091MG/ML	SENSORCAINE (INJECTABLE; INJECTION)	ASTRA PHARM PRODS	18-304 09-02-83		
BUPIVACAINE HYDROCHLORIDE; EPINEPHRINE BITARTRATE 0.75%; 0.0091MG/ML	SENSORCAINE (INJECTABLE; INJECTION)	ASTRA PHARM PRODS	18-304 09-02-83		
BUTORPHANOL TARTRATE 1MG/ML	STADOL (INJECTABLE; INJECTION)	BRISTOL LABS/B-M	17-857 08-22-78	3819635 06-25-91	
BUTORPHANOL TARTRATE 2MG/ML	STADOL (INJECTABLE; INJECTION)	BRISTOL LABS/B-M	17-857 08-22-78	3819635 06-25-91	
CALCEFEDIOL, ANHYDROUS 0.02MG	CALDEROL (CAPSULE; ORAL)	UPJOHN	18-312 08-05-80	3833622 09-03-91 3565924 03-23-86	
CALCEFEDIOL, ANHYDROUS 0.05MG	CALDEROL (CAPSULE; ORAL)	UPJOHN	18-312 08-05-80	3833622 09-03-91 3565924 03-23-86	
CALCITONIN 200 IU/VIAL	CALCIMAR (INJECTABLE; INJECTION)	ARMOUR PHARM	17-769 12-21-84		I-18 12-21-87
CALCITONIN 400 IU/VIAL	CALCIMAR (INJECTABLE; INJECTION)	ARMOUR PHARM	17-497 12-21-84		I-18 12-21-87
CALCITRIOL 0.25 UGM	ROCALTROL (CAPSULE; ORAL)	HOFFMANN-LA ROCHE	18-044 08-17-78	3697559 10-10-89 4391802 07-05-00 4341774 07-27-99 4225596 09-30-97	

TABLE IV. NDA'S APPROVED FROM 1-1-82 TO 2-28-85 AND NDA'S WITH APPROPRIATE PATENT AND EXCLUSIVITY INFORMATION

<u>ACTIVE INGREDIENT(S)</u> <u>STRENGTH(S)</u>	<u>TRADE NAME</u> <u>(DOSAGE FORM; ROUTE)</u>	<u>APPLICANT NAME</u>	<u>NDA NO.</u> <u>APPROVAL DATE</u>	<u>PATENT NO.</u> <u>EXP. DATE</u>	<u>EXCLUSIVITY</u> <u>EXP. DATE</u>
CALCITRIOL 0.5 UG	ROCALTRIL (CAPSULE; ORAL)	HOFFMANN-LA ROCHE	18-044 08-17-78	3697559 10-10-89 4391802 07-05-00 4341774 07-27-99 4225596 09-30-97	
CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM CITRATE 34MG/100ML; 5GM/100ML; 30MG/100ML; 74MG/100ML; 640MG/100ML; 500MG/100ML; 74MG/100ML	ISOLYTE E W/ DEXTROSE 5% IN PLASTIC CONTAINER (INJECTABLE; INJECTION)	AM MCGAW/AM HOSP	18-269 01-17-83		
CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE 510MG/100ML; 30GM/100ML; 200MG/100ML; 9.2GM/100ML; 9.6GM/100ML	DIALYTE CONCENTRATE W/ DEXTROSE 30% IN PLASTIC CONTAINER (SOLUTION; INTRAPERITONEAL)	AM MCGAW/AM HOSP	18-807 08-26-83		
CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE 510MG/100ML; 50GM/100ML; 200MG/100ML; 9.2GM/100ML; 9.6GM/100ML	DIALYTE CONCENTRATE W/ DEXTROSE 50% IN PLASTIC CONTAINER (SOLUTION; INTRAPERITONEAL)	AM MCGAW/AM HOSP	18-807 08-26-83		
CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE 510MG/100ML; 30GM/100ML; 200MG/100ML; 9.4GM/100ML; 11GM/100ML	DIALYTE CONCENTRATE W/ DEXTROSE 30% IN PLASTIC CONTAINER (SOLUTION; INTRAPERITONEAL)	AM MCGAW/AM HOSP	18-807 08-26-83		
CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE 510MG/100ML; 50GM/100ML; 200MG/100ML; 9.4GM/100ML; 11GM/100ML	DIALYTE CONCENTRATE W/ DEXTROSE 50% IN PLASTIC CONTAINER (SOLUTION; INTRAPERITONEAL)	AM MCGAW/AM HOSP	18-807 08-26-83		

TABLE IV. NDA'S APPROVED FROM 1-1-82 TO 2-28-85 AND NDA'S WITH APPROPRIATE PATENT AND EXCLUSIVITY INFORMATION

ACTIVE INGREDIENT(S) STRENGTH(S)	TRADE NAME (DOSAGE FORM; ROUTE)	APPLICANT NAME	NDA NO. APPROVAL DATE	PATENT NO. EXP. DATE	EXCLUSIVITY EXP. DATE
CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE 25.7MG/100ML; 1.5GM/100ML; 15.2MG/100ML; 567MG/100ML; 392MG/100ML	DEL FLEX W/ DEXTROSE 1.5% IN PLASTIC CONTAINER (SOLUTION; INTRAPERITONEAL)	DELMED	18-883 11-30-84		
CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE 25.7MG/100ML; 2.5GM/100ML; 15.2MG/100ML; 567MG/100ML; 392MG/100ML	DEL FLEX W/ DEXTROSE 2.5% IN PLASTIC CONTAINER (SOLUTION; INTRAPERITONEAL)	DELMED	18-883 11-30-84		
CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE 25.7MG/100ML; 4.25GM/100ML; 15.2MG/100ML; 567MG/100ML; 392MG/100ML	DEL FLEX W/ DEXTROSE 4.25% IN PLASTIC CONTAINER (SOLUTION; INTRAPERITONEAL)	DELMED	18-883 11-30-84		
CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE 25.7MG/100ML; 1.5GM/100ML; 5.08MG/100ML; 538MG/100ML; 448MG/100ML	DEL FLEX W/ DEXTROSE 1.5% LOW MAGNESIUM IN PLASTIC CONTAINER (SOLUTION; INTRAPERITONEAL)	DELMED	18-883 11-30-84		
CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE 25.7MG/100ML; 2.5GM/100ML; 5.08MG/100ML; 538MG/100ML; 448MG/100ML	DEL FLEX W/ DEXTROSE 2.5% LOW MAGNESIUM IN PLASTIC CONTAINER (SOLUTION; INTRAPERITONEAL)	DELMED	18-883 11-30-84		
CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE 25.7MG/100ML; 4.25GM/100ML; 15.2MG/100ML; 567MG/100ML; 392MG/100ML	DEL FLEX W/ DEXTROSE 4.25% LOW MAGNESIUM IN PLASTIC CONTAINER (SOLUTION; INTRAPERITONEAL)	DELMED	18-883 11-30-84		

TABLE IV. NDA'S APPROVED FROM 1-1-82 TO 2-28-85 AND NDA'S WITH APPROPRIATE PATENT AND EXCLUSIVITY INFORMATION

<u>ACTIVE INGREDIENT(S)</u> <u>STRENGTH(S)</u>	<u>TRADE NAME</u> <u>(DOSAGE FORM; ROUTE)</u>	<u>APPLICANT NAME</u>	<u>NDA NO.</u> <u>APPROVAL DATE</u>	<u>PATENT NO.</u> <u>EXP. DATE</u>	<u>EXCLUSIVITY</u> <u>EXP. DATE</u>
CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE 25.7MG/100ML; 1.5GM/100ML; 5.08MG/100ML; 538MG/100ML; 448MG/100ML	INPERSOL-LM W/ DEXTROSE 1.5% IN PLASTIC CONTAINER (SOLUTION; INTRAPERITONEAL)	ABBOTT LABORATORIES	18-379 07-07-82		
CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE 25.7MG/100ML; 2.5GM/100ML; 5.08MG/100ML; 538MG/100ML; 448MG/100ML	INPERSOL-LM W/ DEXTROSE 2.5% IN PLASTIC CONTAINER (SOLUTION; INTRAPERITONEAL)	ABBOTT LABORATORIES	18-379 07-07-82		
CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE 25.7MG/100ML; 4.25GM/100ML; 5.08MG/100ML; 538MG/100ML; 448MG/100ML	INPERSOL-LM W/ DEXTROSE 4.25% IN PLASTIC CONTAINER (SOLUTION; INTRAPERITONEAL)	ABBOTT LABORATORIES	18-379 07-07-82		
CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE 26MG/100ML; 2.5GM/100ML; 15MG/100ML; 560MG/100ML; 390MG/100ML	DIALYTE W/ DEXTROSE 2.5% IN PLASTIC CONTAINER (SOLUTION; INTRAPERITONEAL)	AM MCGAW/AM HOSP	18-460 11-02-83		
CALCIUM CHLORIDE; DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE 33MG/100ML; 5GM/100ML; 30MG/100ML; 860MG/100ML	DEXTROSE 5% AND RINGER'S IN PLASTIC CONTAINER (INJECTABLE; INJECTION)	TRAVENOL LABS	18-635 02-07-83		
CALCIUM CHLORIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE 16.5MG/ML; 25.4MG/ML; 74.6MG/ML; 121MG/ML; 16.1MG/ML	TPN ELECTROLYTES IN PLASTIC CONTAINER (INJECTABLE; INJECTION)	ABBOTT LABORATORIES	18-895 07-20-84		NC 09-24-86
CALCIUM CHLORIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM CITRATE 35MG/100ML; 30MG/100ML; 74MG/100ML; 640MG/100ML; 500MG/100ML; 74MG/100ML	ISOLYTE E IN PLASTIC CONTAINER (INJECTABLE; INJECTION)	AM MCGAW/AM HOSP	18-899 10-31-83		

TABLE IV. NDA'S APPROVED FROM 1-1-82 TO 2-28-85 AND NDA'S WITH APPROPRIATE PATENT AND EXCLUSIVITY INFORMATION

<u>ACTIVE INGREDIENT(S)</u> <u>STRENGTH(S)</u>	<u>TRADE NAME</u> <u>(DOSAGE FORM; ROUTE)</u>	<u>APPLICANT NAME</u>	<u>NDA NO.</u> <u>APPROVAL DATE</u>	<u>PATENT NO.</u> <u>EXP. DATE</u>	<u>EXCLUSIVITY</u> <u>EXP. DATE</u>
CALCIUM CHLORIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE 17.6MG/100ML; 325.3MG/100ML; 119.3MG/100ML; 643MG/100ML	PLEGISOL IN PLASTIC CONTAINER (SOLUTION; PERFUSION, CARDIAC)	ABBOTT LABORATORIES	18-608 02-26-82		NC 09-24-86
SODIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE 20MG/100ML; 30MG/100ML; 380MG/100ML; 600MG/100ML	ACETATED RINGER'S IN PLASTIC CONTAINER (INJECTABLE; INJECTION)	AM MCGAW/AM HOSP	18-725 11-29-82		
CALCIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE 33MG/100ML; 30MG/100ML; 860MG/100ML	RINGER'S IN PLASTIC CONTAINER (SOLUTION; IRRIGATION)	TRAVENOL LABS	18-495 02-19-82		
CALCIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE 33MG/100ML; 30MG/100ML; 860MG/100ML	RINGERS INJECTION IN PLASTIC CONTAINER (INJECTABLE; INJECTION)	TRAVENOL LABS	18-648 02-07-83		
CALCIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE 33MG/100ML; 30MG/100ML; 860MG/100ML	RINGER'S IN PLASTIC CONTAINER (INJECTABLE; INJECTION)	AM MCGAW/AM HOSP	18-721 11-09-82		
CALCIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE 20MG/100ML; 30MG/100ML; 600MG/100ML; 310MG/100ML	LACTATED RINGER'S IN PLASTIC CONTAINER (SOLUTION; IRRIGATION)	TRAVENOL LABS	18-494 02-19-82		
CALCIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE 20MG/100ML; 30MG/100ML; 600MG/100ML; 310MG/100ML	LACTATED RINGER'S IN PLASTIC CONTAINER (SOLUTION; IRRIGATION)	AM MCGAW/AM HOSP	18-681 12-27-82		
CALCIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE 20MG/100ML; 30MG/100ML; 600MG/100ML; 310MG/100ML	LACTATED RINGER'S IN PLASTIC CONTAINER (SOLUTION; IRRIGATION)	TRAVENOL LABS	18-921 04-03-84		

TABLE IV. NDA'S APPROVED FROM 1-1-82 TO 2-28-85 AND NDA'S WITH APPROPRIATE PATENT AND EXCLUSIVITY INFORMATION

<u>ACTIVE INGREDIENT(S)</u> <u>STRENGTH(S)</u>	<u>TRADE NAME</u> <u>(DOSAGE FORM; ROUTE)</u>	<u>APPLICANT NAME</u>	<u>NDA NO.</u> <u>APPROVAL DATE</u>	<u>PATENT NO.</u> <u>EXP. DATE</u>	<u>EXCLUSIVITY</u> <u>EXP. DATE</u>
CALCIUM METRIZOATE; MAGNESIUM METRIZOATE; MEGLUMINE METRIZOATE; METRIZOATE SODIUM 0.78MG/ML; 0.15MG/ML; 75.9MG/ML; 16.6MG/ML	ISOPAQUE 440 (INJECTABLE; INJECTION)	WINTHROP LABS/STERL	16-847 11-17-73	3476802 11-04-86	
CALCIUM; MEGLUMINE; METRIZOIC ACID 0.35MG/ML; 140.1MG/ML; 461.8MG/ML	ISOPAQUE 280 (INJECTABLE; INJECTION)	WINTHROP LABS/STERL	17-506 04-30-74	3476802 11-04-86	
CAPTOPRIL 12.5MG	CAPOTEN (TABLET; ORAL)	ER SQUIBB AND SONS	18-343 01-17-85	4105776 08-08-95	I-20 09-24-86 D-7 10-12-87
CAPTOPRIL 25MG	CAPOTEN (TABLET; ORAL)	ER SQUIBB AND SONS	18-343 04-06-81	4105776 08-08-95	I-20 09-24-86 D-7 10-12-87
CAPTOPRIL 50MG	CAPOTEN (TABLET; ORAL)	ER SQUIBB AND SONS	18-343 04-06-81	4105776 08-08-95	I-20 09-24-86 D-7 10-12-87
CAPTOPRIL 100MG	CAPOTEN (TABLET; ORAL)	ER SQUIBB AND SONS	18-343 04-06-81	4105776 08-08-95	I-20 09-24-86 D-7 10-12-87
CAPTOPRIL; HYDROCHLOROTHIAZIDE 25MG; 15MG	CAPOZIDE 25/15 (TABLET; ORAL)	ER SQUIBB AND SONS	18-709 10-12-84	4105776 08-08-95 4217347 08-12-97	NC 10-12-87
CAPTOPRIL; HYDROCHLOROTHIAZIDE 50MG; 15MG	CAPOZIDE 50/15 (TABLET; ORAL)	ER SQUIBB AND SONS	18-709 10-12-84	4105776 08-08-95 4217347 08-12-97	NC 10-12-87
CAPTOPRIL; HYDROCHLOROTHIAZIDE 50MG; 25MG	CAPOZIDE 50/25 (TABLET; ORAL)	ER SQUIBB AND SONS	18-709 10-12-84	4105776 08-08-95 4217347 08-12-97	NC 10-12-87

TABLE IV. NDA'S APPROVED FROM 1-1-82 TO 2-28-85 AND NDA'S WITH APPROPRIATE PATENT AND EXCLUSIVITY INFORMATION

<u>ACTIVE INGREDIENT(S)</u> <u>STRENGTH(S)</u>	<u>TRADE NAME</u> <u>(DOSAGE FORM; ROUTE)</u>	<u>APPLICANT NAME</u>	<u>NDA NO.</u> <u>APPROVAL DATE</u>	<u>PATENT NO.</u> <u>EXP. DATE</u>	<u>EXCLUSIVITY</u> <u>EXP. DATE</u>
CARBAMAZEPINE 200MG	TEGRETOL (TABLET; ORAL)	GEIGY/CIBA-GEIGY	16-608 03-11-68	4409212 10-11-00	
CARBAMAZEPINE 100MG	TEGRETOL (TABLET, CHEWABLE; ORAL)	GEIGY/CIBA-GEIGY	18-281 12-14-81	4409212 10-11-00	
CARBIDOPA 25MG	LODOSYN (TABLET; ORAL)	MS&D/MERCK	17-830 04-25-77	3462536 08-19-86 3830827 08-20-91 3781415 12-25-90	
CARBIDOPA; LEVODOPA 10MG; 100MG	SINEMET (TABLET; ORAL)	MS&D/MERCK	17-555 05-02-75	3462536 08-19-86 3769424 10-30-90 3781415 12-25-90 3830827 08-20-91 RE29892 10-30-90	
CARBIDOPA; LEVODOPA 25MG; 250MG	SINEMET (TABLET; ORAL)	MS&D/MERCK	17-555 05-02-75	3462536 08-19-86 3769424 10-30-90 3781415 12-25-90 3830827 08-20-91 RE29892 10-30-90	

TABLE IV. NDA'S APPROVED FROM 1-1-82 TO 2-28-85 AND NDA'S WITH APPROPRIATE PATENT AND EXCLUSIVITY INFORMATION

<u>ACTIVE INGREDIENT(S)</u> <u>STRENGTH(S)</u>	<u>TRADE NAME</u> <u>(DOSAGE FORM; ROUTE)</u>	<u>APPLICANT NAME</u>	<u>NDA NO.</u> <u>APPROVAL DATE</u>	<u>PATENT NO.</u> <u>EXP. DATE</u>	<u>EXCLUSIVITY</u> <u>EXP. DATE</u>
CARBIDOPA; LEVODOPA 25MG; 100MG	SINEMET (TABLET; ORAL)	MS&D/MERCK	17-555 05-02-75	3462536 08-19-86 3769424 10-30-90 3781415 12-25-90 3830827 08-20-91 RE29892 10-30-90	
CARBOPROST TROMETHAMINE EQ 0.25MG BASE/ML	PROSTIN/15M (INJECTABLE; INJECTION)	UPJOHN	17-989 01-09-79	3728382 04-17-90	
CELLULOSE SODIUM PHOSPHATE 2.5GM/PACKET	CALCIBIND (POWDER; ORAL)	MISSION PHARMACAL	18-757 12-28-82		NCE 12-28-92
CERULETIDE DIETHYLAMINE 0.02MG/ML	TYMPHAN (INJECTABLE; INJECTION)	ADRIA LABORATORIES	18-296 12-24-81	3472832 10-14-86	
CHENODIOL 250MG	CHENIX (TABLET; ORAL)	ROWELL LABORATORIES	18-513 07-28-83		NCE 07-28-93
CHLORDIAZEPOXIDE 25MG	LIBRITABS (TABLET; ORAL)	ROCHE PRODUCTS	13-071 10-31-66	4316897 02-23-99	
CHLORDIAZEPOXIDE 5MG	LIBRITABS (TABLET; ORAL)	ROCHE PRODUCTS	13-071 10-31-66	4316897 02-23-99	
CHLORDIAZEPOXIDE 10MG	LIBRITABS (TABLET; ORAL)	ROCHE PRODUCTS	13-071 10-31-66	4316897 02-23-99	
CHLORDIAZEPOXIDE 30MG	LIBRELEASE (CAPSULE, CONTROLLED RELEASE; ORAL)	HOFFMANN-LA ROCHE	17-813 09-12-83	4316897 02-23-99	NDF 09-24-86
CHLORDIAZEPOXIDE HYDROCHLORIDE 5MG	LIBRIUM (CAPSULE; ORAL)	ROCHE PRODUCTS	12-249 02-24-60	4316897 02-23-99	
CHLORDIAZEPOXIDE HYDROCHLORIDE 10MG	LIBRIUM (CAPSULE; ORAL)	ROCHE PRODUCTS	12-249 02-24-60	4316897 02-23-99	

TABLE IV. NDA'S APPROVED FROM 1-1-82 TO 2-28-85 AND NDA'S WITH APPROPRIATE PATENT AND EXCLUSIVITY INFORMATION

ACTIVE INGREDIENT(S) STRENGTH(S)	TRADE NAME (DOSAGE FORM; ROUTE)	APPLICANT NAME	NDA NO. APPROVAL DATE	PATENT NO. EXP. DATE	EXCLUSIVITY EXP. DATE
CHLORDIAZEPOXIDE HYDROCHLORIDE 25MG	LIBRIUM (CAPSULE; ORAL)	ROCHE PRODUCTS	12-249 02-24-60	4316897 02-23-99	
CHLORDIAZEPOXIDE HYDROCHLORIDE 100MG/AMP	LIBRIUM (INJECTABLE; INJECTION)	HOFFMANN-LA ROCHE	12-301 07-21-61	4316897 02-23-99	
CHLORDIAZEPOXIDE HYDROCHLORIDE; CLIDINIUM BROMIDE 5MG; 2.5MG	LIBRAX (CAPSULE; ORAL)	HOFFMANN-LA ROCHE	12-750 05-02-61	4316897 02-23-99	
CHLORDIAZEPOXIDE; ESTROGENS, CONJUGATED 5MG; 0.2MG	MENRIUM 5-2 (TABLET; ORAL)	HOFFMANN-LA ROCHE	14-740 10-27-69	4316897 02-23-99	
CHLORDIAZEPOXIDE; ESTROGENS, CONJUGATED 5MG; 0.4MG	MENRIUM 5-4 (TABLET; ORAL)	HOFFMANN-LA ROCHE	14-740 10-27-69	4316897 02-23-99	
CHLORDIAZEPOXIDE; ESTROGENS, CONJUGATED 10MG; 0.4MG	MENRIUM 10-4 (TABLET; ORAL)	HOFFMANN-LA ROCHE	14-740 10-27-69	4316897 02-23-99	
CHLOROXINE 2%	CAPITROL (SHAMPOO; TOPICAL)	WESTWOOD PHARMS	17-594 10-19-76	3886277 05-27-92	
CHLORTHALIDONE; CLONIDINE HYDROCHLORIDE 15MG; 0.1MG	COMBIPRES (TABLET; ORAL)	BOEHRINGER INGELHEIM	17-503 08-22-74	3454701 07-08-86	
CHLORTHALIDONE; CLONIDINE HYDROCHLORIDE 15MG; 0.2MG	COMBIPRES (TABLET; ORAL)	BOEHRINGER INGELHEIM	17-503 08-22-74	3454701 07-08-86	
CHLORTHALIDONE; CLONIDINE HYDROCHLORIDE 15MG; 0.3MG	COMBIPRES (TABLET; ORAL)	BOEHRINGER INGELHEIM	17-503 04-10-84	3454701 07-08-86	
CHOLESTYRAMINE EQ 4GM RESIN/PACKET	QUESTRAN (POWDER; ORAL)	MEAD JOHNSON/B-M	16-019 12-06-66	3383281 05-18-85	I-23 09-24-86
CHOLESTYRAMINE EQ 4GM RESIN/PACKET	QUESTRAN (POWDER; ORAL)	MEAD JOHNSON/B-M	16-640 08-03-73	3383281 05-18-85	I-23 09-24-86
CHYMOPAPAIN 12,500 UNITS/VIAL	DISCARE (INJECTABLE; INJECTION)	TRAVENOL LABS	18-625 01-18-84		NCE 11-10-92

TABLE IV. NDA'S APPROVED FROM 1-1-82 TO 2-28-85 AND NDA'S WITH APPROPRIATE PATENT AND EXCLUSIVITY INFORMATION

<u>ACTIVE INGREDIENT(S)</u> <u>STRENGTH(S)</u>	<u>TRADE NAME</u> <u>(DOSAGE FORM; ROUTE)</u>	<u>APPLICANT NAME</u>	<u>NDA NO.</u> <u>APPROVAL DATE</u>	<u>PATENT NO.</u> <u>EXP. DATE</u>	<u>EXCLUSIVITY</u> <u>EXP. DATE</u>
CHYMOPAPAIN 10,000 UNITS/VIAL	CHYMODIACTIN (INJECTABLE; INJECTION)	SMITH LABORATORIES	18-663 11-10-82	4439423 03-26-01	NCE 11-10-92
CHYMOPAPAIN 4,000 UNITS/VIAL	CHYMODIACTIN (INJECTABLE; INJECTION)	SMITH LABORATORIES	18-663 08-21-84	4439423 03-26-01	NCE 11-10-92
CICLOPIROX OLAMINE 1%	LOPROX (CREAM; TOPICAL)	HOECHST-ROUSSEL	18-748 12-30-82	3883545 05-13-92	NCE 12-30-92
CIMETIDINE 200MG	TAGAMET (TABLET; ORAL)	SK&F LAB	17-920 08-16-77	3950333 04-13-93 4024271 05-17-94	
CIMETIDINE 300MG	TAGAMET (TABLET; ORAL)	SK&F LAB	17-920 08-16-77	3950333 04-13-93 4024271 05-17-94	
CIMETIDINE 400MG	TAGAMET (TABLET; ORAL)	SK&F LAB	17-920 12-14-83	3950333 04-13-93 4024271 05-17-94	NS 09-24-86
CIMETIDINE HYDROCHLORIDE EQ 300MG BASE/5ML	TAGAMET (SOLUTION; ORAL)	SK&F LAB	17-924 08-16-77	3950333 04-13-93 4024271 05-17-94	
CIMETIDINE HYDROCHLORIDE EQ 150MG BASE/ML	TAGAMET (INJECTABLE; INJECTION)	SK&F LAB	17-939 08-16-77	3950333 04-13-93 4024271 05-17-94	
CINOXACIN 250MG	CINOBAC (CAPSULE; ORAL)	ELI LILLY	18-067 06-13-80	3669965 06-13-89	
CINOXACIN 500MG	CINOBAC (CAPSULE; ORAL)	ELI LILLY	18-067 06-13-80	3669965 06-13-89	

TABLE IV. NDA'S APPROVED FROM 1-1-82 TO 2-28-85 AND NDA'S WITH APPROPRIATE PATENT AND EXCLUSIVITY INFORMATION

ACTIVE INGREDIENT(S) STRENGTH(S)	TRADE NAME (DOSAGE FORM; ROUTE)	APPLICANT NAME	NDA NO. APPROVAL DATE	PATENT NO. EXP. DATE	EXCLUSIVITY EXP. DATE
CISPLATIN 0.5MG/ML	PLATINOL-AQ	BRISTOL LABS/B-M	18-507 07-18-84	4177263 12-04-96	NDF 09-24-86
CITRIC ACID; MAGNESIUM OXIDE; SODIUM CARBONATE 3.24GM/100ML; 380MG/100ML; 430MG/100ML	IRRIGATING SOLUTION G IN PLASTIC CONTAINER (SOLUTION; IRRIGATION)	TRAVENOL LABS	18-519 06-22-82		NC 09-24-86
CITRIC ACID; MAGNESIUM OXIDE; SODIUM CARBONATE 3.24GM/100ML; 380MG/100ML; 430MG/100ML	UROLOGIC G IN PLASTIC CONTAINER (SOLUTION; IRRIGATION)	ABBOTT LABORATORIES	18-904 05-27-83		NC 09-24-86
CLENASTINE FUMARATE; PHENYLPROPANOLAMINE HYDROCHLORIDE EQ 1MG BASE; 75MG	TAVIST D (TABLET, CONTROLLED RELEASE; ORAL)	DORSEY LABS/SANDOZ	18-298 12-15-82	3933999 01-20-93	NDF 09-24-86
CLONIPHENE CITRATE 50MG	CLONIPHENE CITRATE (TABLET; ORAL)	PLANTEK/IKAPHARM	18-361 03-22-82		
CLONAZEPAM 0.5MG	CLONOPIN (TABLET; ORAL)	HOFFMANN-LA ROCHE	17-533 06-04-75	4316897 02-23-99	
CLONAZEPAM 1MG	CLONOPIN (TABLET; ORAL)	HOFFMANN-LA ROCHE	17-533 06-04-75	4316897 02-23-99	
CLONAZEPAM 2MG	CLONOPIN (TABLET; ORAL)	HOFFMANN-LA ROCHE	17-533 06-04-75	4316897 02-23-99	
CLONIDINE 2.5MG	CATAPRES-TTS-1 (FILM, CONTROLLED RELEASE; PERCUTANEOUS)	BOEHRINGER INGELHEIM	18-891 10-10-84	3454701 07-08-86	NR 10-10-87
CLONIDINE 5MG	CATAPRES-TTS-2 (FILM, CONTROLLED RELEASE; PERCUTANEOUS)	BOEHRINGER INGELHEIM	18-891 10-10-84	3454701 07-08-86	NR 10-10-87
CLONIDINE 7.5MG	CATAPRES-TTS-3 (FILM, CONTROLLED RELEASE; PERCUTANEOUS)	BOEHRINGER INGELHEIM	18-891 10-10-84	3454701 07-08-86	NR 10-10-87
CLONIDINE HYDROCHLORIDE 0.1MG	CATAPRES (TABLET; ORAL)	BOEHRINGER INGELHEIM	17-407 09-03-74	3454701 07-08-86	

TABLE IV. NDA'S APPROVED FROM 1-1-82 TO 2-28-85 AND NDA'S WITH APPROPRIATE PATENT AND EXCLUSIVITY INFORMATION

<u>ACTIVE INGREDIENT(S)</u> <u>STRENGTH(S)</u>	<u>TRADE NAME</u> <u>(DOSAGE FORM; ROUTE)</u>	<u>APPLICANT NAME</u>	<u>NDA NO.</u> <u>APPROVAL DATE</u>	<u>PATENT NO.</u> <u>EXP. DATE</u>	<u>EXCLUSIVITY</u> <u>EXP. DATE</u>
CLONIDINE HYDROCHLORIDE 0.2MG	CATAPRES (TABLET; ORAL)	BOEHRINGER INGELHEIM	17-407 09-03-74	3454701 07-08-86	
CLONIDINE HYDROCHLORIDE 0.3MG	CATAPRES (TABLET; ORAL)	BOEHRINGER INGELHEIM	17-407 09-20-79	3454701 07-08-86	
CLORAZEPATE DIPOTASSIUM 3.75MG	TRANXENE (CAPSULE; ORAL)	ABBOTT LABORATORIES	17-105 06-23-72	RE28315 06-23-87	
CLORAZEPATE DIPOTASSIUM 7.5MG	TRANXENE (CAPSULE; ORAL)	ABBOTT LABORATORIES	17-105 06-23-72	RE28315 06-23-87	
CLORAZEPATE DIPOTASSIUM 15MG	TRANXENE (CAPSULE; ORAL)	ABBOTT LABORATORIES	17-105 06-23-72	RE28315 06-23-87	
CLORAZEPATE DIPOTASSIUM 22.5MG	TRANXENE SD (TABLET; ORAL)	ABBOTT LABORATORIES	17-105 03-31-75	RE28315 06-23-87	
CLORAZEPATE DIPOTASSIUM 11.25MG	TRANXENE SD (TABLET; ORAL)	ABBOTT LABORATORIES	17-105 08-04-76	RE28315 06-23-87	
CLORAZEPATE DIPOTASSIUM 3.75MG	TRANXENE (TABLET; ORAL)	ABBOTT LABORATORIES	17-105 03-10-80	RE28315 06-23-87	
CLORAZEPATE DIPOTASSIUM 7.5MG	TRANXENE (TABLET; ORAL)	ABBOTT LABORATORIES	17-105 03-10-80	RE28315 06-23-87	
CLORAZEPATE DIPOTASSIUM 15MG	TRANXENE (TABLET; ORAL)	ABBOTT LABORATORIES	17-105 03-10-80	RE28315 06-23-87	
CLOTRIMAZOLE 1%	LOTIMIN (SOLUTION; TOPICAL)	SCHERING	17-613 02-03-75	3660577 05-02-89 3705172 12-05-89 3839573 10-01-91	

TABLE IV. NDA'S APPROVED FROM 1-1-82 TO 2-28-85 AND NDA'S WITH APPROPRIATE PATENT AND EXCLUSIVITY INFORMATION

<u>ACTIVE INGREDIENT(S)</u> <u>STRENGTH(S)</u>	<u>TRADE NAME</u> <u>(DOSAGE FORM; ROUTE)</u>	<u>APPLICANT NAME</u>	<u>NDA NO.</u> <u>APPROVAL DATE</u>	<u>PATENT NO.</u> <u>EXP. DATE</u>	<u>EXCLUSIVITY</u> <u>EXP. DATE</u>
CLOTRIMAZOLE 1%	LOTIRIMIN (CREAM; TOPICAL)	SCHERING	17-619 03-18-75	3660577 05-02-89 3705172 12-05-89 3839573 10-01-91	
CLOTRIMAZOLE 1%	GYNE-LOTIRIMIN (CREAM; VAGINAL)	SCHERING	18-052 11-08-78	3839573 10-01-91 3705172 12-05-89 3660577 05-02-89	
CLOTRIMAZOLE 100MG	GYNE-LOTIRIMIN (TABLET; VAGINAL)	SCHERING	17-717 03-24-76	3839573 10-01-91 3705172 12-05-89 3660577 05-02-89	
CLOTRIMAZOLE 1%	MYCELEX (SOLUTION; TOPICAL)	MILES PHARMS/MILES	18-181 01-15-79	3839573 10-01-91 3705172 12-05-89 3660577 05-02-89	
CLOTRIMAZOLE 100MG	MYCELEX-G (TABLET; VAGINAL)	MILES PHARMS/MILES	18-182 02-27-79	3839573 10-01-91 3705172 12-05-89 3660577 05-02-89	
CLOTRIMAZOLE 1%	MYCELEX (CREAM; TOPICAL)	MILES PHARMS/MILES	18-183 01-15-79	3839573 10-01-91 3705172 12-05-89 3660577 05-02-89	

TABLE IV. NDA'S APPROVED FROM 1-1-82 TO 2-28-85 AND NDA'S WITH APPROPRIATE PATENT AND EXCLUSIVITY INFORMATION

<u>ACTIVE INGREDIENT(S)</u> <u>STRENGTH(S)</u>	<u>TRADE NAME</u> <u>(DOSAGE FORM; ROUTE)</u>	<u>APPLICANT NAME</u>	<u>NDA NO.</u> <u>APPROVAL DATE</u>	<u>PATENT NO.</u> <u>EXP. DATE</u>	<u>EXCLUSIVITY</u> <u>EXP. DATE</u>
CLOTRIMAZOLE 1%	MYCELEX-G (CREAM; VAGINAL)	MILES PHARMS/MILES	18-230 02-16-79	3839573 10-01-91 3705172 12-05-89 3660577 05-02-89	
CLOTRIMAZOLE 10MG	MYCELEX (TROCHE/LOZENGE; ORAL)	MILES PHARMS/MILES	18-713 06-17-83	3839573 10-01-91 3705172 12-05-89 3660577 05-02-89	NDF 09-24-86
CLOTRIMAZOLE 1%	LOTIMIN (LOTION; TOPICAL)	SCHERING	18-813 02-17-84	3839573 10-01-91 3705172 12-05-89 3660577 05-02-89	
CODEINE PHOSPHATE; PHENYLEPHRINE HYDROCHLORIDE; PROMETHAZINE HYDROCHLORIDE 10MG/5ML; 5MG/5ML; 6.25MG/5ML	PHENERGAN VC W/ CODEINE (SYRUP; ORAL)	WYETH LABS/AMHO	08-306 04-02-84		
CODEINE PHOSPHATE; PROMETHAZINE HYDROCHLORIDE 10MG/5ML; 6.25MG/5ML	PHENERGAN W/ CODEINE (SYRUP; ORAL)	WYETH LABS/AMHO	08-306 04-02-84		
CODEINE PHOSPHATE; PSEUDOEPHEDRINE HYDROCHLORIDE; TRIPROLIDINE HYDROCHLORIDE 10MG/5ML; 30MG/5ML; 1.25MG/5ML	ACTIFED W/ CODEINE (SYRUP; ORAL)	BURROUGHS WELLCOME	12-575 04-04-84		
COLESTIPOL HYDROCHLORIDE 5GM/PACKET	COLESTID (GRANULE; ORAL)	UPJOHN	17-563 04-04-77	3692895 09-19-89	I-24 09-24-86
COLESTIPOL HYDROCHLORIDE 500GM/BOT	COLESTID (GRANULE; ORAL)	UPJOHN	17-563 04-04-77	3692895 09-19-89	I-24 09-24-86

TABLE IV. NDA'S APPROVED FROM 1-1-82 TO 2-28-85 AND NDA'S WITH APPROPRIATE PATENT AND EXCLUSIVITY INFORMATION

ACTIVE INGREDIENT(S) STRENGTH(S)	TRADE NAME (DOSAGE FORM; ROUTE)	APPLICANT NAME	NDA NO. APPROVAL DATE	PATENT NO. EXP. DATE	EXCLUSIVITY EXP. DATE
COPPER 89MG	CU-7 (INTRAUTERINE DEVICE; INTRAUTERINE)	SEARLE PHARMS	17-408 02-25-74	3563235 02-16-88 4040417 08-09-94 3783861 01-08-91 3803308 12-01-87 RE28399 04-29-92	
COPPER 120MG	TATUM-T (INTRAUTERINE DEVICE; INTRAUTERINE)	SEARLE PHARMS	18-205 08-16-79	3563235 02-16-88 4040417 08-09-94 3783861 01-08-91 3803308 12-01-87 RE28399 04-29-92	
CROMOLYN SODIUM 20MG	INTAL (CAPSULE; INHALATION)	FISONS	16-990 06-20-73	3686412 08-22-89 3777033 08-22-89 3419578 12-31-85	I-22 09-24-86
CROMOLYN SODIUM 4%	NASALCROM (SOLUTION; NASAL)	FISONS	18-306 03-18-83	3686412 08-22-89 3777033 08-22-89 3419578 12-31-85 3975536 08-17-93 4053628 10-11-94	NDF 09-24-86

TABLE IV. NDA'S APPROVED FROM 1-1-82 TO 2-28-85 AND NDA'S WITH APPROPRIATE PATENT AND EXCLUSIVITY INFORMATION

<u>ACTIVE INGREDIENT(S)</u> <u>STRENGTH(S)</u>	<u>TRADE NAME</u> <u>(DOSAGE FORM; ROUTE)</u>	<u>APPLICANT NAME</u>	<u>NDA NO.</u> <u>APPROVAL DATE</u>	<u>PATENT NO.</u> <u>EXP. DATE</u>	<u>EXCLUSIVITY</u> <u>EXP. DATE</u>
CROMOLYN SODIUM 4%	OPTICROM (SOLUTION; OPHTHALMIC)	FISONS	18-155 10-03-84	3686412 08-22-89 3777033 08-22-89 3419578 12-31-85 3975536 08-17-93 4053628 10-11-94	NDF 10-03-87
CROMOLYN SODIUM 10MG/ML	INTAL (SOLUTION; INHALATION)	FISONS	18-596 05-28-82	3686412 08-22-89 3777033 08-22-89 3419578 12-31-85 3975536 08-17-93	I-22 01-19-88
CYCLOBENZAPRINE HYDROCHLORIDE 5MG	FLEXERIL (TABLET; ORAL)	MS&D/MERCK	17-821 08-26-77	3454643 07-08-86 3882246 05-06-92	
CYCLOBENZAPRINE HYDROCHLORIDE 10MG	FLEXERIL (TABLET; ORAL)	MS&D/MERCK	17-821 08-26-77	3454643 07-08-86 3882246 05-06-92	
CYCLOPHOSPHAMIDE 1GM/VIAL	CYTOXAN (INJECTABLE; INJECTION)	MEAD JOHNSON/B-M	12-142 08-30-82		NS 09-24-86
CYCLOPHOSPHAMIDE 1GM/VIAL	NEOSAR (INJECTABLE; INJECTION)	ADRIA LABORATORIES	87-442 07-08-83		NS 09-24-86
CYCLOPHOSPHAMIDE 2GM/VIAL	CYTOXAN (INJECTABLE; INJECTION)	MEAD JOHNSON/B-M	12-142 08-30-82		NS 09-24-86

TABLE IV. NDA'S APPROVED FROM 1-1-82 TO 2-28-85 AND NDA'S WITH APPROPRIATE PATENT AND EXCLUSIVITY INFORMATION

ACTIVE INGREDIENT(S) STRENGTH(S)	TRADE NAME (DOSAGE FORM; ROUTE)	APPLICANT NAME	NDA NO. APPROVAL DATE	PATENT NO. EXP. DATE	EXCLUSIVITY EXP. DATE
DANTROLENE SODIUM 25MG	DANTRIUM (CAPSULE; ORAL)	NORWICH EATON/P&G	17-443 01-15-74	3415821 12-10-85	
DANTROLENE SODIUM 100MG	DANTRIUM (CAPSULE; ORAL)	NORWICH EATON/P&G	17-443 01-15-74	3415821 12-10-85	
DANTROLENE SODIUM 50MG	DANTRIUM (CAPSULE; ORAL)	NORWICH EATON/P&G	17-443 10-10-75	3415821 12-10-85	
DANTROLENE SODIUM 20MG/VIAL	DANTRIUM (INJECTABLE; INJECTION)	NORWICH EATON/P&G	18-264 09-18-79	3415821 12-10-85	
DEFEROXAMINE MESYLATE 500MG/VIAL	DEFERAL MESYLATE (INJECTABLE; INJECTION)	CIBA/CIBA-GEIGY	16-267 04-01-68	3471476 10-07-86	
DESIPRAMINE HYDROCHLORIDE 25MG	PERTOFRANE (CAPSULE; ORAL)	USV LABORATORIES	13-621 12-18-64	3454698 07-08-86 3454554 07-08-86	
DESIPRAMINE HYDROCHLORIDE 50MG	PERTOFRANE (CAPSULE; ORAL)	USV LABORATORIES	13-621 04-10-68	3454698 07-08-86 3454554 07-08-86	
DESIPRAMINE HYDROCHLORIDE 25MG	NORPRAMIN (TABLET; ORAL)	MERRELL DOW/DOW CHEM	14-399 11-20-64	3454698 07-08-86 3454554 07-08-86	
DESIPRAMINE HYDROCHLORIDE 50MG	NORPRAMIN (TABLET; ORAL)	MERRELL DOW/DOW CHEM	14-399 01-09-67	3454698 07-08-86 3454554 07-08-86	
DESIPRAMINE HYDROCHLORIDE 75MG	NORPRAMIN (TABLET; ORAL)	MERRELL DOW/DOW CHEM	14-399 03-01-77	3454698 07-08-86 3454554 07-08-86	

TABLE IV. NDA'S APPROVED FROM 1-1-82 TO 2-28-85 AND NDA'S WITH APPROPRIATE PATENT AND EXCLUSIVITY INFORMATION

<u>ACTIVE INGREDIENT(S)</u> <u>STRENGTH(S)</u>	<u>TRADE NAME</u> <u>(DOSAGE FORM; ROUTE)</u>	<u>APPLICANT NAME</u>	<u>NDA NO.</u> <u>APPROVAL DATE</u>	<u>PATENT NO.</u> <u>EXP. DATE</u>	<u>EXCLUSIVITY</u> <u>EXP. DATE</u>
DESIPRAMINE HYDROCHLORIDE 100MG	NORPRAMIN (TABLET; ORAL)	MERRELL DOW/DOW CHEM	14-399 03-01-77	3454698 07-08-86 3454554 07-08-86	
DESIPRAMINE HYDROCHLORIDE 150MG	NORPRAMIN (TABLET; ORAL)	MERRELL DOW/DOW CHEM	14-399 03-01-77	3454698 07-08-86 3454554 07-08-86	
DESIPRAMINE HYDROCHLORIDE 10MG	NORPRAMIN (TABLET; ORAL)	MERRELL DOW/DOW CHEM	14-399 02-11-82	3454698 07-08-86 3454554 07-08-86	NS 09-24-86
DESMOPRESSIN ACETATE 0.01%	DDAVP (SOLUTION; NASAL)	ARMOUR PHARM	17-922 02-21-78	3497491 02-24-87	
DESMOPRESSIN ACETATE 0.004MG/ML	DDAVP (INJECTABLE; INJECTION)	ARMOUR PHARM	18-938 03-30-84	3497491 02-24-87	NDF 09-24-86
DESONIDE 0.05%	DESOWEN (CREAM; TOPICAL)	OWEN LABS/DERM PRODS	19-048 12-14-84		
DESOXIMETASONE 0.05%	TOPICORT (GEL; TOPICAL)	HOECHST-ROUSSEL	18-586 03-29-82		NDF 09-24-86
DESOXIMETASONE 0.05%	TOPICORT (OINTMENT; TOPICAL)	HOECHST-ROUSSEL	18-594 01-17-85		NDF 09-24-86
DESOXIMETASONE 0.25%	TOPICORT (OINTMENT; TOPICAL)	HOECHST-ROUSSEL	18-763 09-30-83		NDF 09-24-86
DEXAMETHASONE 0.5MG	DECADRON (TABLET; ORAL)	MS&D/MERCK	11-664 10-30-58	3375261 03-26-85 RE28369 03-26-85	
DEXAMETHASONE 0.75MG	DECADRON (TABLET; ORAL)	MS&D/MERCK	11-664 10-30-58	3375261 03-26-85 RE28369 03-26-85	

TABLE IV. NDA'S APPROVED FROM 1-1-82 TO 2-28-85 AND NDA'S WITH APPROPRIATE PATENT AND EXCLUSIVITY INFORMATION

<u>ACTIVE INGREDIENT(S)</u> <u>STRENGTH(S)</u>	<u>TRADE NAME</u> <u>(DOSAGE FORM; ROUTE)</u>	<u>APPLICANT NAME</u>	<u>NDA NO.</u> <u>APPROVAL DATE</u>	<u>PATENT NO.</u> <u>EXP. DATE</u>	<u>EXCLUSIVITY</u> <u>EXP. DATE</u>
DEXAMETHASONE 1.5MG	DECADRON (TABLET; ORAL)	MS&D/MERCK	11-664 10-30-58	3375261 03-26-85 RE28369 03-26-85	
DEXAMETHASONE 0.25MG	DECADRON (TABLET; ORAL)	MS&D/MERCK	11-664 07-26-79	3375261 03-26-85 RE28369 03-26-85	
DEXAMETHASONE 4MG	DECADRON (TABLET; ORAL)	MS&D/MERCK	11-664 07-26-79	3375261 03-26-85 RE28369 03-26-85	
DEXAMETHASONE 6MG	DECADRON (TABLET; ORAL)	MS&D/MERCK	11-664 07-30-82	3375261 03-26-85 RE28369 03-26-85	NS 09-24-86
DEXAMETHASONE 6MG	DEXAMETHASONE (TABLET; ORAL)	PAR PHARMACEUTICAL	88-481 11-28-83		NS 09-24-86
DEXAMETHASONE 6MG	DEXAMETHASONE (TABLET; ORAL)	ROXANE LABORATORIES	88-316 09-15-83		NS 09-24-86
DEXAMETHASONE 0.5MG/5ML	DECADRON (ELIXIR; ORAL)	MS&D/MERCK	12-376 09-02-60	3375261 03-26-85 RE28369 03-26-85	
DEXAMETHASONE 0.5MG/5ML	HEXADROL (ELIXIR; ORAL)	ORGANON/AKZONA	12-674 04-23-64	RE28369 03-26-85	
DEXAMETHASONE 0.5MG	HEXADROL (TABLET; ORAL)	ORGANON/AKZONA	12-675 07-01-78	RE28369 03-26-85	
DEXAMETHASONE 0.75MG	HEXADROL (TABLET; ORAL)	ORGANON/AKZONA	12-675 07-01-78	RE28369 03-26-85	

TABLE IV. NDA'S APPROVED FROM 1-1-82 TO 2-28-85 AND NDA'S WITH APPROPRIATE PATENT AND EXCLUSIVITY INFORMATION

<u>ACTIVE INGREDIENT(S)</u> <u>STRENGTH(S)</u>	<u>TRADE NAME</u> <u>(DOSAGE FORM; ROUTE)</u>	<u>APPLICANT NAME</u>	<u>NDA NO.</u> <u>APPROVAL DATE</u>	<u>PATENT NO.</u> <u>EXP. DATE</u>	<u>EXCLUSIVITY</u> <u>EXP. DATE</u>
DEXAMETHASONE 1.5MG	HEXADROL (TABLET; ORAL)	ORGANON/AKZONA	12-675 09-24-65	RE28369 03-26-85	
DEXAMETHASONE 4MG	HEXADROL (TABLET; ORAL)	ORGANON/AKZONA	12-675 07-01-74	RE28369 03-26-85	
DEXAMETHASONE 10MG/25GM	DECASPRAY (AEROSOL; TOPICAL)	MS&D/MERCK	12-731 03-29-61	3375261 03-26-85 RE28369 03-26-85	
DEXAMETHASONE 0.04%	HEXADROL (CREAM; TOPICAL)	ORGANON/AKZONA	13-304 01-09-67	RE28369 03-26-85	
DEXAMETHASONE 0.1%	DECADERM (GEL; TOPICAL)	MS&D/MERCK	13-538 05-03-65	3375261 03-26-85 RE28369 03-26-85	
DEXAMETHASONE ACETATE EQ 8MG BASE/ML	DECADRON-LA (INJECTABLE; INJECTION)	MS&D/MERCK	16-675 09-06-73	3375261 03-26-85 RE28369 03-26-85	
DEXAMETHASONE SODIUM PHOSPHATE EQ 0.05% PHOSPHATE	DECADRON (OINTMENT; OPHTHALMIC)	MS&D/MERCK	11-977 09-02-59	3375261 03-26-85 RE28369 03-26-85	
DEXAMETHASONE SODIUM PHOSPHATE EQ 0.1% PHOSPHATE	DECADRON (CREAM; TOPICAL)	MS&D/MERCK	11-983 08-26-59	3375261 03-26-85 RE28369 03-26-85	
DEXAMETHASONE SODIUM PHOSPHATE EQ 0.1% PHOSPHATE	DECADRON (SOLUTION; OPHTHALMIC, OTIC)	MS&D/MERCK	11-984 09-23-59	3375261 03-26-85 RE28369 03-26-85	

TABLE IV. NDA'S APPROVED FROM 1-1-82 TO 2-28-85 AND NDA'S WITH APPROPRIATE PATENT AND EXCLUSIVITY INFORMATION

<u>ACTIVE INGREDIENT(S)</u> <u>STRENGTH(S)</u>	<u>TRADE NAME</u> <u>(DOSAGE FORM; ROUTE)</u>	<u>APPLICANT NAME</u>	<u>NDA NO.</u> <u>APPROVAL DATE</u>	<u>PATENT NO.</u> <u>EXP. DATE</u>	<u>EXCLUSIVITY</u> <u>EXP. DATE</u>
DEXAMETHASONE SODIUM PHOSPHATE EQ 4MG PHOSPHATE/ML	DECADRON (INJECTABLE; INJECTION)	MS&D/MERCK	12-071 05-12-61	3375261 03-26-85 RE28369 03-26-85	
DEXAMETHASONE SODIUM PHOSPHATE EQ 24MG PHOSPHATE/ML	DECADRON (INJECTABLE; INJECTION)	MS&D/MERCK	12-071 03-01-77	3375261 03-26-85 RE28369 03-26-85	
DEXAMETHASONE SODIUM PHOSPHATE EQ 0.1MG PHOSPHATE/INH	DECADRON (AEROSOL; INHALATION)	MS&D/MERCK	13-413 09-17-62	3375261 03-26-85 RE28369 03-26-85	
DEXAMETHASONE SODIUM PHOSPHATE EQ 0.1MG PHOSPHATE/INH	DECADRON (AEROSOL; NASAL)	MS&D/MERCK	14-242 12-17-65	3375261 03-26-85 RE28369 03-26-85	
DEXAMETHASONE SODIUM PHOSPHATE EQ 4MG PHOSPHATE/ML	HEXADROL (INJECTABLE; INJECTION)	ORGANON/AKZONA	14-694 03-14-75	RE28369 03-26-85	
DEXAMETHASONE SODIUM PHOSPHATE EQ 10MG PHOSPHATE/ML	HEXADROL (INJECTABLE; INJECTION)	ORGANON/AKZONA	14-694 03-14-75	RE28369 03-26-85	
DEXAMETHASONE SODIUM PHOSPHATE EQ 20MG PHOSPHATE/ML	HEXADROL (INJECTABLE; INJECTION)	ORGANON/AKZONA	14-694 04-27-81	RE28369 03-26-85	
DEXAMETHASONE SODIUM PHOSPHATE; LIDOCAINE HYDROCHLORIDE EQ 4MG PHOSPHATE/ML; 10MG/ML	DECADRON W/ XYLOCAINE (INJECTABLE; INJECTION)	MS&D/MERCK	13-334 07-11-62	3375261 03-26-85 RE28369 03-26-85	
DEXTROMETHORPHAN HYDROBROMIDE; PROMETHAZINE HYDROCHLORIDE 15MG/5ML; 6.25MG/5ML	PHENERGAN W/ DEXTROMETHORPHAN (SYRUP; ORAL)	HYETH LABS/AMHO	11-265 04-02-84		
DEXTROSE 60GM/100ML	DEXTROSE 60% IN PLASTIC CONTAINER (INJECTABLE; INJECTION)	TRAVENOL LABS	17-521 03-26-82		

TABLE IV. NDA'S APPROVED FROM 1-1-82 TO 2-28-85 AND NDA'S WITH APPROPRIATE PATENT AND EXCLUSIVITY INFORMATION

ACTIVE INGREDIENT(S) STRENGTH(S)	TRADE NAME (DOSAGE FORM; ROUTE)	APPLICANT NAME	NDA NO. APPROVAL DATE	PATENT NO. EXP. DATE	EXCLUSIVITY EXP. DATE
DEXTROSE 70GM/100ML	DEXTROSE 70% IN PLASTIC CONTAINER (INJECTABLE; INJECTION)	TRAVENOL LABS	17-521 03-26-82		
DEXTROSE 60GM/100ML	DEXTROSE 60% IN PLASTIC CONTAINER (INJECTABLE; INJECTION)	ABBOTT LABORATORIES	19-346 01-25-85		
DEXTROSE 30GM/100ML	DEXTROSE 30% IN PLASTIC CONTAINER (INJECTABLE; INJECTION)	ABBOTT LABORATORIES	19-345 01-26-85		
DEXTROSE 60GM/100ML	DEXTROSE 60% IN PLASTIC CONTAINER (INJECTABLE; INJECTION)	AM MCGAW/AM HOSP	17-995 04-27-78	3729568 04-24-90	
DEXTROSE 60GM/100ML	DEXTROSE 60% (INJECTABLE; INJECTION)	AM MCGAW/AM HOSP	17-995 09-22-82	3729568 04-24-90	
DEXTROSE 70GM/100ML	DEXTROSE 70% IN PLASTIC CONTAINER (INJECTABLE; INJECTION)	ABBOTT LABORATORIES	18-561 03-23-82		
DEXTROSE 40GM/100ML	DEXTROSE 40% IN PLASTIC CONTAINER (INJECTABLE; INJECTION)	ABBOTT LABORATORIES	18-562 03-23-82		
DEXTROSE 50GM/100ML	DEXTROSE 50% IN PLASTIC CONTAINER (INJECTABLE; INJECTION)	ABBOTT LABORATORIES	18-563 03-23-82		
DEXTROSE 20GM/100ML	DEXTROSE 20% IN PLASTIC CONTAINER (INJECTABLE; INJECTION)	ABBOTT LABORATORIES	18-564 03-23-82		
DEXTROSE 38.5GM/100ML	DEXTROSE 38.5% IN PLASTIC CONTAINER (INJECTABLE; INJECTION)	ABBOTT LABORATORIES	18-923 09-19-84		

TABLE IV. NDA'S APPROVED FROM 1-1-82 TO 2-28-85 AND NDA'S WITH APPROPRIATE PATENT AND EXCLUSIVITY INFORMATION

<u>ACTIVE INGREDIENT(S)</u> <u>STRENGTH(S)</u>	<u>TRADE NAME</u> <u>(DOSAGE FORM; ROUTE)</u>	<u>APPLICANT NAME</u>	<u>NDA NO.</u> <u>APPROVAL DATE</u>	<u>PATENT NO.</u> <u>EXP. DATE</u>	<u>EXCLUSIVITY</u> <u>EXP. DATE</u>
DEXTROSE 50MG/ML	DEXTROSE 5% IN PLASTIC CONTAINER (INJECTABLE; INJECTION)	ABBOTT LABORATORIES	19-222 07-13-84		
DEXTROSE; DOPAMINE HYDROCHLORIDE 5GM/100ML; 80MG/100ML	DOPAMINE HCL (INJECTABLE; INJECTION)	ABBOTT LABORATORIES	18-132 02-04-82		NC 09-24-86
DEXTROSE; DOPAMINE HYDROCHLORIDE 5GM/100ML; 160MG/100ML	DOPAMINE HCL (INJECTABLE; INJECTION)	ABBOTT LABORATORIES	18-132 02-04-82		NC 09-24-86
DEXTROSE; DOPAMINE HYDROCHLORIDE 5GM/100ML; 80MG/100ML	DOPAMINE HCL IN PLASTIC CONTAINER (INJECTABLE; INJECTION)	ABBOTT LABORATORIES	18-826 09-30-83		NC 09-24-86
DEXTROSE; DOPAMINE HYDROCHLORIDE 5GM/100ML; 160MG/100ML	DOPAMINE HCL IN PLASTIC CONTAINER (INJECTABLE; INJECTION)	ABBOTT LABORATORIES	18-826 09-30-83		NC 09-24-86
DEXTROSE; DOPAMINE HYDROCHLORIDE 5GM/100ML; 320MG/100ML	DOPAMINE HCL IN PLASTIC CONTAINER (INJECTABLE; INJECTION)	ABBOTT LABORATORIES	18-826 09-30-83		NC 09-24-86
DEXTROSE; HEPARIN SODIUM 5GM/100ML; 200 UNITS/100ML	HEPARIN SODIUM 1,000 UNITS AND DEXTROSE 5% IN PLASTIC CONTAINER (INJECTABLE; INJECTION)	AM MCGAW/AM HOSP	19-130 12-31-83		NC 09-24-86
DEXTROSE; HEPARIN SODIUM 5GM/100ML; 200 UNITS/100ML	HEPARIN SODIUM 2,000 UNITS AND DEXTROSE 5% IN PLASTIC CONTAINER (INJECTABLE; INJECTION)	AM MCGAW/AM HOSP	19-130 12-31-83		NC 09-24-86
DEXTROSE; HEPARIN SODIUM 5GM/100ML; 1,000 UNITS/100ML	HEPARIN SODIUM 5,000 UNITS AND DEXTROSE 5% IN PLASTIC CONTAINER (INJECTABLE; INJECTION)	AM MCGAW/AM HOSP	19-130 12-31-83		NC 09-24-86

TABLE IV. NDA'S APPROVED FROM 1-1-82 TO 2-28-85 AND NDA'S WITH APPROPRIATE PATENT AND EXCLUSIVITY INFORMATION

<u>ACTIVE INGREDIENT(S)</u> <u>STRENGTH(S)</u>	<u>TRADE NAME</u> <u>(DOSAGE FORM; ROUTE)</u>	<u>APPLICANT NAME</u>	<u>NDA NO.</u> <u>APPROVAL DATE</u>	<u>PATENT NO.</u> <u>EXP. DATE</u>	<u>EXCLUSIVITY</u> <u>EXP. DATE</u>
DEXTROSE; HEPARIN SODIUM 5GM/100ML; 4,000 UNITS/100ML	HEPARIN SODIUM 20,000 UNITS AND DEXTROSE 5% IN PLASTIC CONTAINER (INJECTABLE; INJECTION)	TRAVENOL LABS	18-814 10-31-83		NC 09-24-86
DEXTROSE; HEPARIN SODIUM 5GM/100ML; 5,000 UNITS/100ML	HEPARIN SODIUM 12,500 UNITS IN DEXTROSE 5% (INJECTABLE; INJECTION)	ABBOTT LABORATORIES	18-911 01-30-85		
DEXTROSE; HEPARIN SODIUM 5GM/100ML; 10,000 UNITS/100ML	HEPARIN SODIUM 10,000 UNITS IN DEXTROSE 5% (INJECTABLE; INJECTION)	ABBOTT LABORATORIES	18-911 01-30-85		
DEXTROSE; HEPARIN SODIUM 5GM/100ML; 10,000 UNITS/100ML	HEPARIN SODIUM 25,000 UNITS IN DEXTROSE 5% (INJECTABLE; INJECTION)	ABBOTT LABORATORIES	18-911 01-30-85		
DEXTROSE; LIDOCAINE HYDROCHLORIDE 5GM/100ML; 800MG/100ML	LIDOCAINE HCL 0.8% IN DEXTROSE 5% IN PLASTIC CONTAINER (INJECTABLE; INJECTION)	ABBOTT LABORATORIES	18-388 11-05-82		NS 09-24-86
DEXTROSE; LIDOCAINE HYDROCHLORIDE 5GM/100ML; 800MG/100ML	LIDOCAINE HCL 0.8% AND DEXTROSE 5% IN PLASTIC CONTAINER (INJECTABLE; INJECTION)	TRAVENOL LABS	18-461 02-22-82		NS 09-24-86
DEXTROSE; LIDOCAINE HYDROCHLORIDE 5GM/100ML; 200MG/100ML	LIDOCAINE HCL 0.2% AND DEXTROSE 5% IN PLASTIC CONTAINER (INJECTABLE; INJECTION)	AM MCGAW/AM HOSP	18-967 03-30-84		NS 09-24-86
DEXTROSE; LIDOCAINE HYDROCHLORIDE 5GM/100ML; 400MG/100ML	LIDOCAINE HCL 0.4% AND DEXTROSE 5% IN PLASTIC CONTAINER (INJECTABLE; INJECTION)	AM MCGAW/AM HOSP	18-967 03-30-84		NS 09-24-86

TABLE IV. NDA'S APPROVED FROM 1-1-82 TO 2-28-85 AND NDA'S WITH APPROPRIATE PATENT AND EXCLUSIVITY INFORMATION

<u>ACTIVE INGREDIENT(S)</u> <u>STRENGTH(S)</u>	<u>TRADE NAME</u> <u>(DOSAGE FORM; ROUTE)</u>	<u>APPLICANT NAME</u>	<u>NDA NO.</u> <u>APPROVAL DATE</u>	<u>PATENT NO.</u> <u>EXP. DATE</u>	<u>EXCLUSIVITY</u> <u>EXP. DATE</u>
DEXTROSE; LIDOCAINE HYDROCHLORIDE 5GM/100ML; 800MG/100ML	LIDOCAINE HCL 0.8% AND DEXTROSE 5% IN PLASTIC CONTAINER (INJECTABLE; INJECTION)	AM MCGAW/AM HOSP	18-967 03-30-84		NS 09-24-86
DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE DIBASIC ; SODIUM ACETATE 5GM/100ML; 31MG/100ML; 130MG/100ML; 26MG/100ML; 320MG/100ML	ISOLYTE P W/ DEXTROSE 5% IN PLASTIC CONTAINER (INJECTABLE; INJECTION)	AM MCGAW/AM HOSP	19-025 12-27-84		
DEXTROSE; POTASSIUM CHLORIDE 5GM/100ML; 75MG/100ML	DEXTROSE 5% AND POTASSIUM CHLORIDE 0.075% IN PLASTIC CONTAINER (INJECTABLE; INJECTION)	AM MCGAW/AM HOSP	18-744 11-09-82		
DEXTROSE; POTASSIUM CHLORIDE 5GM/100ML; 150MG/100ML	DEXTROSE 5% AND POTASSIUM CHLORIDE 0.15% IN PLASTIC CONTAINER (INJECTABLE; INJECTION)	AM MCGAW/AM HOSP	18-744 11-09-82		
DEXTROSE; POTASSIUM CHLORIDE 5GM/100ML; 220MG/100ML	DEXTROSE 5% AND POTASSIUM CHLORIDE 0.22% IN PLASTIC CONTAINER (INJECTABLE; INJECTION)	AM MCGAW/AM HOSP	18-744 11-09-82		
DEXTROSE; POTASSIUM CHLORIDE 5GM/100ML; 300MG/100ML	DEXTROSE 5% AND POTASSIUM CHLORIDE 0.3% IN PLASTIC CONTAINER (INJECTABLE; INJECTION)	AM MCGAW/AM HOSP	18-744 11-09-82		
DEXTROSE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, MONOBASIC; SODIUM CHLORIDE; SODIUM LACTATE 5GM/100ML; 205MG/100ML; 100MG/100ML; 120MG/100ML; 220MG/100ML	DEXTROSE 5% AND ELECTROLYTE NO 75 IN PLASTIC CONTAINER (INJECTABLE; INJECTION)	TRAVENOL LABS	18-840 06-29-83		
DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE 5GM/100ML; 150MG/100ML; 450MG/100ML	DEXTROSE 5%, SODIUM CHLORIDE 0.45% AND POTASSIUM CHLORIDE 10MEQ IN PLASTIC CONTAINER (INJECTABLE; INJECTION)	TRAVENOL LABS	18-566 02-10-83		

TABLE IV. NDA'S APPROVED FROM 1-1-82 TO 2-28-85 AND NDA'S WITH APPROPRIATE PATENT AND EXCLUSIVITY INFORMATION

<u>ACTIVE INGREDIENT(S)</u> <u>STRENGTH(S)</u>	<u>TRADE NAME</u> <u>(DOSAGE FORM; ROUTE)</u>	<u>APPLICANT NAME</u>	<u>NDA NO.</u> <u>APPROVAL DATE</u>	<u>PATENT NO.</u> <u>EXP. DATE</u>	<u>EXCLUSIVITY</u> <u>EXP. DATE</u>
DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE 5GM/100ML; 224MG/100ML; 450MG/100ML	DEXTROSE 5%, SODIUM CHLORIDE 0.45% AND POTASSIUM CHLORIDE 15MEQ IN PLASTIC CONTAINER (INJECTABLE; INJECTION)	TRAVENOL LABS	18-566 02-10-83		
DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE 5GM/100ML; 300MG/100ML; 450MG/100ML	DEXTROSE 5%, SODIUM CHLORIDE 0.45% AND POTASSIUM CHLORIDE 20MEQ IN PLASTIC CONTAINER (INJECTABLE; INJECTION)	TRAVENOL LABS	18-566 02-10-83		
DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE 5GM/100ML; 150MG/100ML; 450MG/100ML	DEXTROSE 5%, SODIUM CHLORIDE 0.45% AND POTASSIUM CHLORIDE 20MEQ IN PLASTIC CONTAINER (INJECTABLE; INJECTION)	TRAVENOL LABS	18-566 02-10-83		
DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE 5GM/100ML; 224MG/100ML; 450MG/100ML	DEXTROSE 5%, SODIUM CHLORIDE 0.45% AND POTASSIUM CHLORIDE 30MEQ IN PLASTIC CONTAINER (INJECTABLE; INJECTION)	TRAVENOL LABS	18-566 02-10-83		
DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE 5GM/100ML; 300MG/100ML; 450MG/100ML	DEXTROSE 5%, SODIUM CHLORIDE 0.45% AND POTASSIUM CHLORIDE 40MEQ IN PLASTIC CONTAINER (INJECTABLE; INJECTION)	TRAVENOL LABS	18-566 02-10-83		
DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE 5GM/100ML; 150MG/100ML; 200MG/100ML	DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 10MEQ IN PLASTIC CONTAINER (INJECTABLE; INJECTION)	TRAVENOL LABS	18-567 02-16-83		
DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE 5GM/100ML; 224MG/100ML; 200MG/100ML	DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 15MEQ IN PLASTIC CONTAINER (INJECTABLE; INJECTION)	TRAVENOL LABS	18-567 02-16-83		
DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE 5GM/100ML; 150MG/100ML; 200MG/100ML	DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 20MEQ IN PLASTIC CONTAINER (INJECTABLE; INJECTION)	TRAVENOL LABS	18-567 02-16-83		

TABLE IV. NDA'S APPROVED FROM 1-1-82 TO 2-28-85 AND NDA'S WITH APPROPRIATE PATENT AND EXCLUSIVITY INFORMATION

<u>ACTIVE INGREDIENT(S)</u> <u>STRENGTH(S)</u>	<u>TRADE NAME</u> <u>(DOSAGE FORM; ROUTE)</u>	<u>APPLICANT NAME</u>	<u>NDA NO.</u> <u>APPROVAL DATE</u>	<u>PATENT NO.</u> <u>EXP. DATE</u>	<u>EXCLUSIVITY</u> <u>EXP. DATE</u>
DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE 5GM/100ML; 224MG/100ML; 200MG/100ML	DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 30MEQ IN PLASTIC CONTAINER (INJECTABLE; INJECTION)	TRAVENOL LABS	18-567 02-16-83		
DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE 5GM/100ML; 75MG/100ML; 330MG/100ML	DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 5MEQ IN PLASTIC CONTAINER (INJECTABLE; INJECTION)	TRAVENOL LABS	18-629 03-23-82		
DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE 5GM/100ML; 150MG/100ML; 330MG/100ML	DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 10MEQ IN PLASTIC CONTAINER (INJECTABLE; INJECTION)	TRAVENOL LABS	18-629 03-23-82		
DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE 5GM/100ML; 224MG/100ML; 330MG/100ML	DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 15MEQ IN PLASTIC CONTAINER (INJECTABLE; INJECTION)	TRAVENOL LABS	18-629 03-23-82		
DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE 5GM/100ML; 150MG/100ML; 330MG/100ML	DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 20MEQ IN PLASTIC CONTAINER (INJECTABLE; INJECTION)	TRAVENOL LABS	18-629 03-23-82		
DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE 5GM/100ML; 75MG/100ML; 330MG/100ML	DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 10MEQ IN PLASTIC CONTAINER (INJECTABLE; INJECTION)	TRAVENOL LABS	18-629 03-23-82		
DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE 5GM/100ML; 300MG/100ML; 330MG/100ML	DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 20MEQ IN PLASTIC CONTAINER (INJECTABLE; INJECTION)	TRAVENOL LABS	18-629 03-23-82		
DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE 5GM/100ML; 224MG/100ML; 330MG/100ML	DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 30MEQ IN PLASTIC CONTAINER (INJECTABLE; INJECTION)	TRAVENOL LABS	18-629 03-23-82		

TABLE IV. NDA'S APPROVED FROM 1-1-82 TO 2-28-85 AND NDA'S WITH APPROPRIATE PATENT AND EXCLUSIVITY INFORMATION

<u>ACTIVE INGREDIENT(S)</u> <u>STRENGTH(S)</u>	<u>TRADE NAME</u> <u>(DOSAGE FORM; ROUTE)</u>	<u>APPLICANT NAME</u>	<u>NDA NO.</u> <u>APPROVAL DATE</u>	<u>PATENT NO.</u> <u>EXP. DATE</u>	<u>EXCLUSIVITY</u> <u>EXP. DATE</u>
DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE 5GM/100ML; 300MG/100ML; 330MG/100ML	DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 40MEQ IN PLASTIC CONTAINER (INJECTABLE; INJECTION)	TRAVENOL LABS	18-629 03-23-82		
DEXTROSE; THEOPHYLLINE 5GM/100ML; 40MG/100ML	THEOPHYLLINE IN DEXTROSE 5% IN PLASTIC CONTAINER (INJECTABLE; INJECTION)	ABBOTT LABORATORIES	19-211 12-14-84		
DEXTROSE; THEOPHYLLINE 5GM/100ML; 40MG/100ML	THEOPHYLLINE 0.04% AND DEXTROSE 5% IN PLASTIC CONTAINER (INJECTABLE; INJECTION)	AM MCGAW/AM HOSP	19-083 11-07-84		
DEXTROSE; THEOPHYLLINE 5GM/100ML; 80MG/100ML	THEOPHYLLINE IN DEXTROSE 5% IN PLASTIC CONTAINER (INJECTABLE; INJECTION)	ABBOTT LABORATORIES	19-211 12-14-84		
DEXTROSE; THEOPHYLLINE 5GM/100ML; 80MG/100ML	THEOPHYLLINE 0.08% AND DEXTROSE 5% IN PLASTIC CONTAINER (INJECTABLE; INJECTION)	AM MCGAW/AM HOSP	19-083 11-07-84		
DEXTROSE; THEOPHYLLINE 5GM/100ML; 160MG/100ML	THEOPHYLLINE IN DEXTROSE 5% IN PLASTIC CONTAINER (INJECTABLE; INJECTION)	ABBOTT LABORATORIES	19-211 12-14-84		
DEXTROSE; THEOPHYLLINE 5GM/100ML; 160MG/100ML	THEOPHYLLINE 0.16% AND DEXTROSE 5% IN PLASTIC CONTAINER (INJECTABLE; INJECTION)	AM MCGAW/AM HOSP	19-083 11-07-84		
DEXTROSE; THEOPHYLLINE 5GM/100ML; 200MG/100ML	THEOPHYLLINE IN DEXTROSE 5% IN PLASTIC CONTAINER (INJECTABLE; INJECTION)	ABBOTT LABORATORIES	19-211 12-14-84		

TABLE IV. NDA'S APPROVED FROM 1-1-82 TO 2-28-85 AND NDA'S WITH APPROPRIATE PATENT AND EXCLUSIVITY INFORMATION

<u>ACTIVE INGREDIENT(S)</u> <u>STRENGTH(S)</u>	<u>TRADE NAME</u> <u>(DOSAGE FORM; ROUTE)</u>	<u>APPLICANT NAME</u>	<u>NDA NO.</u> <u>APPROVAL DATE</u>	<u>PATENT NO.</u> <u>EXP. DATE</u>	<u>EXCLUSIVITY</u> <u>EXP. DATE</u>
DEXTROSE; THEOPHYLLINE 5GM/100ML; 200MG/100ML	THEOPHYLLINE 0.2% AND DEXTROSE 5% IN PLASTIC CONTAINER (INJECTABLE; INJECTION)	AM MCGAM/AM HOSP	19-212 11-07-84		
DEXTROSE; THEOPHYLLINE 5GM/100ML; 400MG/100ML	THEOPHYLLINE IN DEXTROSE 5% IN PLASTIC CONTAINER (INJECTABLE; INJECTION)	ABBOTT LABORATORIES	19-211 12-14-84		
DEXTROSE; THEOPHYLLINE 5GM/100ML; 400MG/100ML	THEOPHYLLINE 0.4% AND DEXTROSE 5% IN PLASTIC CONTAINER (INJECTABLE; INJECTION)	AM MCGAM/AM HOSP	19-212 11-07-84		
DEXTROSE; THEOPHYLLINE 5GM/100ML; 400MG/100ML	THEOPHYLLINE AND DEXTROSE 5% IN PLASTIC CONTAINER (INJECTABLE; INJECTION)	TRAVENOL LABS	18-649 07-26-82		
DEXTROSE; THEOPHYLLINE 5GM/100ML; 80MG/100ML	THEOPHYLLINE AND DEXTROSE 5% IN PLASTIC CONTAINER (INJECTABLE; INJECTION)	TRAVENOL LABS	18-649 07-26-82		
DEXTROSE; THEOPHYLLINE 5GM/100ML; 160MG/100ML	THEOPHYLLINE AND DEXTROSE 5% IN PLASTIC CONTAINER (INJECTABLE; INJECTION)	TRAVENOL LABS	18-649 07-26-82		
DEXTROSE; THEOPHYLLINE 5GM/100ML; 200MG/100ML	THEOPHYLLINE AND DEXTROSE 5% IN PLASTIC CONTAINER (INJECTABLE; INJECTION)	TRAVENOL LABS	18-649 07-26-82		
DEXTROSE; THEOPHYLLINE 5GM/100ML; 400MG/100ML	THEOPHYLLINE AND DEXTROSE 5% IN PLASTIC CONTAINER (INJECTABLE; INJECTION)	TRAVENOL LABS	18-649 07-26-82		

TABLE IV. NDA'S APPROVED FROM 1-1-82 TO 2-28-85 AND NDA'S WITH APPROPRIATE PATENT AND EXCLUSIVITY INFORMATION

<u>ACTIVE INGREDIENT(S)</u> <u>STRENGTH(S)</u>	<u>TRADE NAME</u> <u>(DOSAGE FORM; ROUTE)</u>	<u>APPLICANT NAME</u>	<u>NDA NO.</u> <u>APPROVAL DATE</u>	<u>PATENT NO.</u> <u>EXP. DATE</u>	<u>EXCLUSIVITY</u> <u>EXP. DATE</u>
DIATRIZOATE MEGLUMINE 30%	RENO-M-DIP (INJECTABLE; INJECTION)	ER SQUIBB AND SONS	10-040 01-08-60		I-7; I-8 09-24-86
DIATRIZOATE MEGLUMINE; DIATRIZOATE SODIUM 52%; 8%	RENOGRAFIN-60 (INJECTABLE; INJECTION)	ER SQUIBB AND SONS	10-040 08-29-74		I-8 09-24-86
DIATRIZOATE MEGLUMINE; DIATRIZOATE SODIUM 66%; 10%	RENOGRAFIN-76 (INJECTABLE; INJECTION)	ER SQUIBB AND SONS	10-040 10-27-72		I-5 09-24-86
DIAZEPAM 2MG	VALIUM (TABLET; ORAL)	HOFFMANN-LA ROCHE	13-263 11-15-63	4316897 02-23-99	
DIAZEPAM 5MG	VALIUM (TABLET; ORAL)	HOFFMANN-LA ROCHE	13-263 11-15-63	4316897 02-23-99	
DIAZEPAM 10MG	VALIUM (TABLET; ORAL)	HOFFMANN-LA ROCHE	13-263 11-15-63	4316897 02-23-99	
DIAZEPAM 5MG/ML	VALIUM (INJECTABLE; INJECTION)	HOFFMANN-LA ROCHE	16-087 08-24-66	4316897 02-23-99	
DIAZEPAM 15MG	VALRELEASE (CAPSULE, CONTROLLED RELEASE; ORAL)	HOFFMANN-LA ROCHE	18-179 03-12-81	4316897 02-23-99	
DIAZOXIDE 15MG/ML	HYPERSTAT (INJECTABLE; INJECTION)	SCHERING	16-996 01-22-73		I-1 09-24-86
DICICLOMINE HYDROCHLORIDE 10MG	BENTYL (CAPSULE; ORAL)	MERRELL DOW/DOW CHEM	07-409 10-15-84		
DICICLOMINE HYDROCHLORIDE 20MG	BENTYL (CAPSULE; ORAL)	MERRELL DOW/DOW CHEM	07-409 10-15-84		
DICICLOMINE HYDROCHLORIDE 10MG/ML	BENTYL (INJECTABLE; INJECTION)	MERRELL DOW/DOW CHEM	08-370 10-15-84		

TABLE IV. NDA'S APPROVED FROM 1-1-82 TO 2-28-85 AND NDA'S WITH APPROPRIATE PATENT AND EXCLUSIVITY INFORMATION

<u>ACTIVE INGREDIENT(S)</u> <u>STRENGTH(S)</u>	<u>TRADE NAME</u> <u>(DOSAGE FORM; ROUTE)</u>	<u>APPLICANT NAME</u>	<u>NDA NO.</u> <u>APPROVAL DATE</u>	<u>PATENT NO.</u> <u>EXP. DATE</u>	<u>EXCLUSIVITY</u> <u>EXP. DATE</u>
DICYCLIMINE HYDROCHLORIDE 10MG/5ML	BENTYL (SYRUP; ORAL)	MERRELL DOW/DOW CHEM	07-961 10-15-84		
DIFLORASONE DIACETATE 0.05%	FLORONE (CREAM; TOPICAL)	UPJOHN	17-741 09-14-77	3980778 09-14-93	
DIFLORASONE DIACETATE 0.05%	FLORONE (OINTMENT; TOPICAL)	UPJOHN	17-994 03-01-78	3980778 09-14-93	
DIFLUNISAL 250MG	DOLOBID (TABLET; ORAL)	MS&D/MERCK	18-445 04-19-82	3714226 08-01-89 3674870 07-04-89	NCE 04-19-92
DIFLUNISAL 500MG	DOLOBID (TABLET; ORAL)	MS&D/MERCK	18-445 04-19-82	3714226 08-01-89 3674870 07-04-89	NCE 04-19-92
DIGOXIN 0.2MG	LANOXICAPS (CAPSULE; ORAL)	BURROUGHS WELLCOME	18-118 07-26-82		NDF 09-24-86
DIGOXIN 0.05MG	LANOXICAPS (CAPSULE; ORAL)	BURROUGHS WELLCOME	18-118 07-26-82		NDF 09-24-86
DIGOXIN 0.1MG	LANOXICAPS (CAPSULE; ORAL)	BURROUGHS WELLCOME	18-118 07-26-82		NDF 09-24-86
DIHYDROERGOTAMINE MESYLATE; HEPARIN SODIUM; LIDOCAINE HYDROCHLORIDE 0.5MG/0.5ML; 2500 UNITS/0.5ML; 5.33MG/0.5ML	EMBOLEX (INJECTABLE; INJECTION)	SANDOZ PHARMS/SANDOZ	18-885 11-30-84	4451458 05-29-01	NC 11-30-87
DIHYDROERGOTAMINE MESYLATE; HEPARIN SODIUM; LIDOCAINE HYDROCHLORIDE 0.5MG/0.7ML; 5000 UNITS/0.7ML; 7.46MG/0.7ML	EMBOLEX (INJECTABLE; INJECTION)	SANDOZ PHARMS/SANDOZ	18-885 11-30-84	4451458 05-29-01	NC 11-30-87
DILTIAZEM HYDROCHLORIDE 30MG	CARDIZEM (TABLET; ORAL)	MARION LABORATORIES	18-602 11-05-82	3562257 02-09-88	NCE 11-05-92

TABLE IV. NDA'S APPROVED FROM 1-1-82 TO 2-28-85 AND NDA'S WITH APPROPRIATE PATENT AND EXCLUSIVITY INFORMATION

<u>ACTIVE INGREDIENT(S)</u> <u>STRENGTH(S)</u>	<u>TRADE NAME</u> <u>(DOSAGE FORM; ROUTE)</u>	<u>APPLICANT NAME</u>	<u>NDA NO.</u> <u>APPROVAL DATE</u>	<u>PATENT NO.</u> <u>EXP. DATE</u>	<u>EXCLUSIVITY</u> <u>EXP. DATE</u>
DILTIAZEM HYDROCHLORIDE 60MG	CARDIZEM (TABLET; ORAL)	MARION LABORATORIES	18-602 11-05-82	3562257 02-09-88	NCE 11-05-92
DINOPROST TROMETHAMINE EQ 5MG BASE/ML	PROSTIN F2 ALPHA (INJECTABLE; INJECTION)	UPJOHN	17-434 11-26-73	3706789 12-19-89 3778506 12-11-90	
DINOPROSTONE 20MG	PROSTIN E2 (SUPPOSITORY; VAGINAL)	UPJOHN	17-810 08-23-77	3899587 08-12-92 3598858 08-10-88	
DIPIVEFRIN HYDROCHLORIDE 0.1%	PROPINE (SOLUTION; OPHTHALMIC)	ALLERGAN PHARMS	18-239 05-02-80	3839584 10-01-91 3809714 05-07-91	
DISOPYRAMIDE PHOSPHATE EQ 100MG BASE	NORPAC CR (CAPSULE, CONTROLLED RELEASE; ORAL)	SEARLE/SEARLE PHARMS	18-655 07-20-82		NDF 09-24-86
DISOPYRAMIDE PHOSPHATE EQ 150MG BASE	NORPAC CR (CAPSULE, CONTROLLED RELEASE; ORAL)	SEARLE/SEARLE PHARMS	18-655 07-20-82		NDF 09-24-86
DIVALPROEX SODIUM EQ 250MG BASE	DEPAKOTE (TABLET, ENTERIC COATED; ORAL)	ABBOTT LABORATORIES	18-723 03-10-83		NE 09-24-86
DIVALPROEX SODIUM EQ 500MG BASE	DEPAKOTE (TABLET, ENTERIC COATED; ORAL)	ABBOTT LABORATORIES	18-723 03-10-83		NE 09-24-86
DOBUTAMINE HYDROCHLORIDE EQ 250MG BASE/VIAL	DOBUTREX (INJECTABLE; INJECTION)	ELI LILLY	17-820 07-18-78	3987200 10-19-93	
DOPAMINE HYDROCHLORIDE 80MG/ML	DOPAMINE HCL (INJECTABLE; INJECTION)	ABBOTT LABORATORIES	18-132 07-09-82		

TABLE IV. NDA'S APPROVED FROM 1-1-82 TO 2-28-85 AND NDA'S WITH APPROPRIATE PATENT AND EXCLUSIVITY INFORMATION

<u>ACTIVE INGREDIENT(S)</u> <u>STRENGTH(S)</u>	<u>TRADE NAME</u> <u>(DOSAGE FORM; ROUTE)</u>	<u>APPLICANT NAME</u>	<u>NDA NO.</u>		<u>PATENT NO.</u>		<u>EXCLUSIVITY</u>	
			<u>APPROVAL DATE</u>		<u>EXP. DATE</u>		<u>EXP. DATE</u>	
DOPAMINE HYDROCHLORIDE 80MG/ML	DOPAMINE (INJECTABLE; INJECTION)	ELKINS-SINN/AHROBINS	18-398	03-22-82				
DOPAMINE HYDROCHLORIDE 40MG/ML	DOPAMINE HCL (INJECTABLE; INJECTION)	BRISTOL LABS/B-M	18-549	03-11-83				
DOPAMINE HYDROCHLORIDE 40MG/ML	DOPAMINE (INJECTABLE; INJECTION)	ASTRA PHARM PRODS	18-656	06-28-83				
DOXEPIN HYDROCHLORIDE EQ 25MG BASE	SINEQUAN (CAPSULE; ORAL)	Pfizer Labs/Pfizer	16-798	09-23-69	3420851	01-07-86		
DOXEPIN HYDROCHLORIDE EQ 50MG BASE	SINEQUAN (CAPSULE; ORAL)	Pfizer Labs/Pfizer	16-798	09-23-69	3420851	01-07-86		
DOXEPIN HYDROCHLORIDE EQ 10MG BASE	SINEQUAN (CAPSULE; ORAL)	Pfizer Labs/Pfizer	16-798	03-31-75	3420851	01-07-86		
DOXEPIN HYDROCHLORIDE EQ 100MG BASE	SINEQUAN (CAPSULE; ORAL)	Pfizer Labs/Pfizer	16-798	03-31-75	3420851	01-07-86		
DOXEPIN HYDROCHLORIDE EQ 75MG BASE	SINEQUAN (CAPSULE; ORAL)	Pfizer Labs/Pfizer	16-798	06-04-76	3420851	01-07-86		
DOXEPIN HYDROCHLORIDE EQ 150MG BASE	SINEQUAN (CAPSULE; ORAL)	Pfizer Labs/Pfizer	16-798	03-15-78	3420851	01-07-86		
DOXEPIN HYDROCHLORIDE EQ 10MG BASE	ADAPIN (CAPSULE; ORAL)	PENNWALT PHARM	16-987	01-31-72	3420851	01-07-86		
DOXEPIN HYDROCHLORIDE EQ 25MG BASE	ADAPIN (CAPSULE; ORAL)	PENNWALT PHARM	16-987	01-31-72	3420851	01-07-86		
DOXEPIN HYDROCHLORIDE EQ 50MG BASE	ADAPIN (CAPSULE; ORAL)	PENNWALT PHARM	16-987	01-31-72	3420851	01-07-86		
DOXEPIN HYDROCHLORIDE EQ 100MG BASE	ADAPIN (CAPSULE; ORAL)	PENNWALT PHARM	16-987	12-12-77	3420851	01-07-86		
DOXEPIN HYDROCHLORIDE EQ 75MG BASE	ADAPIN (CAPSULE; ORAL)	PENNWALT PHARM	16-987	04-15-80	3420851	01-07-86		

TABLE IV. NDA'S APPROVED FROM 1-1-82 TO 2-28-85 AND NDA'S WITH APPROPRIATE PATENT AND EXCLUSIVITY INFORMATION

<u>ACTIVE INGREDIENT(S)</u> <u>STRENGTH(S)</u>	<u>TRADE NAME</u> <u>(DOSAGE FORM; ROUTE)</u>	<u>APPLICANT NAME</u>	<u>NDA NO.</u> <u>APPROVAL DATE</u>	<u>PATENT NO.</u> <u>EXP. DATE</u>	<u>EXCLUSIVITY</u> <u>EXP. DATE</u>
DOXEPIN HYDROCHLORIDE EQ 10MG BASE/ML	SINEQUAN (CONCENTRATE; ORAL)	PFIZER LABS/PFIZER	17-516 03-11-74	3420851 01-07-86	
ECONAZOLE NITRATE 1%	SPECTAZOLE (CREAM; TOPICAL)	ORTHO PHARMACEUTICAL	18-751 12-23-82	3717655 02-20-90 3839574 10-01-91	NCE 12-23-92
ENFLURANE 99.9%	ETHRANE (LIQUID; INHALATION)	ANAQUEST/BOC	17-087 08-28-72	3469011 09-23-86 3527813 09-08-87	
EPINEPHRINE; ETIDOCAINE HYDROCHLORIDE 0.005MG/ML; 0.5%	DURANEST (INJECTABLE; INJECTION)	ASTRA PHARM PRODS	17-751 08-30-76	3862321 01-21-92 3812147 05-21-91	
EPINEPHRINE; ETIDOCAINE HYDROCHLORIDE 0.005MG/ML; 1%	DURANEST (INJECTABLE; INJECTION)	ASTRA PHARM PRODS	17-751 08-30-76	3862321 01-21-92 3812147 05-21-91	
EPINEPHRINE; ETIDOCAINE HYDROCHLORIDE 0.005MG/ML; 1.5%	DURANEST (INJECTABLE; INJECTION)	ASTRA PHARM PRODS	17-751 08-30-76	3862321 01-21-92 3812147 05-21-91	
ERGOLOID MESYLATES 1MG	HYDERGINE LC (CAPSULE; ORAL)	SANDOZ PHARMS/SANDOZ	18-706 01-18-83		NDF 09-24-86
ESTROGENS, CONJUGATED 0.9MG	PREMARIN (TABLET; ORAL)	AYERST LABS/AMHO	04-782 01-26-84		NS 09-24-86
ETHINYL ESTRADIOL; LEVONORGESTREL 0.03MG; 0.15MG	NORDETTE-21 (TABLET; ORAL-21)	WYETH LABS/AMHO	18-668 05-10-82	3666858 05-30-89 3850911 11-26-91 3959322 11-26-91	NC 09-24-86

TABLE IV. NDA'S APPROVED FROM 1-1-82 TO 2-28-85 AND NDA'S WITH APPROPRIATE PATENT AND EXCLUSIVITY INFORMATION

<u>ACTIVE INGREDIENT(S)</u> <u>STRENGTH(S)</u>	<u>TRADE NAME</u> <u>(DOSAGE FORM; ROUTE)</u>	<u>APPLICANT NAME</u>	<u>NDA NO.</u> <u>APPROVAL DATE</u>	<u>PATENT NO.</u> <u>EXP. DATE</u>	<u>EXCLUSIVITY</u> <u>EXP. DATE</u>
ETHINYL ESTRADIOL; LEVONORGESTREL 0.03MG; 0.15MG	NORDETTE-28 (TABLET; ORAL-28)	WYETH LABS/AMHO	18-782 07-21-82	3666858 05-30-89 3850911 11-26-91 3959322 11-26-91	NC 09-24-86
ETHINYL ESTRADIOL; LEVONORGESTREL 0.03MG; 0.05MG 0.04MG; 0.075MG 0.03MG; 0.125MG	TRIPHASIL-28 (TABLET; ORAL-28)	WYETH LABS/AMHO	19-190 11-01-84	3666858 05-30-89 3850911 11-26-91 3959322 11-26-91 3957982 05-18-93	NS 11-01-87
ETHINYL ESTRADIOL; LEVONORGESTREL 0.03MG; 0.05MG 0.04MG; 0.075MG 0.03MG; 0.125MG	TRIPHASIL-21 (TABLET; ORAL-21)	WYETH LABS/AMHO	19-192 11-01-84	3666858 05-30-89 3850911 11-26-91 3959322 11-26-91 3957982 05-18-93	NS 11-01-87
ETHINYL ESTRADIOL; NORETHINDRONE 0.035MG; 0.5MG AND 1MG	ORTHO-NOVUM 10/11-21 (TABLET; ORAL-21)	ORTHO PHARMACEUTICAL	18-354 01-11-82		D-5 09-24-86
ETHINYL ESTRADIOL; NORETHINDRONE 0.035MG; 0.5MG AND 1MG	ORTHO-NOVUM 10/11-28 (TABLET; ORAL-28)	ORTHO PHARMACEUTICAL	18-354 01-11-82		D-5 09-24-86
ETHINYL ESTRADIOL; NORETHINDRONE 0.035MG; 0.5MG AND 1MG	TRI-NORINYL 21-DAY (TABLET; ORAL-21)	SYNTEX (FP)	18-977 04-13-84	4390531 06-28-00	D-6 09-24-86
ETHINYL ESTRADIOL; NORETHINDRONE 0.035MG; 0.5MG AND 1MG	TRI-NORINYL 28-DAY (TABLET; ORAL-28)	SYNTEX (FP)	18-977 04-13-84	4390531 06-28-00	D-6 09-24-86
ETHINYL ESTRADIOL; NORETHINDRONE 0.035MG; 0.5MG, 0.75MG AND 1MG	ORTHO-NOVUM 7/7/7-21 (TABLET; ORAL-21)	ORTHO PHARMACEUTICAL	18-985 04-04-84		D-3 09-24-86

TABLE IV. NDA'S APPROVED FROM 1-1-82 TO 2-28-85 AND NDA'S WITH APPROPRIATE PATENT AND EXCLUSIVITY INFORMATION

<u>ACTIVE INGREDIENT(S)</u> <u>STRENGTH(S)</u>	<u>TRADE NAME</u> <u>(DOSAGE FORM; ROUTE)</u>	<u>APPLICANT NAME</u>	<u>NDA NO.</u>		<u>PATENT NO.</u>		<u>EXCLUSIVITY</u>	
			<u>APPROVAL DATE</u>		<u>EXP. DATE</u>		<u>EXP. DATE</u>	
ETHINYL ESTRADIOL; NORETHINDRONE 0.035MG; 0.5MG, 0.75MG AND 1MG ETHINYL ESTRADIOL; NORETHINDRONE 0.035MG; 0.5MG AND 1MG ETHINYL ESTRADIOL; NORETHINDRONE 0.035MG; 0.5MG AND 1MG ETHINYL ESTRADIOL; NORGESTREL 0.05MG; 0.5MG	ORTHO-NOVUM 7/7/7-28 (TABLET; ORAL-28)	ORTHO PHARMACEUTICAL	18-985	04-04-84			D-3	09-24-86
	ORTHO-NOVUM 7/14-21 (TABLET; ORAL-21)	ORTHO PHARMACEUTICAL	19-004	04-04-84			D-4	09-24-86
	ORTHO-NOVUM 7/14-28 (TABLET; ORAL-28)	ORTHO PHARMACEUTICAL	19-004	04-04-84			D-4	09-24-86
	OVRAL (TABLET; ORAL-21)	WYETH LABS/AMHO	16-672	04-16-68	3666858	05-30-89		
ETHINYL ESTRADIOL; NORGESTREL 0.05MG; 0.5MG ETHINYL ESTRADIOL; NORGESTREL 0.03MG; 0.3MG ETHINYL ESTRADIOL; NORGESTREL 0.03MG; 0.3MG	OVRAL-28 (TABLET; ORAL-28)	WYETH LABS/AMHO	16-806	11-26-68	3666858	05-30-89		
					3850911	11-26-91		
					3959322	11-26-91		
					11-26-91	11-26-91		
ETHINYL ESTRADIOL; NORGESTREL 0.03MG; 0.3MG ETHINYL ESTRADIOL; NORGESTREL 0.03MG; 0.3MG ETHIDOCANE HYDROCHLORIDE 0.5%	LO/OVRAL (TABLET; ORAL-21)	WYETH LABS/AMHO	17-612	03-17-75	3666858	05-30-89		
					3850911	11-26-91		
					3959322	11-26-91		
					11-26-91	11-26-91		
ETHIDOCANE HYDROCHLORIDE 0.5%	LO/OVRAL-28 (TABLET; ORAL-28)	WYETH LABS/AMHO	17-802	03-16-76	3666858	05-30-89		
					3850911	11-26-91		
					3959322	11-26-91		
					11-26-91	11-26-91		
ETHIDOCANE HYDROCHLORIDE 0.5%	DURANEST (INJECTABLE; INJECTION)	ASTRA PHARM PRODS	17-751	08-30-76	3862321	01-21-92		
					3812147	05-21-91		

TABLE IV. NDA'S APPROVED FROM 1-1-82 TO 2-28-85 AND NDA'S WITH APPROPRIATE PATENT AND EXCLUSIVITY INFORMATION

<u>ACTIVE INGREDIENT(S) STRENGTH(S)</u>	<u>TRADE NAME (DOSAGE FORM; ROUTE)</u>	<u>APPLICANT NAME</u>	<u>NDA NO. APPROVAL DATE</u>	<u>PATENT NO. EXP. DATE</u>	<u>EXCLUSIVITY EXP. DATE</u>
ETIDOCAINE HYDROCHLORIDE 1%	DURANEST (INJECTABLE; INJECTION)	ASTRA PHARM PRODS	17-751 08-30-76	3862321 01-21-92 3812147 05-21-91	
ETIDRONATE DISODIUM 200MG	DIDRONEL (TABLET; ORAL)	NORMICH EATON/P&G	17-831 09-01-77	4254114 03-03-98 4216211 08-05-97 4137309 01-30-96 3683080 08-08-89	
ETIDRONATE DISODIUM 400MG	DIDRONEL (TABLET; ORAL)	NORMICH EATON/P&G	17-831 07-06-84	4254114 03-03-98 4216211 08-05-97 4137309 01-30-96 3683080 08-08-89	NS 09-24-86
ETONIDATE 2MG/ML	AMIDATE (INJECTABLE; INJECTION)	ABBOTT LABORATORIES	18-227 09-07-82		NCE 09-07-92
ETOPOSIDE 20MG/ML	VEPESIO (INJECTABLE; INJECTION)	BRISTOL LABS/B-M	18-768 11-10-83	3524844 08-18-87	NCE 11-10-93
FENFLURAMINE HYDROCHLORIDE 60MG	PONDIMIN (TABLET, CONTROLLED RELEASE; ORAL)	AH ROBINS	16-618 07-27-82		NDF 09-24-86
FENOPROFEN CALCIUM EQ 300MG BASE	NALFON (CAPSULE; ORAL)	DISTA PRODS/LILLY	17-604 03-16-76	3600437 08-17-88	
FENOPROFEN CALCIUM EQ 200MG BASE	NALFON 200 (CAPSULE; ORAL)	DISTA PRODS/LILLY	17-604 10-15-80	3600437 08-17-88	
FENOPROFEN CALCIUM EQ 600MG BASE	NALFON (TABLET; ORAL)	DISTA PRODS/LILLY	17-710 03-16-76	3600437 08-17-88	

TABLE IV. NDA'S APPROVED FROM 1-1-82 TO 2-28-85 AND NDA'S WITH APPROPRIATE PATENT AND EXCLUSIVITY INFORMATION

<u>ACTIVE INGREDIENT(S)</u> <u>STRENGTH(S)</u>	<u>TRADE NAME</u> <u>(DOSAGE FORM; ROUTE)</u>	<u>APPLICANT NAME</u>	<u>NDA NO.</u> <u>APPROVAL DATE</u>	<u>PATENT NO.</u> <u>EXP. DATE</u>	<u>EXCLUSIVITY</u> <u>EXP. DATE</u>
FENTANYL CITRATE EQ 0.05MG BASE/ML	FENTANYL CITRATE (INJECTABLE; INJECTION)	ABBOTT LABORATORIES	19-115 01-12-85		
FENTANYL CITRATE EQ 0.05MG BASE/ML	FENTANYL (INJECTABLE; INJECTION)	ELKINS-SINN/AHROBINS	19-101 07-11-84		
FLUNISOLIDE 0.025MG/INH	BRONALIDE (AEROSOL; INHALATION)	SYNTEX LABS/SYNTEX	18-340 08-17-84		NDF 09-24-86
FLUOCINONIDE 0.05%	LIDEX (SOLUTION; TOPICAL)	SYNTEX LABS/SYNTEX	18-849 04-06-84		NDF 09-24-86
FLUOCINONIDE 0.05%	VASODERM (CREAM; TOPICAL)	K-LINE PHARMS	19-117 06-26-84		
FLUPHENAZINE DECANOATE 25MG/ML	PROLIXIN DECANOATE (INJECTABLE; INJECTION)	ER SQUIBB AND SONS	16-727 06-20-72	3394131 07-23-85	
FLUPHENAZINE ENANTHATE 25MG/ML	PROLIXIN ENANTHATE (INJECTABLE; INJECTION)	ER SQUIBB AND SONS	16-110 03-15-67	3394131 07-23-85	
FLURANDRENOLIDE 0.004MG/SQ CM	CORDRAN (TAPE; TOPICAL)	DISTA PRODS/LILLY	16-455 07-29-69	3632740 01-04-89	
FLURAZEPAM HYDROCHLORIDE 15MG	DALMANE (CAPSULE; ORAL)	ROCHE PRODUCTS	16-721 04-07-70	4316897 02-23-99	
FLURAZEPAM HYDROCHLORIDE 30MG	DALMANE (CAPSULE; ORAL)	ROCHE PRODUCTS	16-721 04-07-70	4316897 02-23-99	
FUROSEMIDE 20MG	FUROSEMIDE (TABLET; ORAL)	CHELSEA LABORATORIES	18-369 05-14-82		
FUROSEMIDE 40MG	FUROSEMIDE (TABLET; ORAL)	CHELSEA LABORATORIES	18-369 05-14-82		
FUROSEMIDE 40MG	FUROSEMIDE (TABLET; ORAL)	SUPERPHARM	18-370 02-10-83		
FUROSEMIDE 20MG	FUROSEMIDE (TABLET; ORAL)	SUPERPHARM	18-370 06-26-84		

TABLE IV. NDA'S APPROVED FROM 1-1-82 TO 2-28-85 AND NDA'S WITH APPROPRIATE PATENT AND EXCLUSIVITY INFORMATION

<u>ACTIVE INGREDIENT(S)</u> <u>STRENGTH(S)</u>	<u>TRADE NAME</u> <u>(DOSAGE FORM; ROUTE)</u>	<u>APPLICANT NAME</u>	<u>NDA NO.</u>		<u>PATENT NO.</u>		<u>EXCLUSIVITY</u>	
			<u>APPROVAL DATE</u>		<u>EXP. DATE</u>		<u>EXP. DATE</u>	
FUROSEMIDE 20MG	FUROSEMIDE (TABLET; ORAL)	ZENITH LABORATORIES	18-413	11-30-83				
FUROSEMIDE 40MG	FUROSEMIDE (TABLET; ORAL)	ZENITH LABORATORIES	18-413	11-30-83				
FUROSEMIDE 20MG	FUROSEMIDE (TABLET; ORAL)	LEDERLE LABS/AM CYAN	18-415	07-27-82				
FUROSEMIDE 40MG	FUROSEMIDE (TABLET; ORAL)	LEDERLE LABS/AM CYAN	18-415	07-27-82				
FUROSEMIDE 80MG	FUROSEMIDE (TABLET; ORAL)	LEDERLE LABS/AM CYAN	18-415	11-26-84				
FUROSEMIDE 20MG	FUROSEMIDE (TABLET; ORAL)	PARKE-DAVIS/W-L	18-419	01-31-83				
FUROSEMIDE 40MG	FUROSEMIDE (TABLET; ORAL)	PARKE-DAVIS/W-L	18-419	01-31-83				
FUROSEMIDE 80MG	FUROSEMIDE (TABLET; ORAL)	PARKE-DAVIS/W-L	18-419	11-13-84				
FUROSEMIDE 10MG/ML	FUROSEMIDE (INJECTABLE; INJECTION)	PARKE-DAVIS/W-L	18-420	02-26-82				
FUROSEMIDE 10MG/ML	FUROSEMIDE (INJECTABLE; INJECTION)	LYPHOMED	18-507	07-30-82				
FUROSEMIDE 80MG	FUROSEMIDE (TABLET; ORAL)	CORD LABORATORIES	18-569	08-14-84				
FUROSEMIDE 10MG/ML	FUROSEMIDE (INJECTABLE; INJECTION)	NATCON	18-579	11-30-83				
FUROSEMIDE 10MG/ML	FUROSEMIDE (INJECTABLE; INJECTION)	ABBOTT LABORATORIES	18-667	05-28-82				
FUROSEMIDE 10MG/ML	FUROSEMIDE (INJECTABLE; INJECTION)	WYETH LABS/AMHO	18-670	07-20-82				

TABLE IV. NDA'S APPROVED FROM 1-1-82 TO 2-28-85 AND NDA'S WITH APPROPRIATE PATENT AND EXCLUSIVITY INFORMATION

<u>ACTIVE INGREDIENT(S)</u> <u>STRENGTH(S)</u>	<u>TRADE NAME</u> <u>(DOSAGE FORM; ROUTE)</u>	<u>APPLICANT NAME</u>	<u>NDA NO.</u> <u>APPROVAL DATE</u>	<u>PATENT NO.</u> <u>EXP. DATE</u>	<u>EXCLUSIVITY</u> <u>EXP. DATE</u>
FUROSEMIDE 40MG	FUROSEMIDE (TABLET; ORAL)	DRUMMER/PHOENIX	18-750 07-30-84		
FUROSEMIDE 20MG	FUROSEMIDE (TABLET; ORAL)	INTL MEDICATION SYS	18-753 02-28-84		
FUROSEMIDE 40MG	FUROSEMIDE (TABLET; ORAL)	INTL MEDICATION SYS	18-753 02-28-84		
FUROSEMIDE 40MG	FUROSEMIDE (TABLET; ORAL)	BARR LABORATORIES	18-790 11-29-83		
FUROSEMIDE 20MG	FUROSEMIDE (TABLET; ORAL)	ROXANE LABORATORIES	18-823 11-10-83		
FUROSEMIDE 40MG	FUROSEMIDE (TABLET; ORAL)	ROXANE LABORATORIES	18-823 11-10-83		
FUROSEMIDE 20MG	FUROSEMIDE (TABLET; ORAL)	KALAPHARM	18-868 06-28-83		
FUROSEMIDE 40MG	FUROSEMIDE (TABLET; ORAL)	KALAPHARM	18-868 06-28-83		
FUROSEMIDE 10MG/ML	FUROSEMIDE (INJECTABLE; INJECTION)	INVENEX LABS/LIFE	18-902 05-22-84		
FUROSEMIDE 10MG/ML	FUROSEMIDE (INJECTABLE; INJECTION)	INVENEX LABS/LIFE	19-036 08-13-84		
GENFIBROZIL 200MG	LOPID (CAPSULE; ORAL)	PARKE-DAVIS/W-L	18-422 12-21-81	3674836 07-04-89	
GENFIBROZIL 300MG	LOPID (CAPSULE; ORAL)	PARKE-DAVIS/W-L	18-422 12-21-81	3674836 07-04-89	
GLIPIZIDE 5MG	GLUCOTROL (TABLET; ORAL)	ROERIG/PFIZER	17-783 05-08-84	3669966 04-21-92	NCE 05-08-94
GLIPIZIDE 10MG	GLUCOTROL (TABLET; ORAL)	ROERIG/PFIZER	17-783 05-08-84	3669966 04-21-92	NCE 05-08-94

TABLE IV. NDA'S APPROVED FROM 1-1-82 TO 2-28-85 AND NDA'S WITH APPROPRIATE PATENT AND EXCLUSIVITY INFORMATION

<u>ACTIVE INGREDIENT(S)</u> <u>STRENGTH(S)</u>	<u>TRADE NAME</u> <u>(DOSAGE FORM; ROUTE)</u>	<u>APPLICANT NAME</u>	<u>NDA NO.</u> <u>APPROVAL DATE</u>	<u>PATENT NO.</u> <u>EXP. DATE</u>	<u>EXCLUSIVITY</u> <u>EXP. DATE</u>
GLYBURIDE 1.25MG	MICRONASE (TABLET; ORAL)	UPJOHN	17-498	3426067	NCE
			05-01-84	04-21-92	05-01-94
				3454635	
				04-21-92	
				3507954	
GLYBURIDE 2.5MG	MICRONASE (TABLET; ORAL)	UPJOHN		04-21-92	
				3507961	
				04-21-92	
			17-498	3426067	NCE
			05-01-84	04-21-92	05-01-94
GLYBURIDE 5MG	MICRONASE (TABLET; ORAL)	UPJOHN		3454635	
				04-21-92	
				3507954	
				04-21-92	
				3507961	
GLYBURIDE 1.25MG	DIABETA (TABLET; ORAL)	HOECHST-ROUSSEL		04-21-92	
			17-532	3426067	NCE
			05-01-84	04-21-92	05-01-94
				3454635	
				04-21-92	

TABLE IV. NDA'S APPROVED FROM 1-1-82 TO 2-28-85 AND NDA'S WITH APPROPRIATE PATENT AND EXCLUSIVITY INFORMATION

<u>ACTIVE INGREDIENT(S)</u> <u>STRENGTH(S)</u>	<u>TRADE NAME</u> <u>(DOSAGE FORM; ROUTE)</u>	<u>APPLICANT NAME</u>	<u>NDA NO.</u> <u>APPROVAL DATE</u>	<u>PATENT NO.</u> <u>EXP. DATE</u>	<u>EXCLUSIVITY</u> <u>EXP. DATE</u>
GLYBURIDE 2.5MG	DIABETA (TABLET; ORAL)	HOECHST-ROUSSEL	17-532 05-01-84	3426067 04-21-92 3454635 04-21-92 3507961 04-21-92 3507954 04-21-92 4060634 09-07-93	NCE 05-01-94
GLYBURIDE 5MG	DIABETA (TABLET; ORAL)	HOECHST-ROUSSEL	17-532 05-01-84	3426067 04-21-92 3454635 04-21-92 3507961 04-21-92 3507954 04-21-92 4060634 09-07-93	NCE 05-01-94
GONADORELIN HYDROCHLORIDE EQ 0.1MG BASE/VIAL	FACTREL (INJECTABLE; INJECTION)	AYERST LABS/AMHO	18-123 09-30-82	3947569 03-30-93 4110438 08-29-95	NCE 09-30-92
GONADORELIN HYDROCHLORIDE EQ 0.5MG BASE/VIAL	FACTREL (INJECTABLE; INJECTION)	AYERST LABS/AMHO	18-123 09-30-82	3947569 03-30-93 4110438 08-29-95	NCE 09-30-92
GONADOTROPIN, CHORIONIC 2,000 UNITS/VIAL	CHORIONIC GONADOTROPIN (INJECTABLE; INJECTION)	CARTER-GLOGAU LABS	17-016 12-27-84		
GUANABENZ ACETATE EQ 4MG BASE	WYTENSIN (TABLET; ORAL)	WYETH LABS/AMHO	18-587 09-07-82	3658993 04-25-89	NCE 09-07-92
GUANABENZ ACETATE EQ 8MG BASE	WYTENSIN (TABLET; ORAL)	WYETH LABS/AMHO	18-587 09-07-82	3658993 04-25-89	NCE 09-07-92

TABLE IV. NDA'S APPROVED FROM 1-1-82 TO 2-28-85 AND NDA'S WITH APPROPRIATE PATENT AND EXCLUSIVITY INFORMATION

<u>ACTIVE INGREDIENT(S)</u> <u>STRENGTH(S)</u>		<u>TRADE NAME</u> <u>(DOSAGE FORM; ROUTE)</u>	<u>APPLICANT NAME</u>	<u>NDA NO.</u> <u>APPROVAL DATE</u>	<u>PATENT NO.</u> <u>EXP. DATE</u>	<u>EXCLUSIVITY</u> <u>EXP. DATE</u>
GUANADREL SULFATE 10MG		HYLOREL (TABLET; ORAL)	UPJOHN	18-104 12-29-82	3547951 12-15-87	NCE 12-29-92
GUANADREL SULFATE 25MG		HYLOREL (TABLET; ORAL)	UPJOHN	18-104 12-29-82	3547951 12-15-87	NCE 12-29-92
HALAZEPAM 20MG		PAXIPAM (TABLET; ORAL)	SCHERING	17-736 09-24-81	3429874 02-25-86	
HALAZEPAM 40MG		PAXIPAM (TABLET; ORAL)	SCHERING	17-736 09-24-81	3429874 02-25-86	
HALOPERIDOL 0.5MG		HALDOL (TABLET; ORAL)	MCNEIL PHARM	15-921 04-12-67	3438991 04-15-86	NS 09-24-86
HALOPERIDOL 1MG		HALDOL (TABLET; ORAL)	MCNEIL PHARM	15-921 04-12-67	3438991 04-15-86	
HALOPERIDOL 2MG		HALDOL (TABLET; ORAL)	MCNEIL PHARM	15-921 04-12-67	3438991 04-15-86	
HALOPERIDOL 5MG		HALDOL (TABLET; ORAL)	MCNEIL PHARM	15-921 04-16-74	3438991 04-15-86	
HALOPERIDOL 10MG		HALDOL (TABLET; ORAL)	MCNEIL PHARM	15-921 04-16-74	3438991 04-15-86	
HALOPERIDOL 20MG		HALDOL (TABLET; ORAL)	MCNEIL PHARM	15-921 02-02-82	3438991 04-15-86	NS 09-24-86
HALOPERIDOL LACTATE EQ 2MG BASE/ML		HALDOL (CONCENTRATE; ORAL)	MCNEIL LABORATORIES	15-922 04-12-67	3438991 04-15-86	
HALOPERIDOL LACTATE EQ 5MG BASE/ML		HALDOL (INJECTABLE; INJECTION)	MCNEIL LABORATORIES	15-923 05-18-71	3438991 04-15-86	
HEPARIN SODIUM 10 UNITS/ML		HEPARIN LOCK FLUSH (INJECTABLE; INJECTION)	INVENEX LABS/LIFE	17-029 05-06-82		

TABLE IV. NDA'S APPROVED FROM 1-1-82 TO 2-28-85 AND NDA'S WITH APPROPRIATE PATENT AND EXCLUSIVITY INFORMATION

<u>ACTIVE INGREDIENT(S)</u> <u>STRENGTH(S)</u>	<u>TRADE NAME</u> <u>(DOSAGE FORM; ROUTE)</u>	<u>APPLICANT NAME</u>	<u>NDA NO.</u> <u>APPROVAL DATE</u>	<u>PATENT NO.</u> <u>EXP. DATE</u>	<u>EXCLUSIVITY</u> <u>EXP. DATE</u>
HEPARIN SODIUM; SODIUM CHLORIDE 200 UNITS/100ML; 900MG/100ML	HEPARIN SODIUM 1000 UNITS AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER (INJECTABLE; INJECTION)	TRAVENOL LABS	18-609 04-28-82		
HEPARIN SODIUM; SODIUM CHLORIDE 200 UNITS/100ML; 900MG/100ML	HEPARIN SODIUM 2000 UNITS AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER (INJECTABLE; INJECTION)	TRAVENOL LABS	18-609 04-28-82		
HEPARIN SODIUM; SODIUM CHLORIDE 500 UNITS/100ML; 900MG/100ML	HEPARIN SODIUM 5000 UNITS AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER (INJECTABLE; INJECTION)	TRAVENOL LABS	18-609 04-28-82		
HEPARIN SODIUM; SODIUM CHLORIDE 1,000 UNITS/100ML; 900MG/100ML	HEPARIN SODIUM 5000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER (INJECTABLE; INJECTION)	ABBOTT LABORATORIES	18-916 01-31-84		
HEPARIN SODIUM; SODIUM CHLORIDE 10,000 UNITS/100ML; 900MG/100ML	HEPARIN SODIUM 10,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER (INJECTABLE; INJECTION)	ABBOTT LABORATORIES	18-916 01-31-84		
HEPARIN SODIUM; SODIUM CHLORIDE 5,000 UNITS/100ML; 900MG/100ML	HEPARIN SODIUM 12,500 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER (INJECTABLE; INJECTION)	ABBOTT LABORATORIES	18-916 01-31-84		
HEPARIN SODIUM; SODIUM CHLORIDE 100 UNITS/ML; 4.5MG/ML	HEPARIN SODIUM 5,000 UNITS IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER (INJECTABLE; INJECTION)	ABBOTT LABORATORIES	18-916 01-31-84		
HEPARIN SODIUM; SODIUM CHLORIDE 100 UNITS/ML; 4.5MG/ML	HEPARIN SODIUM 5,000 UNITS IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER (INJECTABLE; INJECTION)	ABBOTT LABORATORIES	18-911 01-30-85		

TABLE IV. NDA'S APPROVED FROM 1-1-82 TO 2-28-85 AND NDA'S WITH APPROPRIATE PATENT AND EXCLUSIVITY INFORMATION

<u>ACTIVE INGREDIENT(S) STRENGTH(S)</u>	<u>TRADE NAME (DOSAGE FORM; ROUTE)</u>	<u>APPLICANT NAME</u>	<u>NDA NO. APPROVAL DATE</u>	<u>PATENT NO. EXP. DATE</u>	<u>EXCLUSIVITY EXP. DATE</u>
HEPARIN SODIUM; SODIUM CHLORIDE 10,000 UNITS/100ML; 450MG/100ML	HEPARIN SODIUM 10,000 UNITS IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER (INJECTABLE; INJECTION)	ABBOTT LABORATORIES	18-916 01-31-84		
HEPARIN SODIUM; SODIUM CHLORIDE 10,000 UNITS/100ML; 450MG/100ML	HEPARIN SODIUM 10,000 UNITS IN SODIUM CHLORIDE 0.45% (INJECTABLE; INJECTION)	ABBOTT LABORATORIES	18-911 01-30-85		
HEPARIN SODIUM; SODIUM CHLORIDE 10,000 UNITS/100ML; 900MG/100ML	HEPARIN SODIUM 10,000 UNITS IN SODIUM CHLORIDE 0.9% (INJECTABLE; INJECTION)	ABBOTT LABORATORIES	18-911 01-30-85		
HEPARIN SODIUM; SODIUM CHLORIDE 5,000 UNITS/100ML; 450MG/100ML	HEPARIN SODIUM 12,500 UNITS IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER (INJECTABLE; INJECTION)	ABBOTT LABORATORIES	18-916 01-31-84		
HEPARIN SODIUM; SODIUM CHLORIDE 5,000 UNITS/100ML; 900MG/100ML	HEPARIN SODIUM 12,500 UNITS IN SODIUM CHLORIDE 0.9% (INJECTABLE; INJECTION)	ABBOTT LABORATORIES	18-911 01-30-85		
HEPARIN SODIUM; SODIUM CHLORIDE 5,000 UNITS/100ML; 900MG/100ML	HEPARIN SODIUM 25,000 UNITS IN SODIUM CHLORIDE 0.9% (INJECTABLE; INJECTION)	ABBOTT LABORATORIES	18-911 01-30-85		
HEPARIN SODIUM; SODIUM CHLORIDE 5,000 UNITS/100ML; 450MG/100ML	HEPARIN SODIUM 25,000 UNITS IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER (INJECTABLE; INJECTION)	ABBOTT LABORATORIES	18-916 01-31-84		
HEPARIN SODIUM; SODIUM CHLORIDE 10,000 UNITS/100ML; 450MG/100ML	HEPARIN SODIUM 25,000 UNITS IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER (INJECTABLE; INJECTION)	ABBOTT LABORATORIES	18-916 01-31-84		
HEPARIN SODIUM; SODIUM CHLORIDE 5,000 UNITS/100ML; 900MG/100ML	HEPARIN SODIUM 25,000 UNITS IN SODIUM CHLORIDE 0.9% (INJECTABLE; INJECTION)	ABBOTT LABORATORIES	18-916 01-31-84		

TABLE IV. NDA'S APPROVED FROM 1-1-82 TO 2-28-85 AND NDA'S WITH APPROPRIATE PATENT AND EXCLUSIVITY INFORMATION

<u>ACTIVE INGREDIENT(S)</u> <u>STRENGTH(S)</u>	<u>TRADE NAME</u> <u>(DOSAGE FORM; ROUTE)</u>	<u>APPLICANT NAME</u>	<u>NDA NO.</u> <u>APPROVAL DATE</u>	<u>PATENT NO.</u> <u>EXP. DATE</u>	<u>EXCLUSIVITY</u> <u>EXP. DATE</u>
HEXACHLOROPHENE 3%	TURGEX (SOLUTION; TOPICAL)	XTTRIUM LABS	19-055 11-30-84		
HYDROCHLOROTHIAZIDE; METOPROLOL TARTRATE 25MG; 50MG	LOPRESSOR HCT 50/25 (TABLET; ORAL)	GEIGY/CIBA-GEIGY	18-303 12-31-84	3876802 04-08-92 3998790 12-21-93	NC 12-31-87
HYDROCHLOROTHIAZIDE; METOPROLOL TARTRATE 25MG; 100MG	LOPRESSOR HCT 100/25 (TABLET; ORAL)	GEIGY/CIBA-GEIGY	18-303 12-31-84	3876802 04-08-92 3998790 12-21-93	NC 12-31-87
HYDROCHLOROTHIAZIDE; METOPROLOL TARTRATE 50MG; 100MG	LOPRESSOR HCT 100/50 (TABLET; ORAL)	GEIGY/CIBA-GEIGY	18-303 12-31-84	3876802 04-08-92 3998790 12-21-93	NC 12-31-87
HYDROCHLOROTHIAZIDE; TIMOLOL MALEATE 25MG; 10MG	TIMOLIDE (TABLET; ORAL)	MS&D/MERCK	18-061 12-11-81	3655663 04-11-89 4238485 12-09-97	
HYDROCHLOROTHIAZIDE; TRIAMTERENE 50MG; 75MG	MAXZIDE (TABLET; ORAL)	MYLAN PHARMS	19-129 10-22-84	4444769 04-24-01	NS 10-22-87
HYDROCORTISONE ACETATE 10%	CORTIFOAM (AEROSOL; RECTAL)	REED&CARNRICK PHARMS	17-351 02-10-82		NDF 09-24-86
HYDROCORTISONE BUTYRATE 0.1%	LOCOID (CREAM; TOPICAL)	OWEN LABS/DERM PRODS	18-795 01-07-83		NP 09-24-86
HYDROCORTISONE BUTYRATE 0.1%	LOCOID (OINTMENT; TOPICAL)	OWEN LABS/DERM PRODS	19-106 07-03-84		NP 09-24-86
HYDROCORTISONE VALERATE 0.2%	WESTCORT (OINTMENT; TOPICAL)	WESTWOOD PHARMS	18-726 08-08-83		NDF 09-24-86
HYDROMORPHONE HYDROCHLORIDE 10MG/ML	DILAUDIO-HP (INJECTABLE; INJECTION)	KNOLL PHARMACEUTICAL	19-034 01-11-84		NCE 01-11-94

TABLE IV. NDA'S APPROVED FROM 1-1-82 TO 2-28-85 AND NDA'S WITH APPROPRIATE PATENT AND EXCLUSIVITY INFORMATION

<u>ACTIVE INGREDIENT(S) STRENGTH(S)</u>	<u>TRADE NAME (DOSAGE FORM; ROUTE)</u>	<u>APPLICANT NAME</u>	<u>NDA NO. APPROVAL DATE</u>	<u>PATENT NO. EXP. DATE</u>	<u>EXCLUSIVITY EXP. DATE</u>
HYDROXYUREA 500MG	HYDREA (CAPSULE; ORAL)	ER SQUIBB AND SONS	16-295 12-07-67	3968249 07-06-93	
IBUPROFEN 400MG	MOTRIN (TABLET; ORAL)	UPJOHN MANUFACTURING	17-463 09-19-74	3385886 05-28-85	I-2 09-24-86
IBUPROFEN 300MG	MOTRIN (TABLET; ORAL)	UPJOHN MANUFACTURING	17-463 09-19-74	3385886 05-28-85	I-2 09-24-86
IBUPROFEN 600MG	MOTRIN (TABLET; ORAL)	UPJOHN MANUFACTURING	17-463 03-09-79	3385886 05-28-85	I-2 09-24-86
IBUPROFEN 400MG	RUFEN (TABLET; ORAL)	BOOTS PHARMACEUTICAL	18-197 05-19-81	3385886 05-28-85	I-2 09-24-86
IBUPROFEN 600MG	RUFEN (TABLET; ORAL)	BOOTS PHARMACEUTICAL	18-197 03-05-84	3385886 05-28-85	I-2 09-24-86
INDAPAMIDE 2.5MG	LOZOL (TABLET; ORAL)	USV PHARMACEUTICAL	18-538 07-06-83	3565911 02-23-88	NCE 07-06-93
INDOMETHACIN 50MG	INDOCIN (SUPPOSITORY; RECTAL)	MS&D RES LABS/MERCK	17-814 08-13-84		NDF 09-24-86
INDOMETHACIN 75MG	INDOCIN SR (CAPSULE; CONTROLLED RELEASE; ORAL)	MS&D/MERCK	18-185 02-23-82		NDF 09-24-86
INDOMETHACIN 25MG	INDOMETHACIN (CAPSULE; ORAL)	CHELSEA LABORATORIES	18-690 07-31-84		
INDOMETHACIN 50MG	INDOMETHACIN (CAPSULE; ORAL)	CHELSEA LABORATORIES	18-690 07-31-84		
INDOMETHACIN 25MG	INDOMETHACIN (CAPSULE; ORAL)	ZENITH LABORATORIES	18-730 05-04-84		
INDOMETHACIN 50MG	INDOMETHACIN (CAPSULE; ORAL)	ZENITH LABORATORIES	18-730 05-04-84		

TABLE IV. NDA'S APPROVED FROM 1-1-82 TO 2-28-85 AND NDA'S WITH APPROPRIATE PATENT AND EXCLUSIVITY INFORMATION

<u>ACTIVE INGREDIENT(S)</u> <u>STRENGTH(S)</u>	<u>TRADE NAME</u> <u>(DOSAGE FORM; ROUTE)</u>	<u>APPLICANT NAME</u>	<u>NDA NO.</u>		<u>PATENT NO.</u>		<u>EXCLUSIVITY</u>	
			<u>APPROVAL DATE</u>		<u>EXP. DATE</u>		<u>EXP. DATE</u>	
INDOMETHACIN 50MG	INDOMETHACIN (CAPSULE; ORAL)	PAR PHARMACEUTICAL	18-829	08-06-84				
INDOMETHACIN 25MG	INDOMETHACIN (CAPSULE; ORAL)	PAR PHARMACEUTICAL	18-829	08-06-84				
INDOMETHACIN 25MG	INDOMETHACIN (CAPSULE; ORAL)	LEDERLE LABS/AM CYAN	18-851	05-18-84				
INDOMETHACIN 50MG	INDOMETHACIN (CAPSULE; ORAL)	LEDERLE LABS/AM CYAN	18-851	05-18-84				
INDOMETHACIN 25MG	INDOMETHACIN (CAPSULE; ORAL)	MYLAN PHARMS	18-858	04-20-84				
INDOMETHACIN 50MG	INDOMETHACIN (CAPSULE; ORAL)	MYLAN PHARMS	18-858	04-20-84				
INDOMETHACIN 25MG	INDOMETHACIN (CAPSULE; ORAL)	PARKE-DAVIS/W-L	18-806	11-23-84				
INDOMETHACIN 50MG	INDOMETHACIN (CAPSULE; ORAL)	PARKE-DAVIS/W-L	18-806	11-23-84				
INDOMETHACIN SODIUM TRIHYDRATE EQ 1MG BASE/VIAL	INDOCIN I. V. (INJECTABLE; INJECTION)	MS&D/MERCK	18-878	01-30-85				
IODAMIDE MEGLUMINE 24%	RENOVUE-DIP (INJECTABLE; INJECTION)	ER SQUIBB AND SONS	17-903	07-10-78			I-6 09-24-86	
IODAMIDE MEGLUMINE 65%	RENOVUE-65 (INJECTABLE; INJECTION)	ER SQUIBB AND SONS	17-902	07-24-78			I-6 09-24-86	
IODOHIPPURATE SODIUM, I-123 1MCI/ML	NEPHROFLOW (INJECTABLE; INJECTION)	MEDI-PHYSICS	18-289	12-28-84			NCE 12-28-89	
IODOXANATE MEGLUMINE 9.9%	CHOLOVUE (INJECTABLE; INJECTION)	ER SQUIBB AND SONS	18-076	08-14-81			3654272 04-04-89	

TABLE IV. NDA'S APPROVED FROM 1-1-82 TO 2-28-85 AND NDA'S WITH APPROPRIATE PATENT AND EXCLUSIVITY INFORMATION

<u>ACTIVE INGREDIENT(S)</u> <u>STRENGTH(S)</u>	<u>TRADE NAME</u> <u>(DOSAGE FORM; ROUTE)</u>	<u>APPLICANT NAME</u>	<u>NDA NO.</u> <u>APPROVAL DATE</u>	<u>PATENT NO.</u> <u>EXP. DATE</u>	<u>EXCLUSIVITY</u> <u>EXP. DATE</u>
IODOXAMATE MEGLUKINE 40.3%	CHOLOVUE (INJECTABLE; INJECTION)	ER SQUIBB AND SONS	18-077 08-14-81	3654272 04-04-89	
ISOFLURANE 99.9%	FORANE (GAS; INHALATION)	ANAQUEST/BOC	17-624 12-18-79	3535425 01-24-93 3535388 01-24-93	
ISOTRETINOIN 10MG	ACCUTANE (CAPSULE; ORAL)	HOFFMANN-LA ROCHE	18-662 05-07-82	4200647 04-29-97 4322438 03-30-99 4464394 08-07-01	NCE 05-07-92
ISOTRETINOIN 20MG	ACCUTANE (CAPSULE; ORAL)	HOFFMANN-LA ROCHE	18-662 03-28-83	4200647 04-29-97 4322438 03-30-99 4464394 08-07-01	NCE 05-07-92
ISOTRETINOIN 40MG	ACCUTANE (CAPSULE; ORAL)	HOFFMANN-LA ROCHE	18-662 05-07-82	4200647 04-29-97 4322438 03-30-99 4464394 08-07-01	NCE 05-07-92
KETOCONAZOLE 200MG	NIZORAL (TABLET; ORAL)	JANSSEN PHARMA	18-533 06-12-81	4335125 06-15-99	I-25 09-24-86
LABETALOL HYDROCHLORIDE 200MG	NORMODYNE (TABLET; ORAL)	SCHERING	18-686 08-01-84	4012444 03-15-94 4006755 01-03-95	NCE 08-01-94
LABETALOL HYDROCHLORIDE 300MG	NORMODYNE (TABLET; ORAL)	SCHERING	18-686 08-01-84	4012444 03-15-94 4006755 01-03-95	NCE 08-01-94

TABLE IV. NDA'S APPROVED FROM 1-1-82 TO 2-28-85 AND NDA'S WITH APPROPRIATE PATENT AND EXCLUSIVITY INFORMATION

<u>ACTIVE INGREDIENT(S)</u> <u>STRENGTH(S)</u>	<u>TRADE NAME</u> <u>(DOSAGE FORM; ROUTE)</u>	<u>APPLICANT NAME</u>	<u>NDA NO.</u> <u>APPROVAL DATE</u>	<u>PATENT NO.</u> <u>EXP. DATE</u>	<u>EXCLUSIVITY</u> <u>EXP. DATE</u>
LABETALOL HYDROCHLORIDE 400MG	NORMODYNE (TABLET; ORAL)	SCHERING	18-686 08-01-84	4012444 03-15-94 4006755 01-03-95	NCE 08-01-94
LABETALOL HYDROCHLORIDE 5MG/ML	NORMODYNE (INJECTABLE; INJECTION)	SCHERING	18-687 08-01-84	4012444 03-15-94 4006755 01-03-95 4328213 05-04-99	NCE 08-01-94
LABETALOL HYDROCHLORIDE 200MG	TRANDATE (TABLET; ORAL)	GLAXO	18-716 08-01-84	4012444 03-15-94 4006755 01-03-95	NCE 08-01-94
LABETALOL HYDROCHLORIDE 300MG	TRANDATE (TABLET; ORAL)	GLAXO	18-716 08-01-84	4012444 03-15-94 4006755 01-03-95	NCE 08-01-94
LABETALOL HYDROCHLORIDE 400MG	TRANDATE (TABLET; ORAL)	GLAXO	18-716 08-01-84	4012444 03-15-94 4006755 01-03-95	NCE 08-01-94
LACTULOSE 10GM/15ML	CEPHULAC (SYRUP; ORAL)	MERRELL DOW/DOW CHEM	17-657 03-25-76	3461204 08-12-86 3867524 02-18-92 3860708 01-14-92 3860707 01-14-92 3562388 02-09-88 3558774 01-26-88	

TABLE IV. NDA'S APPROVED FROM 1-1-82 TO 2-28-85 AND NDA'S WITH APPROPRIATE PATENT AND EXCLUSIVITY INFORMATION

ACTIVE INGREDIENT(S) STRENGTH(S)	TRADE NAME (DOSAGE FORM; ROUTE)	APPLICANT NAME	NDA NO. APPROVAL DATE	PATENT NO. EXP. DATE	EXCLUSIVITY EXP. DATE
LEUCOVORIN CALCIUM EQ 5MG BASE	WELLCOVORIN (TABLET; ORAL)	BURROUGHS WELLCOME	18-342 07-08-83		NDF 09-24-86
LEUCOVORIN CALCIUM EQ 25MG BASE	WELLCOVORIN (TABLET; ORAL)	BURROUGHS WELLCOME	18-342 07-08-83		NDF 09-24-86
LITHIUM CARBONATE 450MG	ESKALITH CR (TABLET, CONTROLLED RELEASE; ORAL)	SK&F LABORATORIES	18-152 03-29-82		NS 09-24-86
LITHIUM CARBONATE 300MG	LITHIUM CARBONATE (TABLET; ORAL)	ROXANE LABORATORIES	18-558 01-29-82		
LOPERAMIDE HYDROCHLORIDE 2MG	IMODIUM (CAPSULE; ORAL)	JANSSEN PHARMA	17-694 12-28-76	3714159 01-30-90	I-30 09-24-86
LOPERAMIDE HYDROCHLORIDE 1MG/5ML	IMODIUM (SOLUTION; ORAL)	JANSSEN PHARMA	19-037 07-31-84	3714159 01-30-90	NDF 09-24-86
LOXAPINE HYDROCHLORIDE EQ 50MG BASE/ML	LOXITANE (INJECTABLE; INJECTION)	LEDERLE LABS/AM CYAN	18-039 10-26-79	3546226 12-08-87	
LOXAPINE HYDROCHLORIDE EQ 25MG BASE/ML	LOXITANE (CONCENTRATE; ORAL)	LEDERLE LABS/AM CYAN	17-658 05-04-76	3546226 12-08-87 4049809 09-20-94	
LOXAPINE SUCCINATE EQ 5MG BASE	LOXITANE (CAPSULE; ORAL)	LEDERLE LABS/AM CYAN	17-525 10-25-77	3546226 12-08-87	
LOXAPINE SUCCINATE EQ 10MG BASE	LOXITANE (CAPSULE; ORAL)	LEDERLE LABS/AM CYAN	17-525 02-25-75	3546226 12-08-87	
LOXAPINE SUCCINATE EQ 25MG BASE	LOXITANE (CAPSULE; ORAL)	LEDERLE LABS/AM CYAN	17-525 02-25-75	3546226 12-08-87	
LOXAPINE SUCCINATE EQ 50MG BASE	LOXITANE (CAPSULE; ORAL)	LEDERLE LABS/AM CYAN	17-525 02-25-75	3546226 12-08-87	

TABLE IV. NDA'S APPROVED FROM 1-1-82 TO 2-28-85 AND NDA'S WITH APPROPRIATE PATENT AND EXCLUSIVITY INFORMATION

<u>ACTIVE INGREDIENT(S)</u> <u>STRENGTH(S)</u>	<u>TRADE NAME</u> <u>(DOSAGE FORM; ROUTE)</u>	<u>APPLICANT NAME</u>	<u>NDA NO.</u> <u>APPROVAL DATE</u>	<u>PATENT NO.</u> <u>EXP. DATE</u>	<u>EXCLUSIVITY</u> <u>EXP. DATE</u>
MAFENIDE ACETATE EQ 85MG BASE/GM	SULFAMYLON (CREAM; TOPICAL)	WINTHROP LABS/STERL	16-763 01-24-69	3497599 01-26-88	
MAGNESIUM ACETATE TETRAHYDRATE; POTASSIUM ACETATE; SODIUM CHLORIDE 32MG/100ML; 128MG/100ML; 234MG/100ML	PLASMA-LYTE 56 IN PLASTIC CONTAINER (INJECTABLE; INJECTION)	TRAVENOL LABS	19-047 06-15-84		NC 09-24-86
MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, MONOBASIC; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM GLUCONATE; SODIUM PHOSPHATE 30MG/100ML; 37MG/100ML; 0.82MG/100ML; 370MG/100ML; 530MG/100ML; 500MG/100ML; 12MG/100ML	ISOLYTE PH 7.4 IN PLASTIC CONTAINER (INJECTABLE; INJECTION)	AM MCGAW/AM HOSP	19-006 04-04-84		NC 09-24-86
MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM GLUCONATE 30MG/100ML; 37MG/100ML; 222MG/100ML; 526MG/100ML; 502MG/100ML	PHYSIOSOL IN PLASTIC CONTAINER (SOLUTION; IRRIGATION)	ABBOTT LABORATORIES	17-637 07-08-82		NC 09-24-86
MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM GLUCONATE 30MG/100ML; 37MG/100ML; 222MG/100ML; 526MG/100ML; 502MG/100ML	PHYSIOSOL IN PLASTIC CONTAINER (SOLUTION; IRRIGATION)	ABBOTT LABORATORIES	18-406 07-08-82		NC 09-24-86
MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM GLUCONATE 30MG/100ML; 37MG/100ML; 370MG/100ML; 530MG/100ML; 500MG/100ML	PHYSIOLYTE IN PLASTIC CONTAINER (SOLUTION; IRRIGATION)	AM MCGAW/AM HOSP	19-024 06-08-84		NC 09-24-86
MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM GLUCONATE 30MG/100ML; 37MG/100ML; 368MG/100ML; 526MG/100ML; 502MG/100ML	SYNOVALYTE IN PLASTIC CONTAINER (SOLUTION; IRRIGATION)	TRAVENOL LABS	19-326 01-25-85		

TABLE IV. NDA'S APPROVED FROM 1-1-82 TO 2-28-85 AND NDA'S WITH APPROPRIATE PATENT AND EXCLUSIVITY INFORMATION

<u>ACTIVE INGREDIENT(S)</u> <u>STRENGTH(S)</u>	<u>TRADE NAME</u> <u>(DOSAGE FORM; ROUTE)</u>	<u>APPLICANT NAME</u>	<u>NDA NO.</u> <u>APPROVAL DATE</u>	<u>PATENT NO.</u> <u>EXP. DATE</u>	<u>EXCLUSIVITY</u> <u>EXP. DATE</u>
MAGNESIUM SULFATE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, MONOBASIC; SODIUM CHLORIDE; SODIUM PHOSPHATE 20MG/100ML; 40MG/100ML; 6.25MG/100ML; 800MG/100ML; 8.75MG/100ML	TIS-U-SOL (SOLUTION; IRRIGATION)	TRAVENOL LABS	18-508 02-19-82		NC 09-24-86
MALATHION 0.5%	PRIODERM (LOTION; TOPICAL)	PURDUE FREDERICK	18-613 08-02-82		NCE 08-02-92
MAPROTILINE HYDROCHLORIDE 25MG	LUDIOMIL (TABLET; ORAL)	CIBA/CIBA-GEIGY	17-543 12-01-80	3399201 08-27-85	
MAPROTILINE HYDROCHLORIDE 50MG	LUDIOMIL (TABLET; ORAL)	CIBA/CIBA-GEIGY	17-543 12-01-80	3399201 08-27-85	
MAPROTILINE HYDROCHLORIDE 75MG	LUDIOMIL (TABLET; ORAL)	CIBA/CIBA-GEIGY	17-543 09-30-82	3399201 08-27-85	NS 09-24-86
MAZINDOL 1MG	SANOREX (TABLET; ORAL)	SANDOZ PHARMS/SANDOZ	17-247 06-14-73	3763178 10-02-90	
MAZINDOL 2MG	SANOREX (TABLET; ORAL)	SANDOZ PHARMS/SANDOZ	17-247 06-14-73	3763178 10-02-90	
MAZINDOL 2MG	MAZANOR (TABLET; ORAL)	WYETH LABS/AMHO	17-980 08-28-80	3763178 10-02-90	
MAZINDOL 1MG	MAZANOR (TABLET; ORAL)	WYETH LABS/AMHO	17-980 02-02-82	3763178 10-02-90	
MEBENDAZOLE 100MG	VERMOX (TABLET, CHEWABLE; ORAL)	JANSSEN PHARMA	17-481 06-28-74	3657267 04-18-89	
MEDROXYPROGESTERONE ACETATE 100MG/ML	DEPO-PROVERA (INJECTABLE; INJECTION)	UPJOHN	12-541 01-16-76	3377364 04-09-85	
MEDROXYPROGESTERONE ACETATE 400MG/ML	DEPO-PROVERA (INJECTABLE; INJECTION)	UPJOHN	12-541 01-16-76	3377364 04-09-85	

TABLE IV. NDA'S APPROVED FROM 1-1-82 TO 2-28-85 AND NDA'S WITH APPROPRIATE PATENT AND EXCLUSIVITY INFORMATION

<u>ACTIVE INGREDIENT(S)</u> <u>STRENGTH(S)</u>	<u>TRADE NAME</u> (<u>DOSAGE FORM</u> ; <u>ROUTE</u>)	<u>APPLICANT NAME</u>	<u>NDA NO.</u>		<u>EXCLUSIVITY</u>	
			<u>APPROVAL DATE</u>	<u>PATENT NO.</u> <u>EXP. DATE</u>	<u>EXP. DATE</u>	<u>EXP. DATE</u>
MEGLUMINE; METRIZOIC ACID 140.1MG/ML; 461.8MG/ML	ISOPAQUE-280 (INJECTABLE; INJECTION)	WINTHROP LABS/STERL	17-506 04-30-74	3476802 11-04-86		
METAPROTERENOL SULFATE 20MG	ALUPENT (TABLET; ORAL)	BOEHRINGER INGELHEIM	15-874 05-13-74	3422196 01-14-86		
METAPROTERENOL SULFATE 10MG	ALUPENT (TABLET; ORAL)	BOEHRINGER INGELHEIM	15-874 08-08-77	3422196 01-14-86		
METAPROTERENOL SULFATE 0.65MG/INH	ALUPENT (AEROSOL; INHALATION)	BOEHRINGER INGELHEIM	16-402 07-31-73	3422196 01-14-86		
METAPROTERENOL SULFATE 10MG/5ML	ALUPENT (SYRUP; ORAL)	BOEHRINGER INGELHEIM	17-571 05-23-75	3422196 01-14-86		
METAPROTERENOL SULFATE 5%	ALUPENT (SOLUTION; INHALATION)	BOEHRINGER INGELHEIM	17-659 09-18-80	3422196 01-14-86		
METAPROTERENOL SULFATE 0.6%	ALUPENT (SOLUTION; INHALATION)	BOEHRINGER INGELHEIM	18-761 06-30-83	3422196 01-14-86		
METHYLDOPA 250MG	METHYLDOPA (TABLET; ORAL)	CORD LABORATORIES	18-934 06-29-84			
METHYLDOPA 500MG	METHYLDOPA (TABLET; ORAL)	CORD LABORATORIES	18-934 06-29-84			
METHYLPHENIDATE HYDROCHLORIDE 20MG	RITALIN-SR (TABLET, CONTROLLED RELEASE; ORAL)	CIBA/CIBA-GEIGY	18-029 03-30-82		NDF 09-24-86	
METOCLOPRAMIDE EQ 5MG BASE/5ML	REGLAN (SYRUP; ORAL)	AH ROBINS	18-821 3-25-83		NDF 09-24-86	
METOCLOPRAMIDE HYDROCHLORIDE EQ 5MG BASE/ML	REGLAN (INJECTABLE; INJECTION)	AH ROBINS	17-862 02-07-79		I-12; I-13; I-14 09-24-87	
METOCLOPRAMIDE HYDROCHLORIDE EQ 10MG BASE	REGLAN (TABLET; ORAL)	AH ROBINS	17-854 12-30-80		I-4 09-24-86	

TABLE IV. NDA'S APPROVED FROM 1-1-82 TO 2-28-85 AND NDA'S WITH APPROPRIATE PATENT AND EXCLUSIVITY INFORMATION

<u>ACTIVE INGREDIENT(S)</u> <u>STRENGTH(S)</u>	<u>TRADE NAME</u> <u>(DOSAGE FORM; ROUTE)</u>	<u>APPLICANT NAME</u>	<u>NDA NO.</u> <u>APPROVAL DATE</u>	<u>PATENT NO.</u> <u>EXP. DATE</u>	<u>EXCLUSIVITY</u> <u>EXP. DATE</u>
METOPROLOL TARTRATE 50MG	LOPRESSOR (TABLET; ORAL)	GEIGY/CIBA-GEIGY	17-963 08-07-78	3998790 12-21-93	
METOPROLOL TARTRATE 100MG	LOPRESSOR (TABLET; ORAL)	GEIGY/CIBA-GEIGY	17-963 08-07-78	3998790 12-21-93	
METOPROLOL TARTRATE 1MG/ML	LOPRESSOR (INJECTABLE; INJECTION)	GEIGY/CIBA-GEIGY	18-704 03-30-84	3998790 12-21-93	NDF 09-24-86
METRIZAMIDE 3.75GM/VIAL	AMIPAQUE (INJECTABLE; INJECTION)	WINTHROP LABS/STERL	17-982 08-23-78	3701771 10-31-89	I-26 09-24-86
METRIZAMIDE 6.75GM/VIAL	AMIPAQUE (INJECTABLE; INJECTION)	WINTHROP LABS/STERL	17-982 08-23-78	3701771 10-31-89	I-26 09-24-86
METRONIDAZOLE 500MG	METRONIDAZOLE (TABLET; ORAL)	ZENITH LABORATORIES	18-517 05-05-82		
METRONIDAZOLE 250MG	METRONIDAZOLE (TABLET; ORAL)	CHELSEA LABORATORIES	18-599 09-17-82		
METRONIDAZOLE 500MG	METRONIDAZOLE (TABLET; ORAL)	CHELSEA LABORATORIES	18-599 02-13-84		
METRONIDAZOLE 250MG	METRYL (TABLET; ORAL)	DRUMMER/PHOENIX	18-620 03-04-82		
METRONIDAZOLE 500MG	METRYL 500 (TABLET; ORAL)	DRUMMER/PHOENIX	18-620 06-02-83		
METRONIDAZOLE 500MG/100ML	METRO I.V. (INJECTABLE; INJECTION)	AM MCGAW/AM HOSP	18-674 08-31-82		
METRONIDAZOLE 250MG	METRONIDAZOLE (TABLET; ORAL)	CORD LABORATORIES	18-740 10-22-82		
METRONIDAZOLE 500MG	METRONIDAZOLE (TABLET; ORAL)	CORD LABORATORIES	18-740 10-22-82		
METRONIDAZOLE 250MG	METRONIDAZOLE (TABLET; ORAL)	DANBURY PHARMACAL	18-764 09-17-82		

TABLE IV. NDA'S APPROVED FROM 1-1-82 TO 2-28-85 AND NDA'S WITH APPROPRIATE PATENT AND EXCLUSIVITY INFORMATION

<u>ACTIVE INGREDIENT(S)</u> <u>STRENGTH(S)</u>	<u>TRADE NAME</u> <u>(DOSAGE FORM; ROUTE)</u>	<u>APPLICANT NAME</u>	<u>NDA NO.</u> <u>APPROVAL DATE</u>	<u>PATENT NO.</u> <u>EXP. DATE</u>	<u>EXCLUSIVITY</u> <u>EXP. DATE</u>
METRONIDAZOLE 500MG	METRONIDAZOLE (TABLET; ORAL)	DANBURY PHARMACAL	18-764 12-20-82		
METRONIDAZOLE 250MG	METRONIDAZOLE (TABLET; ORAL)	BARR LABORATORIES	18-818 02-16-83		
METRONIDAZOLE 500MG	METRONIDAZOLE (TABLET; ORAL)	BARR LABORATORIES	18-818 02-16-83		
METRONIDAZOLE 250MG	METRONIDAZOLE (TABLET; ORAL)	PAR PHARMACEUTICAL	18-845 08-18-83		
METRONIDAZOLE 250MG	PROTOSTAT (TABLET; ORAL)	ORTHO PHARMACEUTICAL	18-871 03-02-83		
METRONIDAZOLE 500MG	PROTOSTAT (TABLET; ORAL)	ORTHO PHARMACEUTICAL	18-871 03-02-83		
METRONIDAZOLE 500MG/100ML	METRONIDAZOLE (INJECTABLE; INJECTION)	ABBOTT LABORATORIES	18-889 11-18-83		
METRONIDAZOLE 500MG/100ML	METRONIDAZOLE IN PLASTIC CONTAINER (INJECTABLE; INJECTION)	ABBOTT LABORATORIES	18-890 11-18-83		
METRONIDAZOLE 500MG/100ML	METRO I.V. IN PLASTIC CONTAINER (INJECTABLE; INJECTION)	AM MCGAW/AM HOSP	18-900 09-29-83		
METRONIDAZOLE 500MG/100ML	METRONIDAZOLE (INJECTABLE; INJECTION)	ELKINS-SINN/AHROBINS	18-907 03-30-84		
METRONIDAZOLE 500MG/100ML	FLAGYL I.V. RTU (INJECTABLE; INJECTION)	SEARLE PHARMS	18-353 05-29-81		I-11 12-20-87
METRONIDAZOLE 500MG/100ML	FLAGYL I.V. RTU IN PLASTIC CONTAINER (INJECTABLE; INJECTION)	SEARLE PHARMS	18-657 12-24-81		I-11 12-20-87
METRONIDAZOLE 500MG	METRONIDAZOLE (TABLET; ORAL)	PAR PHARMACEUTICAL	18-930 08-18-83		

TABLE IV. NDA'S APPROVED FROM 1-1-82 TO 2-28-85 AND NDA'S WITH APPROPRIATE PATENT AND EXCLUSIVITY INFORMATION

<u>ACTIVE INGREDIENT(S) STRENGTH(S)</u>	<u>TRADE NAME (DOSAGE FORM; ROUTE)</u>	<u>APPLICANT NAME</u>	<u>NDA NO. APPROVAL DATE</u>	<u>PATENT NO. EXP. DATE</u>	<u>EXCLUSIVITY EXP. DATE</u>
METRONIDAZOLE 250MG	METRONIDAZOLE (TABLET; ORAL)	LNK INTERNATIONAL	19-029 04-10-84		
METRONIDAZOLE HYDROCHLORIDE EQ 500MG BASE/VIAL	FLAGYL I.V. (INJECTABLE; INJECTION)	SEARLE PHARMS	18-353 11-28-80		I-11 12-20-87
MICONAZOLE 10MG/ML	MONISTAT (INJECTABLE; INJECTION)	JANSSEN PHARMA	18-040 10-04-78	3717655 02-20-90 3839574 10-01-91	I-27 09-24-86
MICONAZOLE NITRATE 2%	MONISTAT 7 (CREAM; VAGINAL)	ORTHO PHARMACEUTICAL	17-450 01-30-74	3717655 02-20-90 3839574 10-01-91	
MICONAZOLE NITRATE 2%	MONISTAT-DERM (CREAM; TOPICAL)	ORTHO PHARMACEUTICAL	17-494 01-30-74	3717655 02-20-90 3839574 10-01-91	
MICONAZOLE NITRATE 2%	MONISTAT-DERM (LOTION; TOPICAL)	ORTHO PHARMACEUTICAL	17-739 12-16-75	3717655 02-20-90 3839574 10-01-91	
MICONAZOLE NITRATE 100MG	MONISTAT 7 (SUPPOSITORY; VAGINAL)	ORTHO PHARMACEUTICAL	18-520 03-15-82	3717655 02-20-90 3839574 10-01-91	
MICONAZOLE NITRATE 200MG	MONISTAT 3 (SUPPOSITORY; VAGINAL)	ORTHO PHARMACEUTICAL	18-888 08-15-84	3717655 02-20-90 3839574 10-01-91	NS 09-24-86
MINOXIDIL 2.5MG	LONITEN (TABLET; ORAL)	UPJOHN	18-154 10-18-79	3461461 08-12-86	

TABLE IV. NDA'S APPROVED FROM 1-1-82 TO 2-28-85 AND NDA'S WITH APPROPRIATE PATENT AND EXCLUSIVITY INFORMATION

<u>ACTIVE INGREDIENT(S)</u> <u>STRENGTH(S)</u>	<u>TRADE NAME</u> <u>(DOSAGE FORM; ROUTE)</u>	<u>APPLICANT NAME</u>	<u>NDA NO.</u> <u>APPROVAL DATE</u>	<u>PATENT NO.</u> <u>EXP. DATE</u>	<u>EXCLUSIVITY</u> <u>EXP. DATE</u>
MINOXIDIL 10MG	LONITEN (TABLET; ORAL)	UPJOHN	18-154 10-18-79	3461461 08-12-86	
MOLINDONE HYDROCHLORIDE 5MG	MOBAN (TABLET; ORAL)	DUPONT PHARMS/DUPONT	17-111 07-03-74	3491093 01-20-87	
MOLINDONE HYDROCHLORIDE 10MG	MOBAN (TABLET; ORAL)	DUPONT PHARMS/DUPONT	17-111 07-03-74	3491093 01-20-87	
MOLINDONE HYDROCHLORIDE 25MG	MOBAN (TABLET; ORAL)	DUPONT PHARMS/DUPONT	17-111 07-03-74	3491093 01-20-87	
MOLINDONE HYDROCHLORIDE 50MG	MOBAN (TABLET; ORAL)	DUPONT PHARMS/DUPONT	17-111 01-05-81	3491093 01-20-87	
MOLINDONE HYDROCHLORIDE 100MG	MOBAN (TABLET; ORAL)	DUPONT PHARMS/DUPONT	17-111 01-05-81	3491093 01-20-87	
MOLINDONE HYDROCHLORIDE 20MG/ML	MOBAN (CONCENTRATE; ORAL)	DUPONT PHARMS/DUPONT	17-938 12-28-79	3491093 01-20-87	
MORPHINE SULFATE 0.5MG/ML	DURAMORPH PF (INJECTABLE; INJECTION)	ELKINS-SINN/AHROBINS	18-565 09-18-84		NR; D-8 09-24-86
MORPHINE SULFATE 1MG/ML	DURAMORPH PF (INJECTABLE; INJECTION)	ELKINS-SINN/AHROBINS	18-565 09-18-84		NR; D-8 09-24-86
NADOLOL 40MG	CORGARD (TABLET; ORAL)	ER SQUITBB AND SONS	18-063 12-10-79	3982021 09-21-93 3935267 01-27-93	
NADOLOL 80MG	CORGARD (TABLET; ORAL)	ER SQUITBB AND SONS	18-063 12-10-79	3982021 09-21-93 3935267 01-27-93	
NADOLOL 120MG	CORGARD (TABLET; ORAL)	ER SQUITBB AND SONS	18-063 12-10-79	3982021 09-21-93 3935267 01-27-93	

TABLE IV. NDA'S APPROVED FROM 1-1-82 TO 2-28-85 AND NDA'S WITH APPROPRIATE PATENT AND EXCLUSIVITY INFORMATION

<u>ACTIVE INGREDIENT(S)</u> <u>STRENGTH(S)</u>	<u>TRADE NAME</u> <u>(DOSAGE FORM; ROUTE)</u>	<u>APPLICANT NAME</u>	<u>NDA NO.</u> <u>APPROVAL DATE</u>	<u>PATENT NO.</u> <u>EXP. DATE</u>	<u>EXCLUSIVITY</u> <u>EXP. DATE</u>
NADOLOL 160MG	CORGARD (TABLET; ORAL)	ER SQUIBB AND SONS	18-063 12-10-79	3982021 09-21-93 3935267 01-27-93	
NADOLOL 40MG	CORGARD (TABLET; ORAL)	ER SQUIBB AND SONS	18-064 12-10-79	3982021 09-21-93 3935267 01-27-93	
NADOLOL 80MG	CORGARD (TABLET; ORAL)	ER SQUIBB AND SONS	18-064 12-10-79	3982021 09-21-93 3935267 01-27-93	
NADOLOL 120MG	CORGARD (TABLET; ORAL)	ER SQUIBB AND SONS	18-064 12-10-79	3982021 09-21-93 3935267 01-27-93	
NADOLOL 160MG	CORGARD (TABLET; ORAL)	ER SQUIBB AND SONS	18-064 12-10-79	3982021 09-21-93 3935267 01-27-93	
NALBUPHINE HYDROCHLORIDE 10MG/ML	NUBAIN (INJECTABLE; INJECTION)	DUPONT PHARMS/DUPONT	18-024 05-15-79	3393197 07-16-85	
NALBUPHINE HYDROCHLORIDE 20MG/ML	NUBAIN (INJECTABLE; INJECTION)	DUPONT PHARMS/DUPONT	18-024 05-27-82		NS 09-24-86
NALIDIXIC ACID 250MG	NEGGRAM (TABLET; ORAL)	WINTHROP LABS/STERL	14-214 12-27-67	3590036 06-29-88	
NALIDIXIC ACID 500MG	NEGGRAM (TABLET; ORAL)	WINTHROP LABS/STERL	14-214 03-06-64	3590036 06-29-88	
NALIDIXIC ACID 1GM	NEGGRAM (TABLET; ORAL)	WINTHROP LABS/STERL	14-214 03-06-64	3590036 06-29-88	

TABLE IV. NDA'S APPROVED FROM 1-1-82 TO 2-28-85 AND NDA'S WITH APPROPRIATE PATENT AND EXCLUSIVITY INFORMATION

<u>ACTIVE INGREDIENT(S)</u> <u>STRENGTH(S)</u>	<u>TRADE NAME</u> <u>(DOSAGE FORM; ROUTE)</u>	<u>APPLICANT NAME</u>	<u>NDA NO.</u> <u>APPROVAL DATE</u>	<u>PATENT NO.</u> <u>EXP. DATE</u>	<u>EXCLUSIVITY</u> <u>EXP. DATE</u>
NALIDIXIC ACID 250MG/5ML	NEGRAM (SUSPENSION; ORAL)	WINTHROP LABS/STERL	17-430 04-17-73	3590036 06-29-88	
NALOXONE HYDROCHLORIDE 1MG/ML	NARCAN (INJECTABLE; INJECTION)	DUPONT PHARMS/DUPONT	16-636 06-14-82		NS 09-24-86
NALOXONE HYDROCHLORIDE; PENTAZOCINE HYDROCHLORIDE 0.5MG; EQ 50MG BASE	TALWIN NX (TABLET; ORAL)	WINTHROP LABS/STERL	18-733 12-16-82	4105659 08-08-95	NC 09-24-86
NALTREXONE HYDROCHLORIDE 50MG	TREXAN (TABLET; ORAL)	DUPONT PHARMS/DUPONT	18-932 11-20-84		NCE 11-20-89
NAPROXEN 125MG	NAPROSYN (TABLET; ORAL)	SYNTEX PR	17-581 03-11-76	3998966 12-21-93 4009197 09-09-92 4001301 09-09-92 3904682 09-09-92	NS 09-24-86
NAPROXEN 250MG	NAPROSYN (TABLET; ORAL)	SYNTEX PR	17-581 03-11-76	3998966 12-21-93 4009197 09-09-92 4001301 09-09-92 3904682 09-09-92	
NAPROXEN 375MG	NAPROSYN (TABLET; ORAL)	SYNTEX PR	17-581 07-18-80	3998966 12-21-93 4009197 09-09-92 4001301 09-09-92 3904682 09-09-92	

TABLE IV. NDA'S APPROVED FROM 1-1-82 TO 2-28-85 AND NDA'S WITH APPROPRIATE PATENT AND EXCLUSIVITY INFORMATION

<u>ACTIVE INGREDIENT(S)</u> <u>STRENGTH(S)</u>	<u>TRADE NAME</u> <u>(DOSAGE FORM; ROUTE)</u>	<u>APPLICANT NAME</u>	<u>NDA NO.</u> <u>APPROVAL DATE</u>	<u>PATENT NO.</u> <u>EXP. DATE</u>	<u>EXCLUSIVITY</u> <u>EXP. DATE</u>
NAPROXEN 500MG	NAPROSYN (TABLET; ORAL)	SYNTEX PR	17-581 04-15-82	3998966 12-21-93 4009197 09-09-92 4001301 09-09-92 3904682 09-09-92	NS 09-24-86
NAPROXEN SODIUM 275MG	ANAPROX (TABLET; ORAL)	SYNTEX PR	18-164 09-04-80	3998966 12-21-93 4001301 09-09-92 4009197 09-09-92	
NICLOSAMIDE 500MG	NICLOCIDE (TABLET, CHEWABLE; ORAL)	MILES PHARMS/MILES	18-669 05-14-82		NCE 05-14-92
NICOTINE RESIN COMPLEX EQ 2MG BASE	NICORETTE (GUM, CHEWING; ORAL)	HERRELL DOW/DOW CHEM	18-612 01-13-84		NCE 01-13-94
NIFEDIPINE 10MG	PROCARDIA (CAPSULE; ORAL)	PFIZER LABS/PFIZER	18-482 12-31-81	3644627 02-22-89	
NITROGLYCERIN 0.5MG/ML	TRIDIL (INJECTABLE; INJECTION)	AM CRITICAL CARE/AHS	18-537 06-16-83		NDF 09-24-86
NITROGLYCERIN 5MG/ML	NITROSTAT (INJECTABLE; INJECTION)	PARKE-DAVIS/W-L	18-588 12-23-83		NDF 09-24-86
NITROGLYCERIN 5MG/ML	NITRO-BID (INJECTABLE; INJECTION)	MARION LABORATORIES	18-621 01-05-82		NDF 09-24-86
NITROGLYCERIN 1MG/ML	NITRONAL (INJECTABLE; INJECTION)	G POHL-BOSKAMP	18-672 08-30-83		NDF 09-24-86
NITROGLYCERIN 5MG/ML	NITRONAL (INJECTABLE; INJECTION)	G POHL-BOSKAMP	18-672 08-30-83		NDF 09-24-86

TABLE IV. NDA'S APPROVED FROM 1-1-82 TO 2-28-85 AND NDA'S WITH APPROPRIATE PATENT AND EXCLUSIVITY INFORMATION

<u>ACTIVE INGREDIENT(S)</u> <u>STRENGTH(S)</u>	<u>TRADE NAME</u> <u>(DOSAGE FORM; ROUTE)</u>	<u>APPLICANT NAME</u>	<u>NDA NO.</u> <u>APPROVAL DATE</u>	<u>PATENT NO.</u> <u>EXP. DATE</u>	<u>EXCLUSIVITY</u> <u>EXP. DATE</u>
NITROGLYCERIN 0.8MG/ML	NITROL (INJECTABLE; INJECTION)	KREMERS-URBAN	18-774 01-19-83		NDF 09-24-86
NOMIFENSINE MALEATE 25MG	MERITAL (CAPSULE; ORAL)	HOECHST-ROUSSEL	18-224 12-31-84		NCE 12-31-89
NOMIFENSINE MALEATE 50MG	MERITAL (CAPSULE; ORAL)	HOECHST-ROUSSEL	18-224 12-31-84		NCE 12-31-89
NORETHINDRONE ACETATE 5MG	AYGESTIN (TABLET; ORAL)	AYERST LABS/AMHO	18-405 04-21-82		
NORGESTREL 0.075MG	OVRETTE (TABLET; ORAL)	WYETH LABS/AMHO	17-031 10-23-73	3666858 05-30-89 3850911 11-26-91 3959322 11-26-91	
NORTRIPTYLINE HYDROCHLORIDE EQ 10MG BASE	AVENTYL HCL (CAPSULE; ORAL)	ELI LILLY	14-684 11-06-64	3922305 11-25-92	
NORTRIPTYLINE HYDROCHLORIDE EQ 25MG BASE	AVENTYL HCL (CAPSULE; ORAL)	ELI LILLY	14-684 11-06-64	3922305 11-25-92	
NORTRIPTYLINE HYDROCHLORIDE EQ 10MG BASE/5ML	AVENTYL HCL (SOLUTION; ORAL)	ELI LILLY	14-685 11-06-64	3922305 11-25-92	
NORTRIPTYLINE HYDROCHLORIDE EQ 10MG BASE/5ML	PAMELOR (SOLUTION; ORAL)	SANDOZ PHARMS/SANDOZ	18-012 08-01-77	3922305 11-25-92	
NORTRIPTYLINE HYDROCHLORIDE EQ 10MG BASE	PAMELOR (CAPSULE; ORAL)	SANDOZ PHARMS/SANDOZ	18-013 08-01-77	3922305 11-25-92	
NORTRIPTYLINE HYDROCHLORIDE EQ 25MG BASE	PAMELOR (CAPSULE; ORAL)	SANDOZ PHARMS/SANDOZ	18-013 08-01-77	3922305 11-25-92	
NORTRIPTYLINE HYDROCHLORIDE EQ 75MG BASE	PAMELOR (CAPSULE; ORAL)	SANDOZ PHARMS/SANDOZ	18-013 06-14-79	3922305 11-25-92	

TABLE IV. NDA'S APPROVED FROM 1-1-82 TO 2-28-85 AND NDA'S WITH APPROPRIATE PATENT AND EXCLUSIVITY INFORMATION

<u>ACTIVE INGREDIENT(S)</u> <u>STRENGTH(S)</u>	<u>TRADE NAME</u> <u>(DOSAGE FORM; ROUTE)</u>	<u>APPLICANT NAME</u>	<u>NDA NO.</u> <u>APPROVAL DATE</u>	<u>PATENT NO.</u> <u>EXP. DATE</u>	<u>EXCLUSIVITY</u> <u>EXP. DATE</u>
NORTRIPTYLINE HYDROCHLORIDE EQ 50MG BASE	PAMELOR (CAPSULE; ORAL)	SANDOZ PHARMS/SANDOZ	18-013 06-14-79	3922305 11-25-92	
OXAMNIQUINE 250MG	VANSIL (CAPSULE; ORAL)	PFIZER LABS/PFIZER	18-069 07-23-80	3903283 09-02-92 3821228 06-28-91 3925391 12-09-92	
OXPRENOLOL HYDROCHLORIDE 20MG	TRASICOR (CAPSULE; ORAL)	CIBA/CIBA-GEIGY	18-166 12-28-83	3483221 12-09-86	NCE 12-28-93
OXPRENOLOL HYDROCHLORIDE 40MG	TRASICOR (CAPSULE; ORAL)	CIBA/CIBA-GEIGY	18-166 12-28-83	3483221 12-09-86	NCE 12-28-93
OXPRENOLOL HYDROCHLORIDE 80MG	TRASICOR (CAPSULE; ORAL)	CIBA/CIBA-GEIGY	18-166 12-28-83	3483221 12-09-86	NCE 12-28-93
OXPRENOLOL HYDROCHLORIDE 160MG	TRASICOR (CAPSULE; ORAL)	CIBA/CIBA-GEIGY	18-166 12-28-83	3483221 12-09-86	NCE 12-28-93
PANCURONIUM BROMIDE 2MG/ML	PAVULON (INJECTABLE; INJECTION)	ORGANON/AKZONA	17-015 10-24-72	3553212 01-05-88	
PANCURONIUM BROMIDE 1MG/ML	PAVULON (INJECTABLE; INJECTION)	ORGANON/AKZONA	17-015 09-14-73	3553212 01-05-88	
PARAMETHASONE ACETATE 1MG	HALDRONE (TABLET; ORAL)	ELI LILLY	12-772 04-17-61	3499016 03-03-87	
PARAMETHASONE ACETATE 2MG	HALDRONE (TABLET; ORAL)	ELI LILLY	12-772 04-17-61	3499016 03-03-87	
PENTAGASTRIN 0.25MG/ML	PEPTAVLON (INJECTABLE; INJECTION)	AYERST LABS/AMHO	17-048 07-26-74	3896103 07-22-92	
PENTAMIDINE ISETHIONATE 300MG/VIAL	PENTAM 300 (INJECTABLE; INJECTION)	LYPHOMED	19-264 10-16-84		

TABLE IV. NDA'S APPROVED FROM 1-1-82 TO 2-28-85 AND NDA'S WITH APPROPRIATE PATENT AND EXCLUSIVITY INFORMATION

<u>ACTIVE INGREDIENT(S)</u> <u>STRENGTH(S)</u>	<u>TRADE NAME</u> <u>(DOSAGE FORM; ROUTE)</u>	<u>APPLICANT NAME</u>	<u>NDA NO.</u> <u>APPROVAL DATE</u>	<u>PATENT NO.</u> <u>EXP. DATE</u>	<u>EXCLUSIVITY</u> <u>EXP. DATE</u>
PENTAZOCINE LACTATE EQ 30MG BASE/ML	TALWIN (INJECTABLE; INJECTION)	WINTHROP LABS/STERL	16-194 07-24-67	4105659 08-08-95	
PENTETATE INDIUM DISODIUM, IN-111 1mCi/ML	MPI INDIUM DTPA IN 111 (INJECTABLE; INJECTION)	MEDI-PHYSICS	17-707 02-18-82		NCE 02-18-92
PENTOXIFYLLINE 400MG	TRENTAL (TABLET, CONTROLLED RELEASE; ORAL)	HOECHST-ROUSSEL	18-631 08-30-84	3737433 06-05-90	NCE 08-30-94
PHENYLEPHRINE HYDROCHLORIDE; PROMETHAZINE HYDROCHLORIDE 5MG/5ML; 6.25MG/5ML	PHENERGAN VC (SYRUP; ORAL)	WYETH LABS/AMMO	08-604 04-02-84		
PILOCARPINE 5MG	OCUSERT PILO-20 (INSERT, CONTROLLED RELEASE; OPHTHALMIC)	ALZA	17-431 07-29-74	391628 06-08-93	
PILOCARPINE 11MG	OCUSERT PILO-40 (INSERT, CONTROLLED RELEASE; OPHTHALMIC)	ALZA	17-548 07-29-72	391628 06-08-93	
PILOCARPINE HYDROCHLORIDE 4%	PILOPINE HS (GEL; OPHTHALMIC)	ALCON LABORATORIES	18-796 10-01-84		NDF 10-01-87
PINOZIDE 2MG	ORAP (TABLET; ORAL)	MCNEIL PHARM	17-473 07-31-84		NCE 07-31-94
PINDOLOL 5MG	VISKEN (TABLET; ORAL)	SANDOZ PHARMS/SANDOZ	18-285 09-03-82	3471515 10-07-86	NCE 09-03-92
PINDOLOL 10MG	VISKEN (TABLET; ORAL)	SANDOZ PHARMS/SANDOZ	18-285 09-03-82	3471515 10-07-86	NCE 09-03-92
PINDOLOL 15MG	VISKEN (TABLET; ORAL)	SANDOZ PHARMS/SANDOZ	18-285 09-03-82	3471515 10-07-86	NCE 09-03-92

TABLE IV. NDA'S APPROVED FROM 1-1-82 TO 2-28-85 AND NDA'S WITH APPROPRIATE PATENT AND EXCLUSIVITY INFORMATION

<u>ACTIVE INGREDIENT(S)</u> <u>STRENGTH(S)</u>	<u>TRADE NAME</u> <u>(DOSAGE FORM; ROUTE)</u>	<u>APPLICANT NAME</u>	<u>NDA NO.</u> <u>APPROVAL DATE</u>	<u>PATENT NO.</u> <u>EXP. DATE</u>	<u>EXCLUSIVITY</u> <u>EXP. DATE</u>
PIROXICAM 10MG	FELDENE (CAPSULE; ORAL)	PFIZER LABS/PFIZER	18-147	3591584	NCE
			04-06-82	07-06-88	04-06-92
				3674876	
				07-04-89	
				3862319	
				01-21-92	
				4100347	
				07-11-95	
				3927002	
				12-16-92	
PIROXICAM 20MG	FELDENE (CAPSULE; ORAL)	PFIZER LABS/PFIZER		RE29668	
				12-10-91	
			18-147	3591584	NCE
			04-06-82	07-06-88	04-06-92
				3674876	
				07-04-89	
				3862319	
				01-21-92	
				4100347	
				07-11-95	
POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM SULFATE 236GM/BOT; 2.97GM/BOT; 6.74GM/BOT; 5.86GM/BOT; 22.74GM/BOT	GOLYTELY (POWDER FOR RECONSTITUTION; ORAL)	BRAINTREE LABS		3927002	
				12-16-92	
				RE29668	
				12-10-91	
			19-011		
			07-13-84		

TABLE IV. NDA'S APPROVED FROM 1-1-82 TO 2-28-85 AND NDA'S WITH APPROPRIATE PATENT AND EXCLUSIVITY INFORMATION

<u>ACTIVE INGREDIENT(S)</u> <u>STRENGTH(S)</u>	<u>TRADE NAME</u> <u>(DOSAGE FORM; ROUTE)</u>	<u>APPLICANT NAME</u>	<u>NDA NO.</u> <u>APPROVAL DATE</u>	<u>PATENT NO.</u> <u>EXP. DATE</u>	<u>EXCLUSIVITY</u> <u>EXP. DATE</u>
POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM SULFATE 120GM/PACKET; 1.49GM/PACKET; 3.36GM/PACKET; 2.92GM/PACKET; 11.36GM/PACKET	COLYTE (POWDER FOR RECONSTITUTION; ORAL)	EDLAW PREPARATIONS	18-983 10-26-84		
POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM SULFATE 227.1GM/PACKET; 2.82GM/PACKET; 6.36GM/PACKET; 5.53GM/PACKET; 21.5GM/PACKET	COLYTE (POWDER FOR RECONSTITUTION; ORAL)	EDLAW PREPARATIONS	18-983 10-26-84		
POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM SULFATE 360GM/PACKET; 4.47GM/PACKET; 10.08GM/PACKET; 8.76GM/PACKET; 34.08GM/PACKET	COLYTE (POWDER FOR RECONSTITUTION; ORAL)	EDLAW PREPARATIONS	18-983 10-26-84		
POLYTHIAZIDE; PRAZOSIN HYDROCHLORIDE 0.5MG; 1MG	MINIZIDE (CAPSULE; ORAL)	PFIZER LABS/PFIZER	17-986 06-13-80	3511836 05-12-87 3663706 05-16-89 4130647 12-19-95	

TABLE IV. NDA'S APPROVED FROM 1-1-82 TO 2-28-85 AND NDA'S WITH APPROPRIATE PATENT AND EXCLUSIVITY INFORMATION

<u>ACTIVE INGREDIENT(S)</u> <u>STRENGTH(S)</u>	<u>TRADE NAME</u> <u>(DOSAGE FORM; ROUTE)</u>	<u>APPLICANT NAME</u>	<u>NDA NO.</u> <u>APPROVAL DATE</u>	<u>PATENT NO.</u> <u>EXP. DATE</u>	<u>EXCLUSIVITY</u> <u>EXP. DATE</u>
POLYTHIAZIDE; PRAZOSIN HYDROCHLORIDE 0.5MG; 2MG	MINIZIDE (CAPSULE; ORAL)	PFIZER LABS/PFIZER	17-986 06-13-80	3511836 05-12-87 3663706 05-16-89 4130647 12-19-95	
POLYTHIAZIDE; PRAZOSIN HYDROCHLORIDE 0.5MG; 5MG	MINIZIDE (CAPSULE; ORAL)	PFIZER LABS/PFIZER	17-986 06-13-80	3511836 05-12-87 3663706 05-16-89 4130647 12-19-95	
POTASSIUM ACETATE 2MEQ/ML	POTASSIUM ACETATE IN PLASTIC CONTAINER (INJECTABLE; INJECTION)	ABBOTT LABORATORIES	18-896 07-20-84		NDF 09-24-86
POTASSIUM CHLORIDE 10MEQ	KLOTRIX (TABLET, CONTROLLED RELEASE; ORAL)	MEAD JOHNSON/B-M	17-850 05-22-80	4140756 02-20-96	
POTASSIUM CHLORIDE; SODIUM CHLORIDE 150MG/100ML; 900MG/100ML	SODIUM CHLORIDE 0.9% AND POTASSIUM CHLORIDE 10MEQ IN PLASTIC CONTAINER (INJECTABLE; INJECTION)	TRAVENOL LABS	18-630 02-17-83		
POTASSIUM CHLORIDE; SODIUM CHLORIDE 300MG/100ML; 900MG/100ML	SODIUM CHLORIDE 0.9% AND POTASSIUM CHLORIDE 20MEQ IN PLASTIC CONTAINER (INJECTABLE; INJECTION)	TRAVENOL LABS	18-630 02-17-83		
POTASSIUM CHLORIDE; SODIUM CHLORIDE 150MG/100ML; 900MG/100ML	SODIUM CHLORIDE 0.9% AND POTASSIUM CHLORIDE 20MEQ IN PLASTIC CONTAINER (INJECTABLE; INJECTION)	TRAVENOL LABS	18-630 02-17-83		
POTASSIUM CHLORIDE; SODIUM CHLORIDE 300MG/100ML; 900MG/100ML	SODIUM CHLORIDE 0.9% AND POTASSIUM CHLORIDE 40MEQ IN PLASTIC CONTAINER (INJECTABLE; INJECTION)	TRAVENOL LABS	18-630 02-17-83		

TABLE IV. NDA'S APPROVED FROM 1-1-82 TO 2-28-85 AND NDA'S WITH APPROPRIATE PATENT AND EXCLUSIVITY INFORMATION

<u>ACTIVE INGREDIENT(S)</u> <u>STRENGTH(S)</u>	<u>TRADE NAME</u> <u>(DOSAGE FORM; ROUTE)</u>	<u>APPLICANT NAME</u>	<u>NDA NO.</u> <u>APPROVAL DATE</u>	<u>PATENT NO.</u> <u>EXP. DATE</u>	<u>EXCLUSIVITY</u> <u>EXP. DATE</u>
POTASSIUM CHLORIDE; SODIUM CHLORIDE 75MG/100ML; 900MG/100ML	SODIUM CHLORIDE 0.9% AND POTASSIUM CHLORIDE 0.075% IN PLASTIC CONTAINER (INJECTABLE; INJECTION)	AM MCGAW/AM HOSP	18-722 11-09-82		
POTASSIUM CHLORIDE; SODIUM CHLORIDE 150MG/100ML; 900MG/100ML	SODIUM CHLORIDE 0.9% AND POTASSIUM CHLORIDE 0.15% IN PLASTIC CONTAINER (INJECTABLE; INJECTION)	AM MCGAW/AM HOSP	18-722 11-09-82		
POTASSIUM CHLORIDE; SODIUM CHLORIDE 220MG/100ML; 900MG/100ML	SODIUM CHLORIDE 0.9% AND POTASSIUM CHLORIDE 0.22% IN PLASTIC CONTAINER (INJECTABLE; INJECTION)	AM MCGAW/AM HOSP	18-722 11-09-82		
POTASSIUM CHLORIDE; SODIUM CHLORIDE 300MG/100ML; 900MG/100ML	SODIUM CHLORIDE 0.9% AND POTASSIUM CHLORIDE 0.3% IN PLASTIC CONTAINER (INJECTABLE; INJECTION)	AM MCGAW/AM HOSP	18-722 11-09-82		
PRALIDOXIME CHLORIDE 300MG/ML	PROTOPAM CHLORIDE (INJECTABLE; INJECTION)	AYERST LABS/AMHO	18-799 12-13-82		NDF 09-24-86
PRALIDOXIME CHLORIDE 300MG/ML	PRALIDOXIME CHLORIDE (INJECTABLE; INJECTION)	SURVIVAL TECHNOLOGY	18-986 12-13-82		NDF 09-24-86
PRAZEPAM 20MG	CENTRAX (CAPSULE; ORAL)	PARKE-DAVIS/W-L	18-144 05-10-82		NS 09-24-86
PRAZIQUANTEL 600MG	BILTRICIDE (TABLET; ORAL)	MILES PHARMS/MILES	18-714 12-29-82	4001411 01-04-94	NCE 12-29-92
PRAZOSIN HYDROCHLORIDE 5MG	MINIPRESS (CAPSULE; ORAL)	PFIZER LABS/PFIZER	17-442 06-23-76	3511836 05-12-87 3663706 05-16-89 4092315 05-30-95 4130647 12-19-95	

TABLE IV. NDA'S APPROVED FROM 1-1-82 TO 2-28-85 AND NDA'S WITH APPROPRIATE PATENT AND EXCLUSIVITY INFORMATION

<u>ACTIVE INGREDIENT(S)</u> <u>STRENGTH(S)</u>	<u>TRADE NAME</u> <u>(DOSAGE FORM; ROUTE)</u>	<u>APPLICANT NAME</u>	<u>NDA NO.</u> <u>APPROVAL DATE</u>	<u>PATENT NO.</u> <u>EXP. DATE</u>	<u>EXCLUSIVITY</u> <u>EXP. DATE</u>
PRazosin HYDROCHLORIDE 1MG	MINIPRESS (CAPSULE; ORAL)	PFIZER LABS/PFIZER	17-442 06-23-76	3511836 05-12-87 3663706 05-16-89 4092315 05-30-95 4130647 12-19-95	
PRazosin HYDROCHLORIDE 2MG	MINIPRESS (CAPSULE; ORAL)	PFIZER LABS/PFIZER	17-442 06-23-76	3511836 05-12-87 3663706 05-16-89 4092315 05-30-95 4130647 12-19-95	
PROBUCOL 250MG	LORELCO (TABLET; ORAL)	MERRELL DOW/DOW CHEM	17-535 02-01-77	3576883 04-27-88 3862332 01-21-92	
PROCARBAZINE HYDROCHLORIDE EQ 50MG BASE	MATULANE (CAPSULE; ORAL)	HOFFMANN-LA ROCHE	16-785 07-22-69	3520926 07-21-87	
PROPRANOLOL HYDROCHLORIDE 10MG	INDERAL (TABLET; ORAL)	AYERST LABS/AMHO	16-418 11-13-67		I-15 09-24-86
PROPRANOLOL HYDROCHLORIDE 20MG	INDERAL (TABLET; ORAL)	AYERST LABS/AMHO	16-418 10-16-74		I-15 09-24-86
PROPRANOLOL HYDROCHLORIDE 40MG	INDERAL (TABLET; ORAL)	AYERST LABS/AMHO	16-418 11-13-67		I-15 09-24-86
PROPRANOLOL HYDROCHLORIDE 60MG	INDERAL (TABLET; ORAL)	AYERST LABS/AMHO	16-418 10-18-82		NS 09-24-86
PROPRANOLOL HYDROCHLORIDE 80MG	INDERAL (TABLET; ORAL)	AYERST LABS/AMHO	16-418 10-16-74		I-15 09-24-86

TABLE IV. NDA'S APPROVED FROM 1-1-82 TO 2-28-85 AND NDA'S WITH APPROPRIATE PATENT AND EXCLUSIVITY INFORMATION

<u>ACTIVE INGREDIENT(S)</u> <u>STRENGTH(S)</u>	<u>TRADE NAME</u> <u>(DOSAGE FORM; ROUTE)</u>	<u>APPLICANT NAME</u>	<u>NDA NO.</u> <u>APPROVAL DATE</u>	<u>PATENT NO.</u> <u>EXP. DATE</u>	<u>EXCLUSIVITY</u> <u>EXP. DATE</u>
PROPRANOLOL HYDROCHLORIDE 80MG	INDERAL LA (CAPSULE, CONTROLLED RELEASE; ORAL)	AYERST LABS/AMHO	18-553 04-19-83		NDF 09-24-86
PROPRANOLOL HYDROCHLORIDE 90MG	INDERAL (TABLET; ORAL)	AYERST LABS/AMHO	16-418 10-18-82		NS 09-24-86
PROPRANOLOL HYDROCHLORIDE 120MG	INDERAL LA (CAPSULE, CONTROLLED RELEASE; ORAL)	AYERST LABS/AMHO	18-553 04-19-83		NDF 09-24-86
PROPRANOLOL HYDROCHLORIDE 160MG	INDERAL LA (CAPSULE, CONTROLLED RELEASE; ORAL)	AYERST LABS/AMHO	18-553 04-19-83		NDF 09-24-86
PROTAMINE SULFATE 250MG/VIAL	PROTAMINE SULFATE (INJECTABLE; INJECTION)	UPJOHN	07-413 08-02-84		NS 09-24-86
PROTIRELIN 0.5MG/ML	THYPINONE (INJECTABLE; INJECTION)	ABBOTT LABORATORIES	17-638 11-05-76	3746697 07-17-90	
PROTIRELIN 0.5MG/ML	RELEFACT TRH (INJECTABLE; INJECTION)	HOECHST-ROUSSEL	18-087 07-18-78	3746697 07-17-90	
PROTRIPTYLINE HYDROCHLORIDE 5MG	VIVACTIL (TABLET; ORAL)	MS&D/MERCK	16-012 09-27-67	3372196 03-05-85	
PROTRIPTYLINE HYDROCHLORIDE 10MG	VIVACTIL (TABLET; ORAL)	MS&D/MERCK	16-012 09-27-67	3372196 03-05-85	
PYRANTEL PAMOATE EQ 250MG BASE/5ML	ANTIMINTH (SUSPENSION; ORAL)	ROERIG/PFIZER	16-883 12-30-71	3644624 02-22-89 3549624 12-22-87	
RANITIDINE HYDROCHLORIDE EQ 150MG BASE	ZANTAC (TABLET; ORAL)	GLAXO	18-703 06-09-83	4128658 12-05-95	NCE 06-09-93
RANITIDINE HYDROCHLORIDE EQ 25MG BASE/ML	ZANTAC (INJECTABLE; INJECTION)	GLAXO	19-090 10-19-84	4128658 12-05-95	NCE 06-09-93

TABLE IV. NDA'S APPROVED FROM 1-1-82 TO 2-28-85 AND NDA'S WITH APPROPRIATE PATENT AND EXCLUSIVITY INFORMATION

<u>ACTIVE INGREDIENT(S)</u> <u>STRENGTH(S)</u>	<u>TRADE NAME</u> <u>(DOSAGE FORM; ROUTE)</u>	<u>APPLICANT NAME</u>	<u>NDA NO.</u> <u>APPROVAL DATE</u>	<u>PATENT NO.</u> <u>EXP. DATE</u>	<u>EXCLUSIVITY</u> <u>EXP. DATE</u>
RITODRINE HYDROCHLORIDE 10MG	YUTOPAR (TABLET; ORAL)	ASTRA PHARM PRODS	18-555 12-12-80	3410944 11-12-85	
RITODRINE HYDROCHLORIDE 10MG/ML	YUTOPAR (INJECTABLE; INJECTION)	ASTRA PHARM PRODS	18-580 12-12-80	3410944 11-12-85	
RITODRINE HYDROCHLORIDE 15MG/ML	YUTOPAR (INJECTABLE; INJECTION)	ASTRA PHARM PRODS	18-580 09-27-84	3410944 11-12-85	
SAFFLOWER OIL; SOYBEAN OIL 10%; 10%	LIPOSYN II 20% (INJECTABLE; INJECTION)	ABBOTT LABORATORIES	18-991 08-27-84		NP 09-24-86
SAFFLOWER OIL; SOYBEAN OIL 5%; 5%	LIPOSYN II 10% (INJECTABLE; INJECTION)	ABBOTT LABORATORIES	18-997 08-27-84		NP 09-24-86
SARALASIN ACETATE EQ 0.6MG BASE/ML	SARENIN (INJECTABLE; INJECTION)	NORWICH EATON/P&G	18-009 05-29-81	3932624 01-13-93 3886134 05-27-92	
SCOPOLAMINE 1.5MG	TRANSDERM-SCOP (FILM, CONTROLLED RELEASE; PERCUTANEOUS)	CIBA/CIBA-GEIGY	17-874 12-31-79	4031894 06-28-94 4262003 04-14-98	
SELENIUM SULFIDE 2.5%	SELSUN (SHAMPOO/LOTION; TOPICAL)	ABBOTT LABS	07-936 05-17-51		I-3 09-24-86
SILVER SULFADIAZINE 1%	SILVADENE (CREAM; TOPICAL)	MARION LABORATORIES	17-381 11-26-73	3761590 09-24-90	
SILVER SULFADIAZINE 1%	SSD (CREAM; TOPICAL)	TRAVENOL LABS	18-578 02-25-82		
SINCALIDE 0.005MG/VIAL	KINEVAC (INJECTABLE; INJECTION)	ER SQUIBB AND SONS	17-697 07-21-76	3839315 10-01-91	
SODIUM ACETATE, ANHYDROUS 2MEQ/ML	SODIUM ACETATE IN PLASTIC CONTAINER (INJECTABLE; INJECTION)	ABBOTT LABORATORIES	18-893 05-04-83		PP 09-24-86

TABLE IV. NDA'S APPROVED FROM 1-1-82 TO 2-28-85 AND NDA'S WITH APPROPRIATE PATENT AND EXCLUSIVITY INFORMATION

<u>ACTIVE INGREDIENT(S)</u> <u>STRENGTH(S)</u>	<u>TRADE NAME</u> <u>(DOSAGE FORM; ROUTE)</u>	<u>APPLICANT NAME</u>	<u>NDA NO.</u> <u>APPROVAL DATE</u>	<u>PATENT NO.</u> <u>EXP. DATE</u>	<u>EXCLUSIVITY</u> <u>EXP. DATE</u>
SODIUM CHLORIDE 450MG/100ML	SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER (SOLUTION; IRRIGATION)	TRAVENOL LABS	18-497 02-19-82		
SODIUM CHLORIDE 9MG/ML	BACTERIOSTATIC SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER (INJECTABLE; INJECTION)	ABBOTT LABORATORIES	18-800 10-29-82		
SODIUM CHLORIDE 9MG/ML	SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER (INJECTABLE; INJECTION)	ABBOTT LABORATORIES	18-803 10-29-82		
SODIUM CHLORIDE 2.5MEQ/ML	SODIUM CHLORIDE IN PLASTIC CONTAINER (INJECTABLE; INJECTION)	ABBOTT LABORATORIES	18-897 07-20-84		
SODIUM CHLORIDE 3GM/100ML	SODIUM CHLORIDE 3% IN PLASTIC CONTAINER (INJECTABLE; INJECTION)	TRAVENOL LABS	19-022 11-01-83		
SODIUM CHLORIDE 5GM/100ML	SODIUM CHLORIDE 5% IN PLASTIC CONTAINER (INJECTABLE; INJECTION)	TRAVENOL LABS	19-022 11-01-83		
SODIUM CHLORIDE 9MG/ML	SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER (INJECTABLE; INJECTION)	ABBOTT LABORATORIES	19-217 07-13-84		
SODIUM CHLORIDE 9MG/ML	SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER (INJECTABLE; INJECTION)	ABBOTT LABORATORIES	19-218 07-13-84		
SODIUM IODIDE, I-123 100 UCI	SODIUM IODIDE I 123 (CAPSULE; ORAL)	BENEDICT NUCLR PHARM	18-671 05-27-82		
SODIUM IODIDE, I-123 200 UCI	SODIUM IODIDE I 123 (CAPSULE; ORAL)	BENEDICT NUCLR PHARM	18-671 05-27-82		

TABLE IV. NDA'S APPROVED FROM 1-1-82 TO 2-28-85 AND NDA'S WITH APPROPRIATE PATENT AND EXCLUSIVITY INFORMATION

<u>ACTIVE INGREDIENT(S)</u> <u>STRENGTH(S)</u>	<u>TRADE NAME</u> <u>(DOSAGE FORM; ROUTE)</u>	<u>APPLICANT NAME</u>	<u>NDA NO.</u> <u>APPROVAL DATE</u>	<u>PATENT NO.</u> <u>EXP. DATE</u>	<u>EXCLUSIVITY</u> <u>EXP. DATE</u>
SODIUM IODIDE, I-123 400 UCI	SODIUM IODIDE I 123 (CAPSULE; ORAL)	BENEDICT NUCLR PHARM	18-671 05-27-82		
SODIUM LACTATE 5MEQ/ML	SODIUM LACTATE IN PLASTIC CONTAINER (INJECTABLE; INJECTION)	ABBOTT LABORATORIES	18-947 09-05-84		NS 09-24-86
SODIUM NITROPRUSSIDE 50MG/VIAL	SODIUM NITROPRUSSIDE (INJECTABLE; INJECTION)	ELKINS-SINN/AHROBINS	18-581 07-28-82		
SODIUM PHOSPHATE, DIBASIC; SODIUM PHOSPHATE, MONOBASIC 142MG/ML; 276MG/ML	SODIUM PHOSPHATES IN PLASTIC CONTAINER (INJECTABLE; INJECTION)	ABBOTT LABORATORIES	18-892 05-10-83		NP 09-24-86
SOMATROPIN 2 IU/VIAL	ASELLACRIN 2 (INJECTABLE; INJECTION)	SERONO LABS	17-726 07-21-83		NS 09-24-86
SORBITOL 3GM/100ML	SORBITOL 3% IN PLASTIC CONTAINER (SOLUTION; IRRIGATION)	TRAVENOL LABS	18-512 05-27-82		
SOYBEAN OIL 10%	SOYACAL 10% (INJECTABLE; INJECTION)	ALPHA THERAPEUTIC	18-465 06-29-83		
SOYBEAN OIL 10%	TRAVAMULSION 10% (INJECTABLE; INJECTION)	TRAVENOL LABS	18-660 02-26-82		
SOYBEAN OIL 20%	TRAVAMULSION 20% (INJECTABLE; INJECTION)	TRAVENOL LABS	18-758 02-15-83		
SOYBEAN OIL 20%	SOYACAL 20% (INJECTABLE; INJECTION)	ALPHA THERAPEUTIC	18-786 06-29-83		
SOYBEAN OIL 10%	LIPOSYN III 10% (INJECTABLE; INJECTION)	ABBOTT LABORATORIES	18-969 09-24-84		
SOYBEAN OIL 20%	LIPOSYN III 20% (INJECTABLE; INJECTION)	ABBOTT LABORATORIES	18-970 09-25-84		
STANOZOLOL 2MG	WINSTROL (TABLET; ORAL)	WINTHROP LABS/STERL	12-885 11-30-61	3704295 11-28-89	I-28 09-24-86

TABLE IV. NDA'S APPROVED FROM 1-1-82 TO 2-28-85 AND NDA'S WITH APPROPRIATE PATENT AND EXCLUSIVITY INFORMATION

<u>ACTIVE INGREDIENT(S)</u> <u>STRENGTH(S)</u>	<u>TRADE NAME</u> <u>(DOSAGE FORM; ROUTE)</u>	<u>APPLICANT NAME</u>	<u>NDA NO.</u> <u>APPROVAL DATE</u>	<u>PATENT NO.</u> <u>EXP. DATE</u>	<u>EXCLUSIVITY</u> <u>EXP. DATE</u>
STREPTOZOCIN 1GM/VIAL	ZANOSAR (INJECTABLE; INJECTION)	UPJOHN	17-961 05-07-82		NCE 05-07-92
SUCRALFATE 1GM	CARAFATE (TABLET; ORAL)	MARION LABORATORIES	18-333 10-30-81	3432489 03-11-86	
SUFENTANIL CITRATE EQ 0.05MG BASE/ML	SUFENTA (INJECTABLE; INJECTION)	JANSSEN PHARMA	19-050 05-04-84	3998834 12-21-93	NCE 05-04-94
SULFAMETHOXAZOLE; TRIMETHOPRIM 400MG; 80MG	BACTRIM (TABLET; ORAL)	HOFFMANN-LA ROCHE	17-377 07-30-73	RE28636 06-02-87	
SULFAMETHOXAZOLE; TRIMETHOPRIM 800MG; 160MG	BACTRIM DS (TABLET; ORAL)	HOFFMANN-LA ROCHE	17-377 03-01-78	RE28636 06-02-87	
SULFAMETHOXAZOLE; TRIMETHOPRIM 200MG/5ML; 40MG/5ML	BACTRIM (SUSPENSION; ORAL)	HOFFMANN-LA ROCHE	17-560 04-16-75	RE28636 06-02-87	I-21 09-24-86
SULFAMETHOXAZOLE; TRIMETHOPRIM 200MG/5ML; 40MG/5ML	BACTRIM PEDIATRIC (SUSPENSION; ORAL)	HOFFMANN-LA ROCHE	17-560 12-10-79	RE28636 06-02-87	I-21 09-24-86
SULFAMETHOXAZOLE; TRIMETHOPRIM 80MG/ML; 16MG/ML	BACTRIM (INJECTABLE; INJECTION)	HOFFMANN-LA ROCHE	18-374 06-23-81	3551564 12-29-87 RE28636 06-02-87	
SULFAMETHOXAZOLE; TRIMETHOPRIM 400MG; 80MG	SULFAMETHOXAZOLE AND TRIMETHOPRIM (TABLET; ORAL)	DRUMMER/PHOENIX	18-598 05-19-82		
SULFAMETHOXAZOLE; TRIMETHOPRIM 800MG; 160MG	SULFAMETHOXAZOLE AND TRIMETHOPRIM DOUBLE STRENGTH (TABLET; ORAL)	DRUMMER/PHOENIX	18-598 05-19-82		
SULFAMETHOXAZOLE; TRIMETHOPRIM 200MG/5ML; 40MG/5ML	SULFATRIM PEDIATRIC (SUSPENSION; ORAL)	NATL PHARM MFG/BARRE	18-615 01-07-83		
SULFAMETHOXAZOLE; TRIMETHOPRIM 200MG/5ML; 40MG/5ML	SULFATRIM (SUSPENSION; ORAL)	NATL PHARM MFG/BARRE	18-615 01-07-83		

TABLE IV. NDA'S APPROVED FROM 1-1-82 TO 2-28-85 AND NDA'S WITH APPROPRIATE PATENT AND EXCLUSIVITY INFORMATION

<u>ACTIVE INGREDIENT(S)</u> <u>STRENGTH(S)</u>	<u>TRADE NAME</u> <u>(DOSAGE FORM; ROUTE)</u>	<u>APPLICANT NAME</u>	<u>NDA NO.</u> <u>APPROVAL DATE</u>	<u>PATENT NO.</u> <u>EXP. DATE</u>	<u>EXCLUSIVITY</u> <u>EXP. DATE</u>
SULFAMETHOXAZOLE; TRIMETHOPRIM 200MG/5ML; 40MG/5ML	SMZ-TMP (SUSPENSION; ORAL)	BIOCRAFT LABS	18-812 01-28-83		
SULFAMETHOXAZOLE; TRIMETHOPRIM 200MG/5ML; 40MG/5ML	SMZ-TMP PEDIATRIC (SUSPENSION; ORAL)	BIOCRAFT LABS	18-812 06-10-83		
SULFAMETHOXAZOLE; TRIMETHOPRIM 400MG; 80MG	SULFAMETHOXAZOLE AND TRIMETHOPRIM (TABLET; ORAL)	DANBURY PHARMACAL	18-852 05-09-83		
SULFAMETHOXAZOLE; TRIMETHOPRIM 800MG; 160MG	SULFAMETHOXAZOLE AND TRIMETHOPRIM DOUBLE STRENGTH (TABLET; ORAL)	DANBURY PHARMACAL	18-854 05-09-83		
SULFAMETHOXAZOLE; TRIMETHOPRIM 400MG; 80MG	SULFAMETHOXAZOLE & TRIMETHOPRIM (TABLET; ORAL)	HEATHER DRUG	18-946 08-10-84		
SULFAMETHOXAZOLE; TRIMETHOPRIM 800MG; 160MG	SULFAMETHOXAZOLE & TRIMETHOPRIM (TABLET; ORAL)	HEATHER DRUG	18-946 08-10-84		
SULFASALAZINE 500MG	AZULFIDINE (TABLET, ENTERIC COATED; ORAL)	PHARMACIA/PHARMACIA	07-073 04-06-83		NDF 09-24-86
SULFASALAZINE 500MG	SULFASALAZINE (TABLET, ENTERIC COATED; ORAL)	BOLAR PHARMACEUTICAL	88-052 05-24-83		NDF 09-24-86
SULINDAC 150MG	CLINORIL (TABLET; ORAL)	MS&D/MERCK	17-911 09-27-78	3654349 04-04-89 3725548 04-03-90	
SULINDAC 200MG	CLINORIL (TABLET; ORAL)	MS&D/MERCK	17-911 09-27-78	3725548 04-03-90 3654349 04-04-89	

TABLE IV. NDA'S APPROVED FROM 1-1-82 TO 2-28-85 AND NDA'S WITH APPROPRIATE PATENT AND EXCLUSIVITY INFORMATION

<u>ACTIVE INGREDIENT(S)</u> <u>STRENGTH(S)</u>	<u>TRADE NAME</u> <u>(DOSAGE FORM; ROUTE)</u>	<u>APPLICANT NAME</u>	<u>NDA NO.</u> <u>APPROVAL DATE</u>	<u>PATENT NO.</u> <u>EXP. DATE</u>	<u>EXCLUSIVITY</u> <u>EXP. DATE</u>
SUTILAINS 82,000 UNITS/GM	TRAVASE (OINTMENT; TOPICAL)	TRAVENOL LABS	12-828 06-12-69	3409719 11-05-85	
TECHNETIUM, TC-99M SODIUM PERTECHNETATE GENERATOR 0.22-2.22CI/GENERATOR	MINITEC (SOLUTION; INTRAVENOUS, ORAL)	ER SQUIBB AND SONS	17-339 06-03-74		I-31 09-24-86
TECHNETIUM, TC-99M, ALBUMIN COLLOID KIT N/A	MICROLITE (INJECTABLE; INJECTION)	MED DIAG/NE NUCLEAR	18-263 03-25-83		
TECHNETIUM, TC-99M, DISOFENIN KIT N/A	HEPATOLITE (INJECTABLE; INJECTION)	MED DIAG/NE NUCLEAR	18-467 03-16-82		NP 09-24-86
TECHNETIUM, TC 99M, PYROPHOSPHATE KIT N/A	PHOSPHOTEC (INJECTABLE; INJECTION)	ER SQUIBB AND SONS	17-680 10-20-76		I-9 09-24-86
TECHNETIUM, TC-99M, GLUCEPTATE KIT N/A	TECHNISCAN GLUCEPTATE (INJECTABLE; INJECTION)	MS&D/MERCK	18-272 01-27-82		
TECHNETIUM, TC-99M, MEDRONATE N/A	OSTEOLITE (INJECTABLE; INJECTION)	MED DIAG/NE NUCLEAR	17-972 12-16-77		
TECHNETIUM, TC-99M, MEDRONATE N/A	AMERSCAN (INJECTABLE; INJECTION)	AMERSHAM/RADIOCHEM	18-335 08-05-82		
TECHNETIUM, TC-99M, SUCCIMER KIT N/A	MPI DMSA KIDNEY REAGENT (INJECTABLE; INJECTION)	MEDI-PHYSICS	17-944 05-18-82	4208398 06-17-97 4233285 11-11-97	NP 09-24-86
TERBUTALINE SULFATE 1MG/ML	BRICANYL (INJECTABLE; INJECTION)	MERRELL DOW/DOW CHEM	17-466 03-25-74	3937838 02-10-93 4011258 03-08-94	
TERBUTALINE SULFATE 2.5MG	BRICANYL (TABLET; ORAL)	MERRELL DOW/DOW CHEM	17-618 04-22-75	3937838 02-10-93 4011258 03-08-94	

TABLE IV. NDA'S APPROVED FROM 1-1-82 TO 2-28-85 AND NDA'S WITH APPROPRIATE PATENT AND EXCLUSIVITY INFORMATION

<u>ACTIVE INGREDIENT(S)</u> <u>STRENGTH(S)</u>	<u>TRADE NAME</u> <u>(DOSAGE FORM; ROUTE)</u>	<u>APPLICANT NAME</u>	<u>NDA NO.</u> <u>APPROVAL DATE</u>	<u>PATENT NO.</u> <u>EXP. DATE</u>	<u>EXCLUSIVITY</u> <u>EXP. DATE</u>
TERBUTALINE SULFATE 5MG	BRICANYL (TABLET; ORAL)	MERRELL DOW/DOW CHEM	17-618 04-22-75	3937838 02-10-93 4011258 03-08-94	
TERBUTALINE SULFATE 2.5MG	BRETHINE (TABLET; ORAL)	GEIGY/CIBA-GEIGY	17-849 05-17-76	3937838 02-10-93 4011258 03-08-94	
TERBUTALINE SULFATE 5MG	BRETHINE (TABLET; ORAL)	GEIGY/CIBA-GEIGY	17-849 05-17-76	3937838 02-10-93 4011258 03-08-94	
TERBUTALINE SULFATE 1MG/ML	BRETHINE (INJECTABLE; INJECTION)	GEIGY/CIBA-GEIGY	18-571 11-30-81	3937838 02-10-93 4011258 03-08-94	
TERBUTALINE SULFATE 0.2MG/INH	BRETHAIRE (AEROSOL; INHALATION)	GEIGY/CIBA-GEIGY	18-762 08-17-84	3937838 02-10-93 4011258 03-08-94	NDF 09-24-86
THALLOUS CHLORIDE, TL-201 2MCI/ML	THALLOUS CHLORIDE TL 201 (INJECTABLE; INJECTION)	MEDI-PHYSICS	18-110 02-01-82		NS 09-24-86
THALLOUS CHLORIDE, TL-201 1MCI/ML	THALLOUS CHLORIDE TL 201 (INJECTABLE; INJECTION)	AMERSHAM/RADIOCHEM	18-548 12-30-82		
TIMOLOL MALEATE 5MG	BLOCADREN (TABLET; ORAL)	MS&D/MERCK	18-017 11-25-81	3655663 04-11-89	
TIMOLOL MALEATE 10MG	BLOCADREN (TABLET; ORAL)	MS&D/MERCK	18-017 11-25-81	3655663 04-11-89	
TIMOLOL MALEATE 20MG	BLOCADREN (TABLET; ORAL)	MS&D/MERCK	18-017 11-25-81	3655663 04-11-89	

TABLE IV. NDA'S APPROVED FROM 1-1-82 TO 2-28-85 AND NDA'S WITH APPROPRIATE PATENT AND EXCLUSIVITY INFORMATION

<u>ACTIVE INGREDIENT(S)</u> <u>STRENGTH(S)</u>	<u>TRADE NAME</u> <u>(DOSAGE FORM; ROUTE)</u>	<u>APPLICANT NAME</u>	<u>NDA NO.</u> <u>APPROVAL DATE</u>	<u>PATENT NO.</u> <u>EXP. DATE</u>	<u>EXCLUSIVITY</u> <u>EXP. DATE</u>
TIMOLOL MALEATE EQ 0.25% BASE	TIMOPTIC (SOLUTION; OPHTHALMIC)	MS&D/MERCK	18-086 08-17-78	4195085 03-25-97 3655663 04-11-89	
TIMOLOL MALEATE EQ 0.5% BASE	TIMOPTIC (SOLUTION; OPHTHALMIC)	MS&D/MERCK	18-086 08-17-78	4195085 03-25-97 3655663 04-11-89	
TOCAINIDE HYDROCHLORIDE 400MG	TONOCARD (TABLET; ORAL)	MS&D/MERCK	18-257 11-09-84	4218477 08-19-97 4237068 12-02-97	NCE 11-09-89
TOCAINIDE HYDROCHLORIDE 600MG	TONOCARD (TABLET; ORAL)	MS&D/MERCK	18-257 11-09-84	4218477 08-19-97 4237068 12-02-97	NCE 11-09-89
TOLAZAMIDE 100MG	TOLAZAMIDE (TABLET; ORAL)	ZENITH LABORATORIES	18-894 11-02-84		
TOLAZAMIDE 250MG	TOLAZAMIDE (TABLET; ORAL)	ZENITH LABORATORIES	18-894 11-02-84		
TOLAZAMIDE 500MG	TOLAZAMIDE (TABLET; ORAL)	ZENITH LABORATORIES	18-894 11-02-84		
TOLAZOLINE HYDROCHLORIDE 25MG/ML	PRISCOLINE (INJECTABLE; INJECTION)	CIBA/CIBA-GEIGY	06-403 02-22-85		
TOLMETIN SODIUM EQ 200MG BASE	TOLECTIN (TABLET; ORAL)	MCNEIL LABORATORIES	17-628 03-24-76	3752826 08-14-90	
TOLMETIN SODIUM EQ 400MG BASE	TOLECTIN DS (CAPSULE; ORAL)	MCNEIL LABORATORIES	18-084 10-30-79	3752826 08-14-90	
TRAZODONE HYDROCHLORIDE 50MG	DESYREL (TABLET; ORAL)	MEAD JOHNSON/B-M	18-207 12-24-81	3381009 04-30-85	

TABLE IV. NDA'S APPROVED FROM 1-1-82 TO 2-28-85 AND NDA'S WITH APPROPRIATE PATENT AND EXCLUSIVITY INFORMATION

<u>ACTIVE INGREDIENT(S)</u> <u>STRENGTH(S)</u>	<u>TRADE NAME</u> <u>(DOSAGE FORM; ROUTE)</u>	<u>APPLICANT NAME</u>	<u>NDA NO.</u> <u>APPROVAL DATE</u>	<u>PATENT NO.</u> <u>EXP. DATE</u>	<u>EXCLUSIVITY</u> <u>EXP. DATE</u>
TRAZODONE HYDROCHLORIDE 100MG	DESYREL (TABLET; ORAL)	MEAD JOHNSON/B-M	18-207 12-24-81	3381009 04-30-85	
TRETINOIN 0.05%	RETIN-A (SOLUTION; TOPICAL)	ORTHO PHARMACEUTICAL	16-921 10-20-71	3729568 04-24-90	
TRETINOIN 0.1%	RETIN-A (CREAM; TOPICAL)	ORTHO PHARMACEUTICAL	17-340 01-26-73	3729568 04-24-90	
TRETINOIN 0.05%	RETIN-A (CREAM; TOPICAL)	ORTHO PHARMACEUTICAL	17-522 07-19-74	3729568 04-24-90	
TRETINOIN 0.01%	RETIN-A (GEL; TOPICAL)	ORTHO PHARMACEUTICAL	17-955 10-05-78	3729568 04-24-90	
TRETINOIN 0.025%	RETIN-A (GEL; TOPICAL)	ORTHO PHARMACEUTICAL	17-579 04-18-75	3729568 04-24-90	
TRIAMCINOLONE ACETONIDE 0.25MG/INH	AZMACORT (AEROSOL; INHALATION)	WILLIAM H RORER	18-117 04-23-83	3897779 08-05-92 3927806 12-23-92	NDF 09-24-86
TRIAZOLAM 0.25MG	HALCION (TABLET; ORAL)	UPJOHN	17-892 11-15-82	3980790 09-14-93 3987052 10-19-93	NCE 11-15-92
TRIAZOLAM 0.5MG	HALCION (TABLET; ORAL)	UPJOHN	17-892 11-15-82	3980790 09-14-93 3987052 10-19-93	NCE 11-15-92
TRILOSTANE 30MG	MODRASTANE (CAPSULE; ORAL)	WINTHROP LABS/STERL	18-719 12-21-84		NCE 12-21-89
TRILOSTANE 60MG	MODRASTANE (CAPSULE; ORAL)	WINTHROP LABS/STERL	18-719 12-21-84		NCE 12-21-89
TRIMETHOPRIM 200MG	PROLOPRIM (TABLET; ORAL)	BURROUGHS WELLCOME	17-943 07-14-82		NS 09-24-86

TABLE IV. NDA'S APPROVED FROM 1-1-82 TO 2-28-85 AND NDA'S WITH APPROPRIATE PATENT AND EXCLUSIVITY INFORMATION

ACTIVE INGREDIENT(S) STRENGTH(S)	TRADE NAME (DOSAGE FORM; ROUTE)	APPLICANT NAME	NDA NO.		PATENT NO.		EXCLUSIVITY	
			APPROVAL DATE		EXP. DATE		EXP. DATE	
TRIMETHOPRIM 200MG	TRIMPEX 200 (TABLET; ORAL)	HOFFMANN-LA ROCHE	17-952	11-09-82			NS	09-24-86
TRIMETHOPRIM 100MG	TRIMETHOPRIM (TABLET; ORAL)	BIOCRAFT LABS	18-679	07-30-82				
TRIMPRAMINE MALEATE EQ 100MG BASE	SURMONTIL (CAPSULE; ORAL)	IVES LABS/AMHO	16-792	09-15-82			NS	09-24-86
VECURONIUM BROMIDE 10MG/VIAL	NORCURON (NC-45) (INJECTABLE; INJECTION)	ORGANON/AKZONA	18-776	04-30-84	3553212 01-05-88 4237126 12-02-97 4297351 10-27-98		NCE	04-30-94
VERAPAMIL HYDROCHLORIDE 80MG	ISOPTIN (TABLET; ORAL)	KNOLL PHARMACEUTICAL	18-593	03-08-82			NR	09-24-86
VERAPAMIL HYDROCHLORIDE 120MG	ISOPTIN (TABLET; ORAL)	KNOLL PHARMACEUTICAL	18-593	03-08-82			NR	09-24-86
VERAPAMIL HYDROCHLORIDE 80MG	CALAN (TABLET; ORAL)	SEARLE/SEARLE PHARMS	18-817	09-10-84			NR	09-24-86
VERAPAMIL HYDROCHLORIDE 120MG	CALAN (TABLET; ORAL)	SEARLE/SEARLE PHARMS	18-817	09-10-84			NR	09-24-86
VERAPAMIL HYDROCHLORIDE 2.5MG/ML	CALAN (INJECTABLE; INJECTION)	SEARLE PHARMS	18-925	03-30-84				
VERAPAMIL HYDROCHLORIDE 2.5MG/ML	CALAN (INJECTABLE; INJECTION)	SEARLE PHARMS	19-038	03-30-84				
WATER FOR INJECTION, STERILE 100%	STERILE WATER FOR INJECTION IN PLASTIC CONTAINER (LIQUID; N/A)	TRAVENOL LABS	18-595	01-17-83				
WATER FOR INJECTION, STERILE 100%	STERILE WATER IN PLASTIC CONTAINER (LIQUID; N/A)	TRAVENOL LABS	18-632	06-30-82				

TABLE IV. NDA'S APPROVED FROM 1-1-82 TO 2-28-85 AND NDA'S WITH APPROPRIATE PATENT AND EXCLUSIVITY INFORMATION

<u>ACTIVE INGREDIENT(S)</u> <u>STRENGTH(S)</u>	<u>TRADE NAME</u> <u>(DOSAGE FORM; ROUTE)</u>	<u>APPLICANT NAME</u>	<u>NDA NO.</u> <u>APPROVAL DATE</u>	<u>PATENT NO.</u> <u>EXP. DATE</u>	<u>EXCLUSIVITY</u> <u>EXP. DATE</u>
WATER FOR INJECTION, STERILE 100%	STERILE WATER IN PLASTIC CONTAINER (LIQUID; N/A)	ABBOTT LABORATORIES	18-801 10-27-82		
WATER FOR INJECTION, STERILE 100%	BACTERIOSTATIC WATER IN PLASTIC CONTAINER (LIQUID; N/A)	ABBOTT LABORATORIES	18-802 10-27-82		
WATER FOR INJECTION, STERILE 100%	STERILE WATER FOR INJECTION IN PLASTIC CONTAINER (LIQUID; N/A)	AM MCGAW/AM HOSP	19-077 03-02-84		
XENON, XE-127 5MCI/VIAL	XENON XE 127 (GAS; INHALATION)	MALLINCKRODT	18-536 10-01-82		NCE 10-01-92
XENON, XE-127 10MCI/VIAL	XENON XE 127 (GAS; INHALATION)	MALLINCKRODT	18-536 10-01-82		NCE 10-01-92
XENON, XE-133 10MCI/VIAL	XENON XE 133 (GAS; INHALATION)	MALLINCKRODT	18-327 03-09-82		
XENON, XE-133 20MCI/VIAL	XENON XE 133 (GAS; INHALATION)	MALLINCKRODT	18-327 03-09-82		

UNIVERSITY OF MICHIGAN



3 9015 07293 1606